[
  {
    "id": "40580757",
    "title_en": "The effect of graphene oxide-polyethylene glycol on lung cell and treatment of sulforaphane.",
    "pub_date": "2026 Jan",
    "abstract_en": "This study explores the cytotoxic and biochemical effects of PEGylated graphene oxide (GO-PEG) nanoparticles, sulforaphane, and Raphanus sativus L. (black radish) juice on BEAS-2B human bronchial epithelial cells. Sulforaphane was extracted from radish juice through pH-adjusted aqueous treatment followed by organic solvent extraction, and quantified via high-performance liquid chromatography (HPLC) at 202Â nm, with a retention time of 11.0Â min. GO-PEG nanoparticles produced from graphites (50Â nm and 400Â nm) were tested at concentrations ranging from 50-225 Î¼gÂ mL<sup>-1</sup> and 100-1000 Î¼gÂ mL<sup>-1</sup> to have IC<sub>50</sub> values, respectively. Sulforaphane and black radish juice were also administered. The MTT assay revealed IC<sub>50</sub> values of 8.7Â Î¼gÂ mL<sup>-1</sup> for sulforaphane, 197.0 mgÂ mL<sup>-1</sup> for black radish juice, 175.8Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (50Â nm), and 650.6Â Î¼gÂ mL<sup>-1</sup> for GO-PEG (400Â nm). Biochemical analyses showed that sulforaphane and radish juice decreased IL-6 levels and increased antioxidant enzyme activities (GSH-Px and CAT). These results highlight the therapeutic potential of GO-PEG, sulforaphane, and black radish juice for anti-inflammatory and antioxidant applications.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é«”å…§çš„ç™¼ç‚åæ‡‰ï¼Œä¸¦æå‡æŠ—æ°§åŒ–é…µç´ çš„æ´»æ€§ï¼Œé€™å°æ–¼ç¶­æŒå‘¼å¸ç³»çµ±å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…æ˜¯éå¸¸é‡è¦çš„ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„å‘¼å¸é“å¥åº·æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šï¼Œé€™å°æ–¼äº†è§£é€™äº›ç‰©è³ªåœ¨å‘¼å¸ç³»çµ±ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨éå¸¸é‡è¦ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œç ”ç©¶è€…æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦é€šéé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­å‰‡æ˜¯å¾çŸ³å¢¨ä¸­è£½å‚™è€Œæˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä»¥æ¸¬é‡ç´°èƒå…§çš„ç™¼ç‚æŒ‡æ¨™å’ŒæŠ—æ°§åŒ–é…µç´ çš„æ´»æ€§ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½ç´°èƒå…§çš„IL-6æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…µç´ ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰çš„æ´»æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ©Ÿåˆ¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ‡‰ç”¨ä¸Šã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é«”å…§çš„ç™¼ç‚åæ‡‰ï¼Œä¸¦æå‡æŠ—æ°§åŒ–é…µç´ çš„æ´»æ€§ï¼Œé€™å°æ–¼ç¶­æŒå‘¼å¸ç³»çµ±å¥åº·å’Œé é˜²ç›¸é—œç–¾ç—…æ˜¯éå¸¸é‡è¦çš„ã€‚é€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨æ”¹å–„å‘¼å¸é“å¥åº·æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨PEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼ˆGO-PEGï¼‰å¥ˆç±³ç²’å­ã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å°äººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼ˆBEAS-2Bï¼‰çš„ç´°èƒæ¯’æ€§å’Œç”ŸåŒ–æ•ˆæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒé€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„æ•ˆæœä¸Šï¼Œé€™å°æ–¼äº†è§£é€™äº›ç‰©è³ªåœ¨å‘¼å¸ç³»çµ±ç–¾ç—…ä¸­çš„æ½›åœ¨æ‡‰ç”¨éå¸¸é‡è¦ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†BEAS-2Bäººé¡æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒä½œç‚ºç ”ç©¶å°è±¡ï¼Œç ”ç©¶è€…æå–äº†é»‘è˜¿è””æ±ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦é€šéé«˜æ•ˆæ¶²ç›¸è‰²è­œæ³•é€²è¡Œå®šé‡åˆ†æã€‚GO-PEGå¥ˆç±³ç²’å­å‰‡æ˜¯å¾çŸ³å¢¨ä¸­è£½å‚™è€Œæˆï¼Œä¸¦åœ¨ä¸åŒæ¿ƒåº¦ä¸‹é€²è¡Œæ¸¬è©¦ã€‚ç ”ç©¶è€…ä½¿ç”¨MTTæ³•ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ï¼Œä¸¦é€²è¡Œç”ŸåŒ–åˆ†æä»¥æ¸¬é‡ç´°èƒå…§çš„ç™¼ç‚æŒ‡æ¨™å’ŒæŠ—æ°§åŒ–é…µç´ çš„æ´»æ€§ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½å¤ é™ä½ç´°èƒå…§çš„IL-6æ°´å¹³ï¼Œä¸¦æé«˜æŠ—æ°§åŒ–é…µç´ ï¼ˆå¦‚GSH-Pxå’ŒCATï¼‰çš„æ´»æ€§ã€‚é€™äº›çµæœè¡¨æ˜ï¼ŒGO-PEGã€è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ï¼Œé›–ç„¶é€™äº›çµæœéœ€è¦é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”æ•ˆæœå’Œæ©Ÿåˆ¶ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿé»‘è˜¿è””ä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½å°æˆ‘å€‘çš„å¥åº·å¤§æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½èƒ½å¹«åŠ©æ¸›å°‘é«”å…§çš„ç™¼ç‚ï¼Œé‚„èƒ½æå‡æŠ—æ°§åŒ–çš„èƒ½åŠ›ï¼Œé€™å°ç¶­æŒå‘¼å¸ç³»çµ±å¥åº·éå¸¸é‡è¦ï¼\n\né€™é …ç ”ç©¶å°ˆæ³¨æ–¼æ¢è¨ä¸€ç¨®ç‰¹æ®Šçš„å¥ˆç±³ç²’å­ï¼ˆPEGåŒ–çŸ³å¢¨çƒ¯æ°§åŒ–ç‰©ï¼‰å’Œè˜¿è””ç¡«ç´ å°æˆ‘å€‘çš„æ”¯æ°£ç®¡ç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…æå–äº†é»‘è˜¿è””ä¸­çš„è˜¿è””ç¡«ç´ ï¼Œä¸¦æ¸¬è©¦äº†é€™äº›ç‰©è³ªå¦‚ä½•å½±éŸ¿ç´°èƒçš„å¥åº·ï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†äººé¡çš„æ”¯æ°£ç®¡ä¸Šçš®ç´°èƒï¼Œä¸¦é€²è¡Œäº†ä¸€ç³»åˆ—æ¸¬è©¦ï¼Œçµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±èƒ½æœ‰æ•ˆé™ä½ç´°èƒå…§çš„ç™¼ç‚æŒ‡æ¨™ï¼Œé‚„èƒ½æå‡æŠ—æ°§åŒ–é…µç´ çš„æ´»æ€§ã€‚\n\nğŸ” é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å’Œé»‘è˜¿è””æ±å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘ç™¼ç‚åæ‡‰ã€‚\n2. é€™äº›æˆåˆ†èƒ½æå‡æŠ—æ°§åŒ–é…µç´ çš„æ´»æ€§ï¼Œå°å‘¼å¸ç³»çµ±å¥åº·æœ‰ç›Šã€‚\n3. ç ”ç©¶çµæœç‚ºæœªä¾†çš„å¥åº·ä¿ƒé€²ç­–ç•¥æä¾›äº†æ–°çš„æ–¹å‘ï¼Œä½†ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ç¢ºèªã€‚ è®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šçš„å¥åº·ç™¼ç¾å§ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental process and main findings of a study on the effects of sulforaphane and black radish juice on human bronchial epithelial cells. Include symbols representing sulforaphane or black radish, simplified representations of human cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Findings' highlighting protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å‘¼å¸ç³»çµ±ç–¾ç—… Respiratory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40580757/"
  },
  {
    "id": "40961586",
    "title_en": "Design, synthesis and biological evaluation of magnolol-sulforaphane hybrid analogues as potential therapeutics of triple-negative breast cancer.",
    "pub_date": "2025 Dec",
    "abstract_en": "Triple-negative breast cancer (TNBC) is an aggressive subtype that primarily relies on chemotherapy. Natural products like magnolol and sulforaphane, especially their synthetic hybrid, have shown promising antitumor activity. To develop more potent agents, we designed and synthesized 15 novel magnolol-sulforaphane hybrid analogues and evaluated their anticancer efficacy. Among them, compound 17a demonstrated the highest potency, exhibiting an average 7.4-fold increase in antiproliferative activity with IC<sub>50</sub> values ranging from 0.85Â Â±Â 0.04Â Î¼M to 1.34Â Â±Â 0.02Â Î¼M in TNBC cell lines compared to the parent hybrid CT1-3. In vitro, 17a significantly suppressed TNBC cell proliferation, colony formation, migration, and invasion while inducing apoptosis. In vivo, administration of 17a effectively inhibited tumor growth without apparent toxicity in an MDA-MB-231 xenograft model, as evidenced by normal organ morphology. Mechanistically, RNA sequencing revealed that 17a downregulated the nucleotide excision repair (NER) and NF-ÎºB pathways, suppressing expression of NER-related genes (ERCC2, POLE2, LIG1, GTF2H3, and DDB2) at mRNA and protein levels and inhibiting phosphorylation of IKKÎ± and p65. These findings position 17a as a potent therapeutic candidate for TNBC treatment, warranting further clinical investigation.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç”¢ç‰©å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„åˆæˆæ··åˆç‰©å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤æ´»æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„æ²»ç™‚å¯èƒ½ä¸åƒ…é™æ–¼åŒ–ç™‚ï¼Œé‚„å¯ä»¥è€ƒæ…®ä½¿ç”¨é€™äº›å¤©ç„¶æˆåˆ†ä¾†é–‹ç™¼æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°å‹çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æ¢è¨å…¶åœ¨ä¸‰é™°æ€§ä¹³ç™Œä¸­çš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°å‹çš„æ··åˆç‰©ï¼Œä¸¦é‡å°å…¶æŠ—ç™Œæ´»æ€§é€²è¡Œäº†è©•ä¼°ã€‚é€™é …ç ”ç©¶é—œæ³¨çš„å•é¡Œæ˜¯å¦‚ä½•æé«˜é€™äº›å¤©ç„¶ç”¢å“çš„æŠ—ç™Œæ•ˆæœï¼Œä»¥æœŸæ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œç‰¹åˆ¥æ˜¯é‡å°é›£ä»¥æ²»ç™‚çš„ä¸‰é™°æ€§ä¹³ç™Œã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆåˆæˆäº†15ç¨®æ–°å‹çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨é«”å¤–æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸åŒçš„ç´°èƒç³»ä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©çš„æŠ—å¢æ®–æ´»æ€§ï¼Œä¸¦é€²è¡Œäº†ç´°èƒå¢æ®–ã€å…‹éš†å½¢æˆã€é·ç§»å’Œä¾µè¥²ç­‰å¤šé …å¯¦é©—ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œå°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„æŠ‘åˆ¶æ•ˆæœé¡¯è‘—ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aèƒ½å¤ ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™å¯èƒ½æ˜¯å…¶æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·çš„æ©Ÿåˆ¶ä¹‹ä¸€ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé‡å°ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®ä¾µç•¥æ€§å¼·çš„ç™Œç—‡é¡å‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚å‚³çµ±ä¸Šï¼Œé€™é¡ç™Œç—‡ä¸»è¦ä¾è³´åŒ–ç™‚ï¼Œä½†ç ”ç©¶é¡¯ç¤ºï¼ŒæŸäº›å¤©ç„¶ç”¢ç‰©å¦‚è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„åˆæˆæ··åˆç‰©å¯èƒ½å…·æœ‰æŠ—è…«ç˜¤æ´»æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†çš„æ²»ç™‚å¯èƒ½ä¸åƒ…é™æ–¼åŒ–ç™‚ï¼Œé‚„å¯ä»¥è€ƒæ…®ä½¿ç”¨é€™äº›å¤©ç„¶æˆåˆ†ä¾†é–‹ç™¼æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆï¼Œå¾è€Œæ”¹å–„æ‚£è€…çš„é å¾Œå’Œç”Ÿæ´»å“è³ªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼å’Œè©•ä¼°ä¸€ç³»åˆ—æ–°å‹çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œä»¥æ¢è¨å…¶åœ¨ä¸‰é™°æ€§ä¹³ç™Œä¸­çš„æŠ—ç™Œæ•ˆæœã€‚ç ”ç©¶è€…è¨­è¨ˆä¸¦åˆæˆäº†15ç¨®æ–°å‹çš„æ··åˆç‰©ï¼Œä¸¦é‡å°å…¶æŠ—ç™Œæ´»æ€§é€²è¡Œäº†è©•ä¼°ã€‚é€™é …ç ”ç©¶é—œæ³¨çš„å•é¡Œæ˜¯å¦‚ä½•æé«˜é€™äº›å¤©ç„¶ç”¢å“çš„æŠ—ç™Œæ•ˆæœï¼Œä»¥æœŸæ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œç‰¹åˆ¥æ˜¯é‡å°é›£ä»¥æ²»ç™‚çš„ä¸‰é™°æ€§ä¹³ç™Œã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆåˆæˆäº†15ç¨®æ–°å‹çš„æœ¨è˜­é…š-è˜¿è””ç¡«ç´ æ··åˆç‰©ï¼Œç„¶å¾Œåœ¨é«”å¤–æ¸¬è©¦é€™äº›åŒ–åˆç‰©å°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­ä½¿ç”¨äº†ä¸åŒçš„ç´°èƒç³»ä¾†è©•ä¼°é€™äº›åŒ–åˆç‰©çš„æŠ—å¢æ®–æ´»æ€§ï¼Œä¸¦é€²è¡Œäº†ç´°èƒå¢æ®–ã€å…‹éš†å½¢æˆã€é·ç§»å’Œä¾µè¥²ç­‰å¤šé …å¯¦é©—ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åœ¨å°é¼ æ¨¡å‹ä¸­é€²è¡Œäº†é«”å…§å¯¦é©—ï¼Œä»¥è§€å¯Ÿé€™äº›åŒ–åˆç‰©å°è…«ç˜¤ç”Ÿé•·çš„æŠ‘åˆ¶æ•ˆæœåŠå…¶æ½›åœ¨çš„æ¯’æ€§ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼ŒåŒ–åˆç‰©17aåœ¨æŠ—å¢æ®–æ´»æ€§æ–¹é¢è¡¨ç¾æœ€ä½³ï¼Œå°ä¸‰é™°æ€§ä¹³ç™Œç´°èƒçš„æŠ‘åˆ¶æ•ˆæœé¡¯è‘—ï¼Œä¸¦ä¸”åœ¨å°é¼ æ¨¡å‹ä¸­èƒ½æœ‰æ•ˆæŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·ï¼Œä¸”æœªè¦‹æ˜é¡¯æ¯’æ€§ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œ17aèƒ½å¤ ä¸‹èª¿èˆ‡æ ¸è‹·é…¸åˆ‡é™¤ä¿®å¾©å’ŒNF-ÎºBé€šè·¯ç›¸é—œçš„åŸºå› è¡¨é”ï¼Œé€™å¯èƒ½æ˜¯å…¶æŠ‘åˆ¶è…«ç˜¤ç”Ÿé•·çš„æ©Ÿåˆ¶ä¹‹ä¸€ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œ17aæœ‰æ½›åŠ›æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ²»ç™‚å€™é¸è—¥ç‰©ï¼Œå€¼å¾—é€²ä¸€æ­¥çš„è‡¨åºŠç ”ç©¶ã€‚",
    "fb_post": "ğŸŒ± æœ‰è½éè˜¿è””ç¡«ç´ å—ï¼Ÿé€™å¯ä¸æ˜¯æ™®é€šçš„é£Ÿæï¼Œå®ƒåœ¨å°æŠ—ä¸‰é™°æ€§ä¹³ç™Œï¼ˆTNBCï¼‰é€™ç¨®é ‘å›ºç™Œç—‡æ–¹é¢å¯èƒ½æœ‰æ–°å¸Œæœ›ï¼\n\næœ€è¿‘çš„ç ”ç©¶è®“æˆ‘å€‘çœ‹åˆ°äº†å¤©ç„¶æˆåˆ†çš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼é–‹ç™¼ä¸€ç¨®æ–°çš„æ··åˆç‰©ï¼Œå°‡è˜¿è””ç¡«ç´ å’Œå¦ä¸€ç¨®å«åšæœ¨è˜­é…šçš„æˆåˆ†çµåˆèµ·ä¾†ï¼Œç›®çš„æ˜¯æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹å¼ã€‚é€™å€‹éç¨‹ä¸­ï¼Œä»–å€‘åˆæˆäº†15ç¨®ä¸åŒçš„æ··åˆç‰©ï¼Œä¸¦åœ¨å¯¦é©—å®¤è£¡æ¸¬è©¦å®ƒå€‘å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚\n\nçµæœéå¸¸ä»¤äººæŒ¯å¥®ï¼å…¶ä¸­ä¸€ç¨®å«åš17açš„åŒ–åˆç‰©åœ¨æŠ‘åˆ¶ç™Œç´°èƒå¢æ®–æ–¹é¢è¡¨ç¾å¾—ç‰¹åˆ¥å¥½ï¼Œç”šè‡³åœ¨å°é¼ æ¨¡å‹ä¸­ä¹Ÿèƒ½æœ‰æ•ˆæ¸›å°‘è…«ç˜¤ç”Ÿé•·ï¼Œè€Œä¸”æ²’æœ‰æ˜é¡¯çš„æ¯’æ€§ã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†æˆ‘å€‘å¯èƒ½æœ‰æ©Ÿæœƒåˆ©ç”¨é€™äº›å¤©ç„¶æˆåˆ†ä¾†æ”¹å–„ç™Œç—‡æ²»ç™‚ã€‚\n\nğŸ” ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å’Œæœ¨è˜­é…šçš„æ··åˆç‰©å¯èƒ½æˆç‚ºä¸‰é™°æ€§ä¹³ç™Œçš„æ–°ç™‚æ³•ã€‚\n2. åŒ–åˆç‰©17aåœ¨å¯¦é©—ä¸­é¡¯ç¤ºå‡ºå„ªè¶Šçš„æŠ—ç™Œæ•ˆæœã€‚\n3. æœªä¾†çš„ç ”ç©¶å°‡é€²ä¸€æ­¥æ¢ç´¢é€™äº›å¤©ç„¶æˆåˆ†çš„æ½›åŠ›ï¼",
    "image_prompt": "Create a flat design infographic on a light background illustrating the experimental process and main results of a study on the anticancer effects of a combination of sulforaphane and magnolol. Include simple icons representing broccoli or sulforaphane, experimental subjects like simplified human, animal, or cell graphics, and arrows or flow lines to indicate experimental steps. Add a section labeled 'Main Results' highlighting protective effects or changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ä¸‰é™°æ€§ä¹³ç™Œ Triple-negative Breast Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40961586/"
  },
  {
    "id": "41108925",
    "title_en": "Enhancing myocardial injury recovery: Nrf2 activation by sulforaphane regulates ferroptosis and oxidative stress in takotsubo-like models.",
    "pub_date": "2025 Dec",
    "abstract_en": "Takotsubo syndrome (TTS), once considered benign, can cause life-threatening myocardial injury. Although oxidative stress and ferroptosis are implicated in its pathogenesis, targeted therapies are not available for TTS. We demonstrate that sulforaphane (SFN), a natural Nrf2 activator, mitigates TTS-related injury in isoproterenol-induced rat models and AC16 cardiomyocytes. Isoproterenol induced ferroptosis and oxidative stress by impairing Nrf2 signaling. SFN treatment restored myocardial structure and function while enhancing antioxidant capacity, reducing mitochondrial damage, and suppressing ferroptosis markers. Additionally, similar to Fer-1 (a ferroptosis inhibitor), SFN reduced intracellular ferrous levels but uniquely activated Nrf2-driven endogenous defenses. Notably, Nrf2 inhibition abrogated the benefits of SFN in both in vitro and in vivo experiments. These findings highlight SFN as a dual-action therapeutic for TTS, simultaneously targeting oxidative stress and ferroptosis via Nrf2 activation. The therapeutic efficacy of SFN, combined with endogenous pathway modulation, underscores its translational potential for improving TTS outcomes.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè‡Ÿå¥åº·æ–¹é¢ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‚Œæå‚·çš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°ç”Ÿå‘½é€ æˆå¨è„…ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•TTSç›¸é—œæå‚·æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æ²»ç™‚ä¸Šã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²å’Œæ²»ç™‚é€™ç¨®å¿ƒè‡Ÿç–¾ç—…ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®ç—‡å€™ç¾¤çš„ç—…ç†æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡åœ¨å…¶ä¸­çš„è§’è‰²ã€‚ç”±æ–¼ç›®å‰å°šç„¡é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ ä¾†æ”¹å–„å¿ƒè‚Œæå‚·çš„æƒ…æ³ï¼Œæˆç‚ºäº†é€™é …ç ”ç©¶çš„é‡é»ã€‚ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨å¿ƒè‡Ÿå¥åº·æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ²»ç™‚æä¾›ä¾æ“šã€‚",
    "para3": "é€™é …å¯¦é©—ä¸»è¦ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒç³»AC16ä¾†é€²è¡Œç ”ç©¶ã€‚ç ”ç©¶è€…ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°TTSçš„ç—‡ç‹€ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„å¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦å•Ÿå‹•Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚åŠ‘ï¼Œå¯èƒ½åœ¨æ”¹å–„TTSçš„çµæœä¸Šå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨å¿ƒè‡Ÿå¥åº·æ–¹é¢ã€‚Takotsuboç—‡å€™ç¾¤ï¼ˆTTSï¼‰æ˜¯ä¸€ç¨®å¯èƒ½å°è‡´å¿ƒè‚Œæå‚·çš„ç–¾ç—…ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå°ç”Ÿå‘½é€ æˆå¨è„…ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨æ¸›è¼•TTSç›¸é—œæå‚·æ–¹é¢çš„æ½›åŠ›ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨é‡å°æ°§åŒ–å£“åŠ›å’Œç´°èƒæ­»äº¡çš„æ²»ç™‚ä¸Šã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½å¤ æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²å’Œæ²»ç™‚é€™ç¨®å¿ƒè‡Ÿç–¾ç—…ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°Takotsuboç—‡å€™ç¾¤çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯é€™ç¨®ç—‡å€™ç¾¤çš„ç—…ç†æ©Ÿåˆ¶ï¼Œç‰¹åˆ¥æ˜¯æ°§åŒ–å£“åŠ›å’Œéµæ­»äº¡åœ¨å…¶ä¸­çš„è§’è‰²ã€‚ç”±æ–¼ç›®å‰å°šç„¡é‡å°TTSçš„ç‰¹å®šæ²»ç™‚æ–¹æ³•ï¼Œå› æ­¤äº†è§£å¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªå¦‚è˜¿è””ç¡«ç´ ä¾†æ”¹å–„å¿ƒè‚Œæå‚·çš„æƒ…æ³ï¼Œæˆç‚ºäº†é€™é …ç ”ç©¶çš„é‡é»ã€‚ç ”ç©¶å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨å¿ƒè‡Ÿå¥åº·æ–¹é¢çš„æ½›åœ¨æ‡‰ç”¨ï¼Œä¸¦ç‚ºæœªä¾†çš„è‡¨åºŠæ²»ç™‚æä¾›ä¾æ“šã€‚\n\né€™é …å¯¦é©—ä¸»è¦ä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒç³»AC16ä¾†é€²è¡Œç ”ç©¶ã€‚ç ”ç©¶è€…ä½¿ç”¨ç•°ä¸™è…ä¸Šè…ºç´ ä¾†èª˜å°TTSçš„ç—‡ç‹€ï¼Œä¸¦è§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…è©•ä¼°äº†å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸¬é‡äº†æŠ—æ°§åŒ–èƒ½åŠ›ã€ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚é€éé€™äº›æ–¹æ³•ï¼Œç ”ç©¶è€…èƒ½å¤ äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å¿ƒè‡Ÿç´°èƒçš„å¥åº·ï¼Œä¸¦æ¢è¨å…¶æ½›åœ¨çš„æ²»ç™‚æ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç·šç²’é«”æå‚·å’Œéµæ­»äº¡çš„æ¨™è¨˜ç‰©ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é™ä½ç´°èƒå…§çš„äºéµæ°´å¹³ï¼Œä¸¦å•Ÿå‹•Nrf2é©…å‹•çš„å…§æºæ€§é˜²ç¦¦æ©Ÿåˆ¶ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œç•¶æŠ‘åˆ¶Nrf2æ™‚ï¼Œè˜¿è””ç¡«ç´ çš„ç™‚æ•ˆæœƒå—åˆ°å½±éŸ¿ï¼Œé€™è¡¨æ˜Nrf2åœ¨å…¶æ²»ç™‚ä½œç”¨ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚é€™äº›çµæœçªé¡¯äº†è˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®é›™é‡ä½œç”¨çš„æ²»ç™‚åŠ‘ï¼Œå¯èƒ½åœ¨æ”¹å–„TTSçš„çµæœä¸Šå…·æœ‰æ½›åœ¨çš„æ‡‰ç”¨åƒ¹å€¼ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿå¿ƒè‡Ÿä¹Ÿæœƒå—åˆ°å£“åŠ›å½±éŸ¿ï¼Œå°±åƒæˆ‘å€‘ä¸€æ¨£ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶ç‰©è³ªå¯èƒ½å°å¿ƒè‡Ÿå¥åº·æœ‰å¹«åŠ©ï¼Œç‰¹åˆ¥æ˜¯å°ä¸€ç¨®å«åšTakotsuboç—‡å€™ç¾¤ï¼ˆç°¡ç¨±TTSï¼‰çš„ç—…ç—‡ã€‚é€™ç¨®ç—…ç—‡æœƒå°è‡´å¿ƒè‚Œæå‚·ï¼Œé›–ç„¶éå»è¢«èªç‚ºæ˜¯è‰¯æ€§çš„ï¼Œä½†å¯¦éš›ä¸Šå¯èƒ½æœƒå±åŠç”Ÿå‘½ã€‚\n\né€™é …ç ”ç©¶çš„åœ˜éšŠä½¿ç”¨äº†å¤§é¼ æ¨¡å‹å’Œå¿ƒè‡Ÿç´°èƒä¾†é€²è¡Œå¯¦é©—ã€‚ä»–å€‘ç”¨ä¸€ç¨®è—¥ç‰©ä¾†èª˜ç™¼TTSçš„ç—‡ç‹€ï¼Œç„¶å¾Œè§€å¯Ÿè˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æ”¹å–„å¿ƒè‚Œçš„çµæ§‹å’ŒåŠŸèƒ½ï¼Œé‚„èƒ½å¢å¼·æŠ—æ°§åŒ–èƒ½åŠ›ï¼Œæ¸›å°‘ç´°èƒæå‚·ã€‚\n\né€™äº›ç™¼ç¾è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ åœ¨å¿ƒè‡Ÿå¥åº·æ–¹é¢çš„æ½›åŠ›å……æ»¿æœŸå¾…ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¿ƒè‡Ÿç–¾ç—…æœ‰ä¿è­·ä½œç”¨ã€‚\n2. å®ƒèƒ½æ”¹å–„å¿ƒè‚Œçµæ§‹å’ŒåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç´°èƒæå‚·ã€‚\n3. Nrf2é€™å€‹å› å­åœ¨è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚",
    "image_prompt": "Create a flat design infographic explaining the experimental methods and main results of a study on the effects of sulforaphane on Takotsubo syndrome. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like rats or heart cells, and arrows or flow lines to indicate the steps of the experiment. Additionally, include a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Takotsuboç—‡å€™ç¾¤ Takotsubo Syndrome",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41108925/"
  },
  {
    "id": "41340527",
    "title_en": "Metabolomics and Transcriptomics Analyses Reveal the Mechanisms of Sulforaphane Conversion and Adaptive Strategies in the Absence of Glucose by <i>Lactiplantibacillus plantarum</i>.",
    "pub_date": "2025 Dec",
    "abstract_en": "Sulforaphane is a beneficial but unstable bioactive compound that can be converted from glucoraphanin by <i>Lactiplantibacillus plantarum</i>. However, the sulforaphane conversion rate is low, and the conversion mechanism of <i>L. plantarum</i> remains unclear. This research utilized the adaptive laboratory evolution technology to enhance the sulforaphane conversion rate of <i>L. plantarum</i>. The results showed that an increase in the glucose replacement ratio significantly downregulated carbohydrate metabolism and upregulated amino acid metabolism. Transcriptomic analysis showed that the ALE-adapted strain significantly upregulated carbohydrate metabolism and amino acid metabolism. In the conversion pathway, glucoraphanin is imported into <i>L. plantarum</i> cells, and its glucose moiety is phosphorylated by bglF (the phosphate group may be derived from phosphoenolpyruvate via the phosphotransferase system). Subsequently, the S-glycosidic bond of phosphorylated glucoraphanin is hydrolyzed by bglA (6-phospho-Î²-glucosidase), followed by nonenzymatic rearrangement and sulfate elimination, ultimately yielding sulforaphane. This research can contribute to revealing the interaction mechanism between microorganisms and natural active substances.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°äººé«”æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé›–ç„¶å®ƒçš„ç©©å®šæ€§è¼ƒå·®ï¼Œä½†å¦‚æœèƒ½æœ‰æ•ˆæé«˜å…¶è½‰æ›ç‡ï¼Œå¯èƒ½æœƒå¢å¼·å…¶åœ¨å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ä¸­çš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¾®ç”Ÿç‰©çš„å¹«åŠ©ï¼Œåƒé’èŠ±æ¤°èœé€™é¡å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœƒåœ¨æœªä¾†çš„é£²é£Ÿä¸­ç™¼æ®æ›´å¤§çš„ä½œç”¨ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æŸäº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ä»£è¬æœ‰é—œçš„å¥åº·å•é¡Œã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸€ç¨®åç‚ºä¹³é…¸èŒçš„å¾®ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯Lactiplantibacillus plantarumï¼Œé€™ç¨®ç´°èŒèƒ½å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”åŒ–åˆç‰©ï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ ã€‚ç”±æ–¼ç›®å‰çš„è½‰æ›æ•ˆç‡ä¸é«˜ï¼Œç ”ç©¶è€…å¸Œæœ›é€éå¯¦é©—ä¾†æ­ç¤ºé€™å€‹è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾åˆ°æå‡è½‰æ›ç‡çš„æ–¹æ³•ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®åç‚ºé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“çš„æ–¹å¼ï¼Œä¾†æ”¹é€²Lactiplantibacillus plantarumçš„æ€§èƒ½ã€‚ä»–å€‘è§€å¯Ÿäº†åœ¨ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡ä¸‹ï¼Œé€™ç¨®ç´°èŒçš„ä»£è¬è®ŠåŒ–ã€‚ç ”ç©¶è€…åˆ†æäº†ç´°èŒçš„è½‰éŒ„çµ„ï¼Œé€™æ¨£å¯ä»¥äº†è§£åœ¨è½‰æ›éç¨‹ä¸­ï¼Œç´°èŒå¦‚ä½•èª¿æ•´å…¶ä»£è¬è·¯å¾‘ï¼Œä»¥æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡æé«˜æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­ï¼Œå¯èƒ½æœƒæ”¹è®Šå…¶ä»£è¬ç­–ç•¥ï¼Œä»¥ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚é€™äº›çµæœä¸åƒ…æœ‰åŠ©æ–¼ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„äº’å‹•æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å°äººé«”æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œé›–ç„¶å®ƒçš„ç©©å®šæ€§è¼ƒå·®ï¼Œä½†å¦‚æœèƒ½æœ‰æ•ˆæé«˜å…¶è½‰æ›ç‡ï¼Œå¯èƒ½æœƒå¢å¼·å…¶åœ¨å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²ä¸­çš„æ½›åŠ›ã€‚é€™æ„å‘³è‘—ï¼Œé€éå¾®ç”Ÿç‰©çš„å¹«åŠ©ï¼Œåƒé’èŠ±æ¤°èœé€™é¡å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¯èƒ½æœƒåœ¨æœªä¾†çš„é£²é£Ÿä¸­ç™¼æ®æ›´å¤§çš„ä½œç”¨ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æŸäº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ä»£è¬æœ‰é—œçš„å¥åº·å•é¡Œã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•æé«˜é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯ä¸€ç¨®åç‚ºä¹³é…¸èŒçš„å¾®ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯Lactiplantibacillus plantarumï¼Œé€™ç¨®ç´°èŒèƒ½å°‡é’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®å‰é«”åŒ–åˆç‰©ï¼ˆè‘¡è„ç³–è‹·é…¸ï¼‰è½‰æ›ç‚ºè˜¿è””ç¡«ç´ ã€‚ç”±æ–¼ç›®å‰çš„è½‰æ›æ•ˆç‡ä¸é«˜ï¼Œç ”ç©¶è€…å¸Œæœ›é€éå¯¦é©—ä¾†æ­ç¤ºé€™å€‹è½‰æ›éç¨‹çš„æ©Ÿåˆ¶ï¼Œä¸¦æ‰¾åˆ°æå‡è½‰æ›ç‡çš„æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®åç‚ºé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“çš„æ–¹å¼ï¼Œä¾†æ”¹é€²Lactiplantibacillus plantarumçš„æ€§èƒ½ã€‚ä»–å€‘è§€å¯Ÿäº†åœ¨ä¸åŒçš„è‘¡è„ç³–æ›¿ä»£æ¯”ç‡ä¸‹ï¼Œé€™ç¨®ç´°èŒçš„ä»£è¬è®ŠåŒ–ã€‚ç ”ç©¶è€…åˆ†æäº†ç´°èŒçš„è½‰éŒ„çµ„ï¼Œé€™æ¨£å¯ä»¥äº†è§£åœ¨è½‰æ›éç¨‹ä¸­ï¼Œç´°èŒå¦‚ä½•èª¿æ•´å…¶ä»£è¬è·¯å¾‘ï¼Œä»¥æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç•¶è‘¡è„ç³–æ›¿ä»£æ¯”ç‡æé«˜æ™‚ï¼Œç´°èŒçš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬é¡¯è‘—ä¸‹é™ï¼Œè€Œæ°¨åŸºé…¸ä»£è¬å‰‡ä¸Šå‡ã€‚é€™è¡¨æ˜ç´°èŒåœ¨é©æ‡‰éç¨‹ä¸­ï¼Œå¯èƒ½æœƒæ”¹è®Šå…¶ä»£è¬ç­–ç•¥ï¼Œä»¥ä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚é€™äº›çµæœä¸åƒ…æœ‰åŠ©æ–¼ç†è§£å¾®ç”Ÿç‰©èˆ‡å¤©ç„¶æ´»æ€§ç‰©è³ªä¹‹é–“çš„äº’å‹•æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°çš„æ€è·¯ã€‚",
    "fb_post": "ğŸ½ï¸ ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åƒ…ç¾å‘³ï¼Œé‚„å¯èƒ½æ˜¯æˆ‘å€‘å¥åº·çš„ç§˜å¯†æ­¦å™¨ï¼é€™ç¯‡ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®å°äººé«”æœ‰ç›Šçš„åŒ–åˆç‰©ï¼Œèƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—ä¸€äº›ç–¾ç—…ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ä»£è¬æœ‰é—œçš„å•é¡Œã€‚  \n  \né€™é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•æå‡é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚ç ”ç©¶è€…ç™¼ç¾ä¸€ç¨®å«åšä¹³é…¸èŒçš„ç´°èŒï¼Œèƒ½æŠŠé’èŠ±æ¤°èœä¸­çš„ä¸€ç¨®åŒ–åˆç‰©è½‰æ›æˆè˜¿è””ç¡«ç´ ã€‚é›–ç„¶ç›®å‰çš„è½‰æ›æ•ˆç‡ä¸é«˜ï¼Œä½†ç§‘å­¸å®¶å€‘å¸Œæœ›é€éå¯¦é©—ä¾†æ­ç¤ºé€™å€‹éç¨‹çš„é‹ä½œæ–¹å¼ï¼Œä¸¦æ‰¾åˆ°æå‡è½‰æ›ç‡çš„æ–¹æ³•ã€‚  \n  \nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘ä½¿ç”¨äº†ä¸€ç¨®å«åšé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ï¼Œä¾†æ”¹é€²é€™ç¨®ç´°èŒçš„æ€§èƒ½ã€‚ä»–å€‘è§€å¯Ÿåˆ°ï¼Œç•¶ç´°èŒåœ¨ä¸åŒçš„ç’°å¢ƒä¸‹ç”Ÿé•·æ™‚ï¼Œå®ƒå€‘çš„ä»£è¬æœƒç™¼ç”Ÿè®ŠåŒ–ï¼Œé€™æœ‰åŠ©æ–¼æé«˜è˜¿è””ç¡«ç´ çš„ç”¢é‡ã€‚  \n  \næœ€çµ‚çš„çµæœé¡¯ç¤ºï¼Œç•¶ç’°å¢ƒä¸­æŸäº›æˆåˆ†çš„æ¯”ä¾‹æé«˜æ™‚ï¼Œç´°èŒæœƒæ”¹è®Šå®ƒå€‘çš„ä»£è¬ç­–ç•¥ï¼Œä¿ƒé€²è˜¿è””ç¡«ç´ çš„ç”Ÿæˆã€‚é€™ä¸åƒ…å¹«åŠ©æˆ‘å€‘ç†è§£å¾®ç”Ÿç‰©å¦‚ä½•èˆ‡å¤©ç„¶ç‰©è³ªäº’å‹•ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å¥åº·ç”¢å“é–‹ç™¼æä¾›æ–°æ€è·¯ã€‚  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å°å¥åº·æœ‰æ½›åœ¨ç›Šè™•ï¼Œå°¤å…¶æ˜¯å°æŠ—ä»£è¬å•é¡Œã€‚  \n2. ä¹³é…¸èŒèƒ½æå‡é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ è½‰æ›ç‡ã€‚  \n3. ç ”ç©¶çµæœæœ‰åŠ©æ–¼æœªä¾†å¥åº·ç”¢å“çš„é–‹ç™¼ã€‚  \n  \nè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…é€™äº›å¥åº·æ–°ç™¼ç¾å§ï¼",
    "image_prompt": "Create an infographic that explains the experimental process and main results of a study on sulforaphane from broccoli. Include simplified illustrations of broccoli and sulforaphane, a representation of the bacteria Lactiplantibacillus plantarum, and arrows or flow lines showing the experimental steps. Add a section labeled 'Main Results' highlighting the increase in sulforaphane production and the metabolic changes of the bacteria. Use a flat design style with a light background and soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41340527/"
  },
  {
    "id": "41341174",
    "title_en": "Sulforaphane attenuates oxidative stress, senescence, and ferroptosis induced by cigarette smoke extract <i>in vitro</i> and <i>in vivo via</i> upregulating the expression of SIRT1.",
    "pub_date": "2025 Dec",
    "abstract_en": "Cigarette smoking induces lung toxicity by triggering oxidative stress, leading to apoptosis, ferroptosis, and senescence. Sulforaphane (SFN), a potent antioxidant, activates the SIRT1 pathway, enhancing cellular stress resistance and survival. This study aimed to evaluate the protective effects of SFN against cigarette smoke extract (CSE)-induced damage in human airway epithelial cells (BEAS-2B) and in mouse lungs, focusing on its role in upregulating SIRT1 expression. BEAS-2B cells were treated with CSE and SFN, and cell viability was assessed using the MTT assay. Cellular senescence was assessed using the SA-Î²-gal assay and the expression of genes associated with senescence (p16 and p21). The expression levels of SIRT1, senescence-associated secretory phenotype (SASP) cytokines (IL-1Î², IL-6, IL-8, TNF-Î±), GPX4, and SLC7A11 were quantified using qRT-PCR. Additionally, ROS production, GSH and MDA levels, and iron content were measured. An emphysema mouse model was induced by intraperitoneal administration of CSE (7.2 mg/kg) alone or in combination with SFN (10.2 mg/kg) over 28 days, and subsequent histopathological changes were evaluated. Our findings revealed that SFN co-treatment effectively mitigated CSE-induced cytotoxicity, senescence, and SASP cytokine secretion, as well as the pronounced emphysematous changes in lung tissues. Furthermore, SFN reversed CSE-induced downregulation of SIRT1 and upregulation of NF-ÎºB. Notably, SFN also inhibited CSE-induced ferroptosis by increasing GPX4 and SLC7A11 expression while reducing iron and MDA levels. The findings of the present study demonstrated that sulforaphane offers protective effects against CSE-induced toxicity by mitigating oxidative stress, ferroptosis, and cellular senescence.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸è¸æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·ã€‚å¸è¸æœƒå°è‡´æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå¼•ç™¼ç´°èƒæ­»äº¡å’Œè€åŒ–ç­‰å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³å½±éŸ¿ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨å¥åº·ã€‚é€™å°æ–¼å¸è¸è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·è¨Šæ¯ï¼Œæç¤ºä»–å€‘å¯ä»¥é€éæŸäº›é£Ÿç‰©æˆåˆ†ä¾†æ”¹å–„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘å¸è¸å¸¶ä¾†çš„é¢¨éšªã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸è¸æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸è¸æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸Šèª¿SIRT1è¡¨é”ä¾†ç™¼æ®ä½œç”¨ã€‚é€™å€‹ç ”ç©¶ä¸åƒ…é—œå¿ƒç´°èƒå±¤é¢çš„è®ŠåŒ–ï¼Œé‚„æ¶‰åŠåˆ°æ•´é«”ç”Ÿç‰©é«”çš„åæ‡‰ï¼Œè©¦åœ–æ‰¾å‡ºæœ‰æ•ˆçš„ä¿è­·æ©Ÿåˆ¶ï¼Œä»¥æ‡‰å°å¸è¸é€ æˆçš„å¥åº·å¨è„…ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸è¸æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ©ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–æƒ…æ³ï¼Œä¸¦é€éqRT-PCRæ¸¬é‡èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†CSEèª˜å°çš„è‚ºæ°£è…«æ¨¡å‹ï¼Œè§€å¯Ÿåœ¨ä¸åŒè™•ç†ä¸‹çš„çµ„ç¹”è®ŠåŒ–ï¼Œé€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸è¸æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰å¸è¸æå–ç‰©å°SIRT1çš„ä¸‹èª¿åŠNF-ÎºBçš„ä¸Šèª¿ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶å¸è¸æå–ç‰©å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ï¼ŒåŒæ™‚é™ä½äº†éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°å¸è¸æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·ã€‚å¸è¸æœƒå°è‡´æ°§åŒ–å£“åŠ›ï¼Œé€²è€Œå¼•ç™¼ç´°èƒæ­»äº¡å’Œè€åŒ–ç­‰å•é¡Œã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä½œç‚ºä¸€ç¨®å¼·æ•ˆæŠ—æ°§åŒ–åŠ‘ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘é€™äº›æœ‰å®³å½±éŸ¿ï¼Œå¾è€Œä¿è­·è‚ºéƒ¨å¥åº·ã€‚é€™å°æ–¼å¸è¸è€…æˆ–é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººä¾†èªªï¼Œå¯èƒ½æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·è¨Šæ¯ï¼Œæç¤ºä»–å€‘å¯ä»¥é€éæŸäº›é£Ÿç‰©æˆåˆ†ä¾†æ”¹å–„å¥åº·ç‹€æ³ï¼Œæ¸›å°‘å¸è¸å¸¶ä¾†çš„é¢¨éšªã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°æ–¼å¸è¸æ‰€å¼•èµ·çš„è‚ºéƒ¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œæ³¨çš„æ˜¯å¸è¸æå–ç‰©å°äººé¡æ°£é“ä¸Šçš®ç´°èƒåŠå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•é€éä¸Šèª¿SIRT1è¡¨é”ä¾†ç™¼æ®ä½œç”¨ã€‚é€™å€‹ç ”ç©¶ä¸åƒ…é—œå¿ƒç´°èƒå±¤é¢çš„è®ŠåŒ–ï¼Œé‚„æ¶‰åŠåˆ°æ•´é«”ç”Ÿç‰©é«”çš„åæ‡‰ï¼Œè©¦åœ–æ‰¾å‡ºæœ‰æ•ˆçš„ä¿è­·æ©Ÿåˆ¶ï¼Œä»¥æ‡‰å°å¸è¸é€ æˆçš„å¥åº·å¨è„…ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†BEAS-2Bäººé¡æ°£é“ä¸Šçš®ç´°èƒå’Œå°é¼ ä½œç‚ºå¯¦é©—å°è±¡ã€‚BEAS-2Bç´°èƒè¢«è™•ç†äº†å¸è¸æå–ç‰©å’Œè˜¿è””ç¡«ç´ ï¼Œä¸¦ä½¿ç”¨MTTæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒçš„å­˜æ´»ç‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„åˆ©ç”¨SA-Î²-galæ¸¬è©¦ä¾†è©•ä¼°ç´°èƒè€åŒ–æƒ…æ³ï¼Œä¸¦é€éqRT-PCRæ¸¬é‡èˆ‡è€åŒ–ç›¸é—œçš„åŸºå› è¡¨é”ã€‚å°æ–¼å°é¼ ï¼Œç ”ç©¶è€…å‰‡ä½¿ç”¨äº†CSEèª˜å°çš„è‚ºæ°£è…«æ¨¡å‹ï¼Œè§€å¯Ÿåœ¨ä¸åŒè™•ç†ä¸‹çš„çµ„ç¹”è®ŠåŒ–ï¼Œé€™æ¨£çš„è¨­è¨ˆæœ‰åŠ©æ–¼å…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„å…±åŒè™•ç†èƒ½æœ‰æ•ˆæ¸›å°‘å¸è¸æå–ç‰©å¼•èµ·çš„ç´°èƒæ¯’æ€§ã€è€åŒ–åŠç›¸é—œç´°èƒå› å­çš„åˆ†æ³Œï¼Œä¸¦æ”¹å–„å°é¼ è‚ºéƒ¨çš„è‚ºæ°£è…«è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰å¸è¸æå–ç‰©å°SIRT1çš„ä¸‹èª¿åŠNF-ÎºBçš„ä¸Šèª¿ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶å¸è¸æå–ç‰©å¼•èµ·çš„éµæ­»äº¡ï¼Œé€™æ˜¯é€éæé«˜GPX4å’ŒSLC7A11çš„è¡¨é”ä¾†å¯¦ç¾çš„ï¼ŒåŒæ™‚é™ä½äº†éµå’ŒMDAçš„æ°´å¹³ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½åœ¨æ¸›è¼•æ°§åŒ–å£“åŠ›ã€éµæ­»äº¡å’Œç´°èƒè€åŒ–æ–¹é¢å…·æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ é€™å€‹å°æˆåˆ†ï¼Œå¯èƒ½å°å¸è¸é€ æˆçš„è‚ºéƒ¨æå‚·æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©ä¿è­·æˆ‘å€‘çš„è‚ºéƒ¨ï¼Œç‰¹åˆ¥æ˜¯å°å¸è¸è€…ä¾†èªªï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—æ³¨æ„çš„å¥åº·è¨Šæ¯ã€‚  \n ç ”ç©¶è€…å€‘è§€å¯Ÿäº†å¸è¸æå–ç‰©å°äººé¡æ°£é“ç´°èƒå’Œå°é¼ è‚ºéƒ¨çš„å½±éŸ¿ï¼Œä¸¦ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é€éèª¿ç¯€æŸäº›åŸºå› çš„è¡¨é”ä¾†ç™¼æ®ä½œç”¨ã€‚ä»–å€‘ä½¿ç”¨äº†ç´°èƒå¯¦é©—å’Œå°é¼ æ¨¡å‹ï¼Œä¾†äº†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨ä¿è­·æ•ˆæœã€‚  \n å¯¦é©—çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæ¸›å°‘å¸è¸å¼•èµ·çš„ç´°èƒæ¯’æ€§å’Œè€åŒ–ï¼Œä¸¦æ”¹å–„å°é¼ çš„è‚ºéƒ¨ç‹€æ³ã€‚æ­¤å¤–ï¼Œå®ƒé‚„èƒ½æŠ‘åˆ¶å¸è¸æå–ç‰©å¼•èµ·çš„æ°§åŒ–å£“åŠ›ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘çš„è‚ºéƒ¨å¯èƒ½å› ç‚ºé€™å€‹æˆåˆ†è€Œè®Šå¾—æ›´å¥åº·ï¼  \n é‡è¦çš„å¹¾é»ï¼š  \n- è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¸è¸å¸¶ä¾†çš„è‚ºéƒ¨æå‚·ã€‚  \n- å®ƒèƒ½æ”¹å–„ç´°èƒçš„å¥åº·ç‹€æ…‹ï¼Œæ¸›å°‘è€åŒ–ã€‚  \n- å°æ–¼é•·æœŸæ¥è§¸äºŒæ‰‹ç…™çš„äººï¼Œé€™æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„é£Ÿç‰©æˆåˆ†ï¼",
    "image_prompt": "Create an infographic that explains the experimental methods and main results of a study on the protective effects of sulforaphane against smoking-related lung damage. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, and cells, arrows or flow lines to indicate the experimental steps, and a section highlighting 'Main Results' such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚ºæ°£è…« Emphysema",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41341174/"
  },
  {
    "id": "41039785",
    "title_en": "Integrative Network Pharmacology and Proteomics Decipher the Immunomodulatory Mechanism of Sulforaphane Against Intrinsic Skin Aging.",
    "pub_date": "2025 Dec",
    "abstract_en": "Skin aging is characterized by declines in structural functions, contributing to age-associated frailty. Sulforaphane (SFN), a natural anti-inflammatory substance, has been widely applied in multiple types of cancer therapies. However, its role in alleviating intrinsic skin aging remains to be elucidated. Integrative network pharmacology and proteomics were utilized to investigate the underlying mechanisms of SFN in intrinsic skin aging. Fifty-one anti-aging targets of SFN were identified, highlighting its promising regulatory impact on the aging process. Based on an 18-month-old natural aging mouse model, significant alleviation in skin structure, redox homeostasis, and immune cell composition was noted after 2 months of SFN supplementation. Additionally, proteomic analysis demonstrated that SFN reversed the proteomic profile of intrinsic skin aging, with 233 differentially expressed proteins (DEPs) identified in SFN-fed aging mice. Of note, the up-regulated DEPs were highly enriched in the apelin signaling pathway (pÂ =Â 0.010). Furthermore, immune cell infiltration and whole blood cell analysis revealed that SFN rescued T cells depletion in dermal tissue, which was strongly correlated with DEPs enriched in the SFN-activated apelin signaling pathway. SFN improves skin morphology and immune functions via activating the apelin signaling pathway, suggesting new prime targets in counteracting intrinsic skin aging.",
    "para1": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åœ¨ä½œç”¨ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡è€å¹´äººçš„ç”Ÿæ´»å“è³ªï¼Œæ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šå•é¡Œï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ï¼Œä½†å…¶å°æ–¼çš®è†šè€åŒ–çš„å½±éŸ¿å°šæœªè¢«å……åˆ†äº†è§£ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œæ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„ç”Ÿç‰©å­¸éç¨‹ï¼Œä¸¦æ‰¾å‡ºå…¶æ½›åœ¨çš„æŠ—è€åŒ–ç›®æ¨™ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¸¦é€šéæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ä¾†é€²è¡Œå¯¦é©—ã€‚ç ”ç©¶è€…é¦–å…ˆç¢ºå®šäº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„è˜¿è””ç¡«ç´ é¶é»ï¼Œæ¥è‘—å°å°é¼ é€²è¡Œç‚ºæœŸå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……ï¼Œè§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éè˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹æ˜é¡¯æ”¹å–„ï¼Œä¸”æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆä¹Ÿæœ‰æ‰€æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»è©²ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "éš¨è‘—å¹´é½¡å¢é•·ï¼Œçš®è†šçš„çµæ§‹åŠŸèƒ½æœƒé€æ¼¸ä¸‹é™ï¼Œé€™å¯èƒ½å°è‡´èˆ‡å¹´é½¡ç›¸é—œçš„è„†å¼±æ€§ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®å¤©ç„¶æŠ—ç™¼ç‚ç‰©è³ªåœ¨æ¸›ç·©å…§åœ¨çš®è†šè€åŒ–æ–¹é¢çš„æ½›åœ¨ä½œç”¨ï¼Œé€™å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰è‘—é‡è¦çš„å•Ÿç¤ºã€‚è‹¥èƒ½æœ‰æ•ˆæ”¹å–„çš®è†šè€åŒ–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æå‡è€å¹´äººçš„ç”Ÿæ´»å“è³ªï¼Œæ¸›å°‘èˆ‡å¹´é½¡ç›¸é—œçš„çš®è†šå•é¡Œï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å…§åœ¨çš®è†šè€åŒ–éç¨‹ä¸­çš„ä½œç”¨åŠå…¶æ©Ÿåˆ¶ã€‚é›–ç„¶è˜¿è””ç¡«ç´ å·²è¢«å»£æ³›æ‡‰ç”¨æ–¼å¤šç¨®ç™Œç—‡æ²»ç™‚ï¼Œä½†å…¶å°æ–¼çš®è†šè€åŒ–çš„å½±éŸ¿å°šæœªè¢«å……åˆ†äº†è§£ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™é …ç ”ç©¶ï¼Œæ­ç¤ºè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„ç”Ÿç‰©å­¸éç¨‹ï¼Œä¸¦æ‰¾å‡ºå…¶æ½›åœ¨çš„æŠ—è€åŒ–ç›®æ¨™ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†18å€‹æœˆå¤§çš„è‡ªç„¶è€åŒ–å°é¼ æ¨¡å‹ï¼Œä¸¦é€šéæ•´åˆç¶²çµ¡è—¥ç†å­¸å’Œè›‹ç™½è³ªçµ„å­¸çš„æ–¹æ³•ä¾†é€²è¡Œå¯¦é©—ã€‚ç ”ç©¶è€…é¦–å…ˆç¢ºå®šäº†51å€‹èˆ‡æŠ—è€åŒ–ç›¸é—œçš„è˜¿è””ç¡«ç´ é¶é»ï¼Œæ¥è‘—å°å°é¼ é€²è¡Œç‚ºæœŸå…©å€‹æœˆçš„è˜¿è””ç¡«ç´ è£œå……ï¼Œè§€å¯Ÿå…¶å°çš®è†šçµæ§‹ã€æ°§åŒ–é‚„åŸå¹³è¡¡åŠå…ç–«ç´°èƒçµ„æˆçš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œç¶“éè˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œå°é¼ çš„çš®è†šçµæ§‹æ˜é¡¯æ”¹å–„ï¼Œä¸”æ°§åŒ–é‚„åŸå¹³è¡¡å’Œå…ç–«ç´°èƒçµ„æˆä¹Ÿæœ‰æ‰€æ”¹å–„ã€‚è›‹ç™½è³ªçµ„å­¸åˆ†æç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½é€†è½‰å…§åœ¨çš®è†šè€åŒ–çš„è›‹ç™½è³ªçµ„ç‰¹å¾µï¼Œä¸¦è­˜åˆ¥å‡º233ç¨®å·®ç•°è¡¨é”çš„è›‹ç™½è³ªã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™äº›ä¸Šèª¿çš„è›‹ç™½è³ªåœ¨apelinä¿¡è™Ÿé€šè·¯ä¸­é«˜åº¦å¯Œé›†ï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½é€éæ¿€æ´»è©²ä¿¡è™Ÿé€šè·¯ä¾†æ”¹å–„çš®è†šå½¢æ…‹å’Œå…ç–«åŠŸèƒ½ï¼Œç‚ºå°æŠ—å…§åœ¨çš®è†šè€åŒ–æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "ğŸŒ± è½èªªè˜¿è””ä¹Ÿèƒ½å¹«æˆ‘å€‘çš„çš®è†šè®Šå¹´è¼•ï¼Ÿ\n\néš¨è‘—å¹´ç´€å¢é•·ï¼Œçš®è†šæœƒæ¼¸æ¼¸å¤±å»å½ˆæ€§ï¼Œé€™è®“å¾ˆå¤šäººæ„Ÿåˆ°å›°æ“¾ã€‚ä¸éï¼Œæœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶ç‰©è³ªï¼Œå¯èƒ½å°æŠ—çš®è†šè€åŒ–æœ‰å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿çš®è†šè€åŒ–çš„éç¨‹ã€‚ç ”ç©¶è€…ä½¿ç”¨äº†18å€‹æœˆå¤§çš„å°é¼ ï¼Œä¸¦é€éå¯¦é©—ä¾†äº†è§£è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œç¶“éå…©å€‹æœˆçš„è£œå……ï¼Œé€™äº›å°é¼ çš„çš®è†šçµæ§‹æ˜é¡¯æ”¹å–„ï¼Œç”šè‡³å…ç–«ç³»çµ±ä¹Ÿè®Šå¾—æ›´å¥åº·ï¼\n\næœ€æœ‰è¶£çš„æ˜¯ï¼Œç ”ç©¶é‚„ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½é€†è½‰çš®è†šè€åŒ–çš„ç‰¹å¾µï¼Œä¸¦ä¸”è­˜åˆ¥å‡º233ç¨®èˆ‡çš®è†šå¥åº·ç›¸é—œçš„è›‹ç™½è³ªã€‚é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„æŠ—è€åŒ–ç ”ç©¶æä¾›äº†æ–°çš„æ–¹å‘ï¼\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„çš®è†šè€åŒ–ã€‚\n2. ç ”ç©¶ä½¿ç”¨å°é¼ æ¨¡å‹ï¼Œè§€å¯Ÿåˆ°çš®è†šçµæ§‹å’Œå…ç–«åŠŸèƒ½çš„æ”¹å–„ã€‚\n3. ç™¼ç¾äº†233ç¨®èˆ‡çš®è†šå¥åº·ç›¸é—œçš„è›‹ç™½è³ªï¼Œç‚ºæŠ—è€åŒ–æä¾›æ–°æ€è·¯ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main results of a study on the effects of sulforaphane on skin aging. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (like mice or cells), arrows or flow lines to show the steps of the experiment, and a section labeled 'Main Results' highlighting protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "çš®è†šè€åŒ– Skin Aging",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41039785/"
  },
  {
    "id": "41027171",
    "title_en": "Multi-omics analysis of gut-liver axis reveals the mechanism by which sulforaphane alleviates liver injury in Cyprinus carpio exposed to triphenyltin.",
    "pub_date": "2025 Dec",
    "abstract_en": "This study investigates the protective effects of sulforaphane (SFN) against triphenyltin (TPT)-induced hepatotoxicity, immune dysfunction and gut microbiota dysbiosis in Cyprinus carpio. Cyprinus carpio were divided into three groups and exposed for 8Â weeks, including control, 10Â Î¼g/L TPT and 10Â Î¼g/L TPTÂ +Â 10Â mg/kg SFN group. This result showed that TPT exposure induced significantly (PÂ <Â 0.05) hepatotoxicity, evidenced by increasing hepatic total bile acid (TBA) and total cholesterol levels, while upregulating Hsp70/90 and downregulating lysozyme gene expression. SFN supplementation reduced TBA accumulation, normalized Hsp90 and lysozyme expression, mitigating TPT-induced lipid dysregulation and immunosuppression. Transcriptomic analysis revealed that TPT exposure activated lipid metabolism pathways (PPAR signaling and cholesterol metabolism), but suppressed immune-related pathways. SFN supplementation restored metabolic homeostasis by enriching glucose and amino acid metabolism pathways and activating AMPK signaling, while also modulating the expression of key genes (PLIN1, ME1, CPT1B). The microbiota composition were changed in SFNÂ +Â TPT, including the increased of beneficial Fusobacteriota and Cetobacterium, and the decreased of pathogenic Proteobacteria and Aeromonas. The gut transcriptome dysregulation were restored in SFNÂ +Â TPT by enhancing immune pathways in Toll-like/NOD-like receptors. The significant correlations linked were found in gut microbes (Kaistia, Vagococcus) to hepatic/intestinal gene expression in SFNÂ +Â TPT. Overall, these findings elucidate novel mechanisms underlying TPT-induced immunotoxicity in liver and intestine and demonstrate the protective role of SFN, providing a theoretical foundation for its application in toxicity mitigation strategies.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±åŠŸèƒ½æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾ä¿è­·è‚è‡Ÿå’Œæ”¹å–„å…ç–«ç³»çµ±çš„å¤©ç„¶æ–¹æ³•å…·æœ‰æ½›åœ¨çš„åƒ¹å€¼ã€‚é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç’°å¢ƒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é¡ä¼¼æ¯’ç´ çš„æƒ…æ³ä¸‹ã€‚",
    "para2": "æœ¬ç ”ç©¶ä¸»è¦é—œæ³¨ä¸‰è‹¯éŒ«ï¼ˆTPTï¼‰å°é­šé¡ï¼ˆé¯‰é­šï¼‰é€ æˆçš„è‚æ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™äº›æƒ…æ³ä¸‹çš„ä¿è­·ä½œç”¨ï¼Œä¸¦æ¢è¨å…¶å¯èƒ½çš„æ©Ÿåˆ¶ã€‚é€™å€‹ä¸»é¡Œä¸åƒ…æ¶‰åŠç’°å¢ƒæ¯’ç´ å°ç”Ÿç‰©çš„å½±éŸ¿ï¼Œé‚„æ¶‰åŠå¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†æ”¹å–„å¥åº·ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°æ¯’ç´ æš´éœ²çš„æƒ…æ³ä¸‹ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ï¼Œä¸¦æŒçºŒæš´éœ²8é€±ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥æ·±å…¥äº†è§£åŸºå› è¡¨é”çš„è®ŠåŒ–åŠå…¶å°è…¸é“å¾®ç”Ÿç‰©çµ„çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚æ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä¸¦å½±éŸ¿äº†ç›¸é—œåŸºå› çš„è¡¨é”ã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æ¸›å°‘äº†è†½é…¸çš„ç©ç´¯ï¼Œä¸¦æ¢å¾©äº†åŸºå› çš„æ­£å¸¸è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å°æŠ—ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚é€™äº›çµæœç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„æ©Ÿåˆ¶ï¼Œä¸¦å±•ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±åŠŸèƒ½æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç”±ä¸‰è‹¯éŒ«å¼•èµ·çš„è‚æ¯’æ€§å’Œå…ç–«åŠŸèƒ½éšœç¤™ï¼Œé€™å°æ–¼å°‹æ‰¾ä¿è­·è‚è‡Ÿå’Œæ”¹å–„å…ç–«ç³»çµ±çš„å¤©ç„¶æ–¹æ³•å…·æœ‰æ½›åœ¨çš„åƒ¹å€¼ã€‚é€™äº›ç™¼ç¾ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£ç’°å¢ƒæ¯’ç´ å°å¥åº·çš„å½±éŸ¿ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯åœ¨é¢å°é¡ä¼¼æ¯’ç´ çš„æƒ…æ³ä¸‹ã€‚\n\næœ¬ç ”ç©¶ä¸»è¦é—œæ³¨ä¸‰è‹¯éŒ«ï¼ˆTPTï¼‰å°é­šé¡ï¼ˆé¯‰é­šï¼‰é€ æˆçš„è‚æ¯’æ€§ã€å…ç–«åŠŸèƒ½éšœç¤™åŠè…¸é“å¾®ç”Ÿç‰©å¤±èª¿çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ åœ¨é€™äº›æƒ…æ³ä¸‹çš„ä¿è­·ä½œç”¨ï¼Œä¸¦æ¢è¨å…¶å¯èƒ½çš„æ©Ÿåˆ¶ã€‚é€™å€‹ä¸»é¡Œä¸åƒ…æ¶‰åŠç’°å¢ƒæ¯’ç´ å°ç”Ÿç‰©çš„å½±éŸ¿ï¼Œé‚„æ¶‰åŠå¦‚ä½•åˆ©ç”¨å¤©ç„¶ç‰©è³ªä¾†æ”¹å–„å¥åº·ç‹€æ³ï¼Œç‰¹åˆ¥æ˜¯åœ¨é¢å°æ¯’ç´ æš´éœ²çš„æƒ…æ³ä¸‹ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥ç‚ºå°ç…§çµ„ã€10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«çµ„ï¼Œä»¥åŠ10å¾®å…‹/å‡çš„ä¸‰è‹¯éŒ«åŠ ä¸Š10æ¯«å…‹/å…¬æ–¤çš„è˜¿è””ç¡«ç´ çµ„ï¼Œä¸¦æŒçºŒæš´éœ²8é€±ã€‚é€éé€™æ¨£çš„è¨­è¨ˆï¼Œç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°é­šé¡å¥åº·çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯è‚è‡Ÿå’Œå…ç–«ç³»çµ±çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…é‚„é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥æ·±å…¥äº†è§£åŸºå› è¡¨é”çš„è®ŠåŒ–åŠå…¶å°è…¸é“å¾®ç”Ÿç‰©çµ„çš„å½±éŸ¿ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«çš„æš´éœ²ç¢ºå¯¦å¼•èµ·äº†è‚æ¯’æ€§ï¼Œè¡¨ç¾ç‚ºè‚è‡Ÿç¸½è†½é…¸å’Œç¸½è†½å›ºé†‡æ°´å¹³çš„ä¸Šå‡ï¼Œä¸¦å½±éŸ¿äº†ç›¸é—œåŸºå› çš„è¡¨é”ã€‚è€Œè˜¿è””ç¡«ç´ çš„è£œå……å‰‡æ¸›å°‘äº†è†½é…¸çš„ç©ç´¯ï¼Œä¸¦æ¢å¾©äº†åŸºå› çš„æ­£å¸¸è¡¨é”ï¼Œé¡¯ç¤ºå‡ºå…¶å°æŠ—ä¸‰è‹¯éŒ«å¼•èµ·çš„è„‚è³ªå¤±èª¿å’Œå…ç–«æŠ‘åˆ¶çš„æ½›åŠ›ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆä¹Ÿç™¼ç”Ÿäº†è®ŠåŒ–ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚é€™äº›çµæœç‚ºç†è§£ä¸‰è‹¯éŒ«å¼•èµ·çš„å…ç–«æ¯’æ€§æä¾›äº†æ–°çš„æ©Ÿåˆ¶ï¼Œä¸¦å±•ç¤ºäº†è˜¿è””ç¡«ç´ çš„ä¿è­·ä½œç”¨ã€‚",
    "fb_post": "ğŸ½ï¸ è˜¿è””ç¡«ç´ ï¼Œé€™å€‹åå­—ä½ è½éå—ï¼Ÿå®ƒä¸åƒ…æ˜¯æˆ‘å€‘é¤æ¡Œä¸Šçš„è”¬èœï¼Œæœ€è¿‘çš„ç ”ç©¶é‚„ç™¼ç¾å®ƒå¯èƒ½å°è‚è‡Ÿå¥åº·å’Œå…ç–«ç³»çµ±æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨ä¸€ç¨®å«åšä¸‰è‹¯éŒ«çš„ç’°å¢ƒæ¯’ç´ ï¼Œå®ƒæœƒå°é­šé¡é€ æˆè‚æ¯’æ€§å’Œå…ç–«ç³»çµ±éšœç¤™ã€‚ç ”ç©¶äººå“¡å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¹«åŠ©æ”¹å–„é€™äº›å•é¡Œã€‚  \n  \nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°‡é¯‰é­šåˆ†æˆä¸‰çµ„ï¼Œåˆ†åˆ¥æ¥å—ä¸åŒçš„è™•ç†ï¼šä¸€çµ„ä¸åŠ ä»»ä½•ç‰©è³ªï¼Œå¦ä¸€çµ„æ¥è§¸ä¸‰è‹¯éŒ«ï¼Œæœ€å¾Œä¸€çµ„å‰‡æ˜¯ä¸‰è‹¯éŒ«åŠ ä¸Šè˜¿è””ç¡«ç´ ã€‚æŒçºŒäº†8é€±å¾Œï¼Œçµæœé¡¯ç¤ºï¼Œä¸‰è‹¯éŒ«ç¢ºå¯¦å°é­šçš„è‚è‡Ÿé€ æˆäº†æå®³ï¼Œä½†ç•¶æ·»åŠ è˜¿è””ç¡«ç´ å¾Œï¼Œè‚è‡Ÿçš„å¥åº·ç‹€æ³æœ‰äº†æ˜é¡¯æ”¹å–„ï¼é€™æ„å‘³è‘—è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—é€™ç¨®æ¯’ç´ å¸¶ä¾†çš„å‚·å®³ã€‚  \n  \nğŸŒ± é€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š  \n- è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ä¿è­·è‚è‡Ÿï¼Œæ¸›å°‘æ¯’ç´ é€ æˆçš„å‚·å®³ã€‚  \n- å®ƒèƒ½æ”¹å–„å…ç–«ç³»çµ±çš„åŠŸèƒ½ï¼Œè®“æˆ‘å€‘çš„èº«é«”æ›´å¼·å£¯ã€‚  \n- é€™é …ç ”ç©¶ç‚ºæœªä¾†å°‹æ‰¾å¤©ç„¶ä¿è­·è‚è‡Ÿçš„æ–¹æ³•æä¾›äº†æ–°çš„æ€è·¯ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment and main findings of the study on radish sulforaphane. Include a symbol for radish or broccoli, simplified illustrations of the experimental subjects (like fish or cells), arrows or flow lines to represent the experimental steps, and a section highlighting the main results such as protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚æ¯’æ€§ Hepatotoxicity",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41027171/"
  },
  {
    "id": "40714240",
    "title_en": "Gut microbiota-related glutathione metabolism is key mechanism for sulforaphane ameliorating ulcerative colitis.",
    "pub_date": "2025 Dec",
    "abstract_en": "Gut barrier dysfunction is associated with dysbiosis of the gut microbiota and its metabolites, which is closely linked to the pathogenesis of ulcerative colitis (UC). Recent studies have demonstrated that Sulforaphane (SFN) exerts beneficial effects on UC. However, the role of the gut microbiota and microbial metabolism in the anti-UC mechanisms of SFN remains inadequately understood. In this study, we observed that SFN administration significantly improved the pathological phenotype, restored gut barrier integrity, and reduced colon inflammation in dextran sulfate sodium (DSS)-induced colitis mice. Gut microbiota analysis illustrated that SFN administration rebalances the alterations in gut microbiota composition, including genera such as Turicibacter, Lactobacillus and Bacteroides, in DSS-induced mice. Furthermore, untargeted metabolomics analysis indicated that the levels of microbial arachidonic acid metabolism, as well as the metabolism of alanine, aspartate, and glutamate, and glutathione metabolism in the gastrointestinal tract, were significantly altered in DSS-induced mice. Interestingly, SFN treatment significantly restore the alterations in glutathione metabolism and the levels of associated metabolites. Additionally, we observed that the MAPK/NF-ÎºB signaling pathway, regulated by glutathione metabolism, was inhibited in the colon of DSS-induced mice following SFN treatment. Collectively, these results suggest that SFN can alleviate DSS-induced colitis in mice by restoring dysregulated gut microbiota and glutathione metabolism, thereby modulating the MAPK/NF-ÎºB signaling pathway, enhancing intestinal barrier function and reducing colonic inflammation. Importantly, our findings elucidate a novel mechanism by which SFN improves gut barrier function, highlighting its potential to advance the development of SFN-derived therapeutics for the clinical management of colitis.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½å°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚æœ‰ç›Šï¼Œé€™æ„å‘³è‘—é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆå’ŒåŠŸèƒ½ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©é é˜²æˆ–ç·©è§£é€™é¡ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå…¶ä»£è¬ç”¢ç‰©ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸è‘¡èšç³–éˆ‰ä¾†èª˜å°è…¸é“ç‚ç—‡ã€‚ç ”ç©¶è€…çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§åŠçµè…¸ç‚ç—‡çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œç ”ç©¶è€…ä¹Ÿé€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ï¼Œå¾è€Œå…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³ç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚å¾Œï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯åœ¨å°é¼ çµè…¸ä¸­å—åˆ°æŠ‘åˆ¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©å’Œä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è…¸é“å¥åº·æ–¹é¢ã€‚è…¸é“å±éšœåŠŸèƒ½çš„å¤±èª¿èˆ‡è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„å¤±è¡¡æœ‰é—œï¼Œé€™å¯èƒ½å°è‡´æ½°ç˜æ€§çµè…¸ç‚ç­‰ç–¾ç—…çš„ç™¼å±•ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½å°æ½°ç˜æ€§çµè…¸ç‚æœ‰ç›Šï¼Œé€™æ„å‘³è‘—é€éæ”¹å–„è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆå’ŒåŠŸèƒ½ï¼Œæˆ–è¨±èƒ½å¤ å¹«åŠ©é é˜²æˆ–ç·©è§£é€™é¡ç–¾ç—…çš„ç—‡ç‹€ï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨æ½°ç˜æ€§çµè…¸ç‚ä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿è…¸é“å¾®ç”Ÿç‰©ç¾¤å’Œå…¶ä»£è¬ç”¢ç‰©ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“å±éšœåŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç”±æ–¼è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡æ‰€å¼•èµ·çš„ç‚ç—‡åæ‡‰ã€‚é€™äº›å•é¡Œçš„è§£ç­”ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œé‚„å¯èƒ½ç‚ºæ½°ç˜æ€§çµè…¸ç‚çš„æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†èª˜å°æ½°ç˜æ€§çµè…¸ç‚çš„å°é¼ æ¨¡å‹ï¼Œé€™äº›å°é¼ æ˜¯é€šéçµ¦äºˆç¡«é…¸è‘¡èšç³–éˆ‰ä¾†èª˜å°è…¸é“ç‚ç—‡ã€‚ç ”ç©¶è€…çµ¦äºˆé€™äº›å°é¼ è˜¿è””ç¡«ç´ ï¼Œä¸¦è§€å¯Ÿå…¶å°è…¸é“ç—…ç†è¡¨ç¾ã€è…¸é“å±éšœå®Œæ•´æ€§åŠçµè…¸ç‚ç—‡çš„å½±éŸ¿ã€‚åŒæ™‚ï¼Œç ”ç©¶è€…ä¹Ÿé€²è¡Œäº†è…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æï¼Œä¸¦ä½¿ç”¨ä»£è¬çµ„å­¸æŠ€è¡“ä¾†è©•ä¼°è…¸é“å…§çš„ä»£è¬è®ŠåŒ–ï¼Œå¾è€Œå…¨é¢äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„çµ¦äºˆé¡¯è‘—æ”¹å–„äº†å°é¼ çš„ç—…ç†è¡¨ç¾ï¼Œæ¢å¾©äº†è…¸é“å±éšœçš„å®Œæ•´æ€§ï¼Œä¸¦æ¸›å°‘äº†çµè…¸çš„ç‚ç—‡ã€‚æ­¤å¤–ï¼Œè…¸é“å¾®ç”Ÿç‰©ç¾¤çš„åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ é‡æ–°å¹³è¡¡è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆï¼Œä¸¦ä¸”ä»£è¬çµ„å­¸åˆ†æé¡¯ç¤ºï¼Œèˆ‡è…¸é“ç›¸é—œçš„å¤šç¨®ä»£è¬ç‰©çš„æ°´å¹³ç™¼ç”Ÿäº†é¡¯è‘—è®ŠåŒ–ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ æ²»ç™‚å¾Œï¼Œèˆ‡è°·èƒ±ç”˜è‚½ä»£è¬ç›¸é—œçš„ä¿¡è™Ÿé€šè·¯åœ¨å°é¼ çµè…¸ä¸­å—åˆ°æŠ‘åˆ¶ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€è…¸é“å¾®ç”Ÿç‰©å’Œä»£è¬ä¾†æ”¹å–„è…¸é“åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘ç‚ç—‡åæ‡‰ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿåƒé»è˜¿è””å¯èƒ½å°ä½ çš„è…¸é“å¥åº·æœ‰å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …æœ‰è¶£çš„ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ½°ç˜æ€§çµè…¸ç‚çš„å½±éŸ¿ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½è®“è…¸é“ç™¼ç‚çš„ç–¾ç—…ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è…¸é“çš„é˜²è­·åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘å› è…¸é“å¾®ç”Ÿç‰©å¤±è¡¡è€Œå¼•èµ·çš„ç‚ç—‡ã€‚ä»–å€‘ç”¨å°é¼ ä¾†é€²è¡Œå¯¦é©—ï¼Œçµ¦å°é¼ æ³¨å…¥ä¸€ç¨®èƒ½å¼•ç™¼è…¸é“ç‚çš„ç‰©è³ªï¼Œéš¨å¾Œå†çµ¦äºˆè˜¿è””ç¡«ç´ ï¼Œè§€å¯Ÿå®ƒçš„æ•ˆæœã€‚çµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…æ”¹å–„äº†å°é¼ çš„è…¸é“ç—…ç†ç‹€æ³ï¼Œé‚„æ¢å¾©äº†è…¸é“çš„é˜²è­·åŠŸèƒ½ï¼Œä¸¦æ¸›å°‘äº†ç‚ç—‡ã€‚åŒæ™‚ï¼Œè…¸é“å…§çš„å¾®ç”Ÿç‰©çµ„æˆä¹Ÿå¾—åˆ°äº†èª¿æ•´ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æ”¹å–„è…¸é“å¥åº·æ–¹é¢çš„æ½›åŠ›ã€‚  \n\né€™è£¡æœ‰å¹¾å€‹é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·ã€‚  \n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ¸›å°‘è…¸é“ç‚ç—‡ã€‚  \n3. èª¿æ•´è…¸é“å¾®ç”Ÿç‰©çµ„æˆå°æ–¼å¥åº·æœ‰æ­£é¢å½±éŸ¿ã€‚  \n\næ‰€ä»¥ï¼Œä¸‹æ¬¡åƒè˜¿è””æ™‚ï¼Œä¸å¦¨æƒ³æƒ³å®ƒå¯èƒ½å¸¶ä¾†çš„å¥åº·ç›Šè™•ï¼",
    "image_prompt": "Create a flat design illustration explaining the experiment and main results of a study on the effects of raphanin on colitis. The image should include simple symbols representing broccoli or raphanin, a simplified illustration of experimental subjects like mice, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed. Use a light background with soft colors in an educational infographic style.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ½°ç˜æ€§çµè…¸ç‚ Ulcerative Colitis",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40714240/"
  },
  {
    "id": "41291551",
    "title_en": "Nanoliposome-mediated delivery of sulforaphane suppresses Ehrlich ascites carcinoma growth and improves liver integrity and therapeutic outcomes in a murine model.",
    "pub_date": "2025 Nov",
    "abstract_en": "The anticancer activity of sulforaphane (SFN) involves multiple signaling pathways, but its mechanism against Ehrlich Ascites Carcinoma (EAC) in mice remains unclear. This study evaluated the antitumor efficacy of SFN-loaded nanoliposomes (SFN-NLPs). Ninety female Swiss albino mice were allocated into six groups: (1) untreated control, (2) SFN alone (50Â mg/kg/day, orally), (3) SFN-NLPs alone (50Â mg/kg/day, orally), (4) EAC-bearing mice (2.5â€‰Ã—â€‰10â¶ cells, intraperitoneally), (5) EACâ€‰+â€‰SFN, and (6) EACâ€‰+â€‰SFN-NLPs. with treatment lasting 20 days in tumor-bearing groups. SFN-NLPs significantly reduced EAC tumor volume, viable cell count, and tumor marker levels, while prolonging survival more effectively than free SFN. SFN-NLPs modulated key molecular pathways by suppressing inflammatory gene expression (NF-ÎºB, COX-2) and shifting the balance toward apoptosis via upregulation of TP53 and Bax and concomitant downregulation of Bcl-2. Regarding liver integrity, SFN-NLPs significantly reduced DNA fragmentation and hepatic oxidative stress, while modulating systemic inflammation through reductions in total leukocyte count, TNF-Î±, and C-reactive protein. In addition, SFN-NLPs conferred superior protection against both histopathological and ultrastructural liver damage. Furthermore, molecular docking analysis suggested plausible interactions of SFN with proteins associated with antioxidant defense, inflammation regulation, and apoptosis, indicating a potential modulatory role. In conclusion, nanoformulated SFN enhances stability, augments efficacy, and facilitates sustained release and bioavailability, thereby strengthening its antitumor, anti-inflammatory, antioxidant, and pro-apoptotic effects in EAC-bearing mice. These findings highlight the potential of SFN-NLPs to suppress tumor growth by modulating inflammatory and apoptotic gene expression while preserving liver integrity.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éä¸åŒçš„åˆ†å­é€”å¾‘å¯èƒ½å°æŠ—ç™Œç—‡ï¼Œé€™è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚æœ‰äº†æ–°çš„æ€è€ƒã€‚é›–ç„¶é€™é …ç ”ç©¶ä¸»è¦æ˜¯åœ¨å°é¼ èº«ä¸Šé€²è¡Œï¼Œä½†å…¶çµæœå¯èƒ½ç‚ºäººé¡çš„ç™Œç—‡æ²»ç™‚æä¾›ä¸€äº›æœ‰åƒ¹å€¼çš„åƒè€ƒï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•æ¸›å°‘è…«ç˜¤ç”Ÿé•·å’Œä¿è­·è‚è‡Ÿæ–¹é¢ã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒä½¿ç§‘å­¸å®¶é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°æŠ—Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·ï¼Œä»¥åŠå®ƒåœ¨æ²»ç™‚éç¨‹ä¸­å¯èƒ½æ¶‰åŠçš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºEACæ˜¯ä¸€ç¨®å¸¸è¦‹çš„å¯¦é©—å®¤å°é¼ è…«ç˜¤æ¨¡å‹ï¼Œèƒ½å¤ å¹«åŠ©ç§‘å­¸å®¶å€‘æ·±å…¥äº†è§£ç™Œç—‡çš„ç™¼å±•åŠå…¶æ²»ç™‚ç­–ç•¥ã€‚",
    "para3": "åœ¨é€™é …å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„ï¼Œé€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›è™•ç†åŒ…æ‹¬ä¸æ²»ç™‚çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„çµ„åˆ¥ã€‚å¯¦é©—æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤çš„é«”ç©ã€å­˜æ´»ç‡ä»¥åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆè®“ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°è…«ç˜¤çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼ŒSFN-NLPsé‚„èƒ½å»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ï¼Œä¸¦æ”¹å–„è‚è‡Ÿçš„å¥åº·ç‹€æ…‹ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”èƒ½å¤ èª¿ç¯€é—œéµçš„åˆ†å­é€”å¾‘ï¼ŒæŠ‘åˆ¶ç™¼ç‚åŸºå› çš„è¡¨é”ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡çš„éç¨‹ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ç´ç±³åŒ–å½¢å¼å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ›´å¼·çš„æ•ˆæœï¼Œç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡æ²»ç™‚æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰é€éä¸åŒçš„åˆ†å­é€”å¾‘å¯èƒ½å°æŠ—ç™Œç—‡ï¼Œé€™è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚æœ‰äº†æ–°çš„æ€è€ƒã€‚é›–ç„¶é€™é …ç ”ç©¶ä¸»è¦æ˜¯åœ¨å°é¼ èº«ä¸Šé€²è¡Œï¼Œä½†å…¶çµæœå¯èƒ½ç‚ºäººé¡çš„ç™Œç—‡æ²»ç™‚æä¾›ä¸€äº›æœ‰åƒ¹å€¼çš„åƒè€ƒï¼Œå°¤å…¶æ˜¯åœ¨å¦‚ä½•æ¸›å°‘è…«ç˜¤ç”Ÿé•·å’Œä¿è­·è‚è‡Ÿæ–¹é¢ã€‚é€™äº›ç™¼ç¾å¯èƒ½æœƒä¿ƒä½¿ç§‘å­¸å®¶é€²ä¸€æ­¥æ¢ç´¢è˜¿è””ç¡«ç´ çš„æ½›åŠ›ï¼Œä¸¦å°‹æ‰¾æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ³•ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°æŠ—Ehrlichè…¹æ°´ç™Œï¼ˆEACï¼‰çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·ï¼Œä»¥åŠå®ƒåœ¨æ²»ç™‚éç¨‹ä¸­å¯èƒ½æ¶‰åŠçš„åˆ†å­æ©Ÿåˆ¶ã€‚é€™æ˜¯ä¸€å€‹é‡è¦çš„ç ”ç©¶æ–¹å‘ï¼Œå› ç‚ºEACæ˜¯ä¸€ç¨®å¸¸è¦‹çš„å¯¦é©—å®¤å°é¼ è…«ç˜¤æ¨¡å‹ï¼Œèƒ½å¤ å¹«åŠ©ç§‘å­¸å®¶å€‘æ·±å…¥äº†è§£ç™Œç—‡çš„ç™¼å±•åŠå…¶æ²»ç™‚ç­–ç•¥ã€‚\n\nåœ¨é€™é …å¯¦é©—ä¸­ï¼Œç ”ç©¶äººå“¡ä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„ï¼Œé€²è¡Œä¸åŒçš„è™•ç†ã€‚é€™äº›è™•ç†åŒ…æ‹¬ä¸æ²»ç™‚çµ„ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ çš„çµ„åˆ¥ã€å–®ç¨çµ¦äºˆè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”çš„çµ„åˆ¥ï¼Œä»¥åŠå¸¶æœ‰EACçš„çµ„åˆ¥ã€‚å¯¦é©—æŒçºŒäº†20å¤©ï¼Œç ”ç©¶è€…è§€å¯Ÿäº†è…«ç˜¤çš„é«”ç©ã€å­˜æ´»ç‡ä»¥åŠç›¸é—œçš„ç”Ÿç‰©æ¨™è¨˜ç‰©ã€‚é€™æ¨£çš„è¨­è¨ˆè®“ç ”ç©¶è€…èƒ½å¤ æ¯”è¼ƒä¸åŒè™•ç†å°è…«ç˜¤çš„å½±éŸ¿ï¼Œä¸¦è©•ä¼°è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ç´ç±³è„‚è³ªé«”ï¼ˆSFN-NLPsï¼‰åœ¨æ¸›å°‘EACè…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ°´å¹³æ–¹é¢ï¼Œæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆã€‚æ­¤å¤–ï¼ŒSFN-NLPsé‚„èƒ½å»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ï¼Œä¸¦æ”¹å–„è‚è‡Ÿçš„å¥åº·ç‹€æ…‹ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”èƒ½å¤ èª¿ç¯€é—œéµçš„åˆ†å­é€”å¾‘ï¼ŒæŠ‘åˆ¶ç™¼ç‚åŸºå› çš„è¡¨é”ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡çš„éç¨‹ã€‚é€™äº›çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ç´ç±³åŒ–å½¢å¼å¯èƒ½åœ¨æŠ—è…«ç˜¤ã€æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–æ–¹é¢å…·æœ‰æ›´å¼·çš„æ•ˆæœï¼Œç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "ğŸ€ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ å¯èƒ½å°æŠ—ç™Œç—‡æœ‰é©šäººçš„æ½›åŠ›ï¼é€™é …ç ”ç©¶è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚æœ‰äº†æ–°çš„æ€è€ƒã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨çš„æ˜¯è˜¿è””ç¡«ç´ åœ¨å°é¼ é«”å…§å°æŠ—ä¸€ç¨®åç‚ºEhrlichè…¹æ°´ç™Œçš„è…«ç˜¤æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™ç¨®å¤©ç„¶åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿è…«ç˜¤çš„ç”Ÿé•·ï¼Œä¸¦æ¢ç´¢å®ƒèƒŒå¾Œçš„åˆ†å­æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶åœ˜éšŠä½¿ç”¨äº†90éš»é›Œæ€§ç‘å£«ç™½é¼ ï¼Œå°‡å®ƒå€‘åˆ†æˆå…­çµ„ï¼Œé€²è¡Œä¸åŒçš„è™•ç†ã€‚å¯¦é©—æŒçºŒäº†20å¤©ï¼Œè§€å¯Ÿè…«ç˜¤çš„å¤§å°ã€å­˜æ´»ç‡ç­‰æŒ‡æ¨™ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ç´ç±³è„‚è³ªé«”ï¼ˆå°±æ˜¯æŠŠè˜¿è””ç¡«ç´ åŒ…è£¹åœ¨å°è„‚è‚ªçƒè£¡ï¼‰åœ¨æ¸›å°‘è…«ç˜¤é«”ç©ã€æ´»ç´°èƒæ•¸é‡å’Œè…«ç˜¤æ¨™è¨˜ç‰©æ–¹é¢ï¼Œæ•ˆæœæ¯”å–®ç¨çš„è˜¿è””ç¡«ç´ æ›´å¥½ï¼è€Œä¸”ï¼Œé€™äº›ç´ç±³è„‚è³ªé«”é‚„èƒ½å»¶é•·å°é¼ çš„å­˜æ´»æ™‚é–“ï¼Œæ”¹å–„è‚è‡Ÿå¥åº·ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘è…«ç˜¤ç”Ÿé•·ã€‚\n2. ç´ç±³è„‚è³ªé«”å½¢å¼çš„è˜¿è””ç¡«ç´ æ•ˆæœæ›´ä½³ã€‚\n3. é€™äº›ç™¼ç¾ç‚ºæœªä¾†çš„ç™Œç—‡æ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ï¼",
    "image_prompt": "Create an informative illustration that explains the experimental method and main results of a study on sulforaphane (SFN) in mice. Use a flat design style with a white or light-colored background and soft color palette. Include symbols of broccoli or sulforaphane, simplified representations of experimental subjects (like mice or cells), and arrows or flow lines to indicate the steps of the experiment. Include a section labeled 'Main Results' highlighting protective effects and changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "Ehrlichè…¹æ°´ç™Œ Ehrlich Ascites Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41291551/"
  },
  {
    "id": "41135276",
    "title_en": "Sulforaphane targets STAT3-CKMT2-AS1 to suppress gastric cancer via PSMB8 downregulation and AIMP1 stabilization.",
    "pub_date": "2025 Nov",
    "abstract_en": "Gastric cancer (GC) remains one of the most formidable threats to human health with limited therapeutic options. Sulforaphane (SFN), a natural isothiocyanate, exhibits antitumor activity; however, its molecular mechanisms of action in GC remain unclear. To investigate the mechanism of action of SFN in gastric cancer. The antitumor effects of SFN were comprehensively assessed in vitro and in vivo, followed by sequencing analysis to identify the targeted lncRNA. Subsequently, the mechanical verification experiments were carried out to determine the upstream and downstream regulatory components involved in the STAT3-CKMT2-AS1 regulatory axis. We demonstrated that SFN strongly inhibits GC. SFN downregulated the expression of the lncRNA CKMT2-AS1. Elevated expression levels of CKMT2-AS1 in human GC tissues are correlated with poor patient survival rates. Knockdown of CKMT2-AS1 significantly inhibited GC proliferation and migration both in vivo and in vitro, whereas CKMT2-AS1 overexpression enhanced malignant phenotypes. Mechanistically, we identified STAT3 as the transcriptional activator driving CKMT2-AS1 expression, with SFN directly binding to, and inhibiting, STAT3 phosphorylation to decrease its transcriptional activity. Interestingly, cytoplasmic CKMT2-AS1 competitively adsorbs miR-451a, leading to the expression of PSMB8, ultimately promoting the progression of the malignant phenotype of GC. Moreover, we discovered that CKMT2-AS1 directly binds to the RNA-binding protein (RBP) AIMP1, promoting ubiquitination-mediated degradation of AIMP1 protein via the proteasomal pathway. The highly expressed AIMP1 protein, in turn, inhibits the phosphorylation of the PI3K/AKT signaling pathway, which is hyperactivated in virtually all solid tumors. Our findings not only elucidate a novel SFN-mediated tumor-suppressive mechanism via the STAT3/CKMT2-AS1 regulatory axis, but also validate CKMT2-AS1 as a promising therapeutic target for GC intervention.",
    "para1": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ï¼Œå¹«åŠ©æ”¹å–„èƒƒç™Œæ‚£è€…çš„é å¾Œï¼Œä¸¦é™ä½å…¶ç™¼ç—…ç‡ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„ä½œç”¨è·¯å¾‘ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ­ç¤ºè˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å­¸åŠŸèƒ½ï¼Œä¹Ÿå¯èƒ½ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para3": "ç ”ç©¶åœ˜éšŠåœ¨é«”å¤–å’Œé«”å…§é€²è¡Œäº†å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é¦–å…ˆé€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…é€²è¡Œäº†æ©Ÿæ¢°é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œå¾è€Œæ·±å…¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿äº†lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§è¡¨ç¾ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "explanation_zh": "èƒƒç™Œæ˜¯ä¸€ç¨®å°äººé¡å¥åº·æ§‹æˆé‡å¤§å¨è„…çš„ç–¾ç—…ï¼Œç›®å‰å¯ç”¨çš„æ²»ç™‚é¸æ“‡æœ‰é™ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ€è·¯ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´æœ‰æ•ˆçš„æ²»ç™‚ç­–ç•¥ï¼Œå¹«åŠ©æ”¹å–„èƒƒç™Œæ‚£è€…çš„é å¾Œï¼Œä¸¦é™ä½å…¶ç™¼ç—…ç‡ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„æŠ—è…«ç˜¤ä½œç”¨åŠå…¶åˆ†å­æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦å°‹æ‰¾å…¶å¯èƒ½çš„ä½œç”¨è·¯å¾‘ã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ­ç¤ºè˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å­¸åŠŸèƒ½ï¼Œä¹Ÿå¯èƒ½ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚\n\nç ”ç©¶åœ˜éšŠåœ¨é«”å¤–å’Œé«”å…§é€²è¡Œäº†å¯¦é©—ï¼Œä»¥å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æŠ—è…«ç˜¤æ•ˆæœã€‚ä»–å€‘é¦–å…ˆé€²è¡Œäº†åŸºå› æ¸¬åºåˆ†æï¼Œä»¥è­˜åˆ¥èˆ‡è˜¿è””ç¡«ç´ ä½œç”¨ç›¸é—œçš„é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ã€‚æ¥è‘—ï¼Œç ”ç©¶è€…é€²è¡Œäº†æ©Ÿæ¢°é©—è­‰å¯¦é©—ï¼Œä»¥ç¢ºå®šåƒèˆ‡STAT3-CKMT2-AS1èª¿æ§è»¸çš„ä¸Šæ¸¸å’Œä¸‹æ¸¸èª¿æ§æˆåˆ†ï¼Œå¾è€Œæ·±å…¥äº†è§£å…¶ä½œç”¨æ©Ÿåˆ¶ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¼·çƒˆæŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œä¸¦ä¸‹èª¿äº†lncRNA CKMT2-AS1çš„è¡¨é”ã€‚CKMT2-AS1åœ¨èƒƒç™Œçµ„ç¹”ä¸­çš„é«˜è¡¨é”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡è¼ƒä½ç›¸é—œã€‚ç•¶CKMT2-AS1è¢«æŠ‘åˆ¶æ™‚ï¼Œèƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»é¡¯è‘—æ¸›å°‘ï¼Œè€ŒCKMT2-AS1çš„éåº¦è¡¨é”å‰‡æœƒåŠ åŠ‡è…«ç˜¤çš„æƒ¡æ€§è¡¨ç¾ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ç™¼ç¾STAT3æ˜¯é©…å‹•CKMT2-AS1è¡¨é”çš„è½‰éŒ„æ¿€æ´»å› å­ï¼Œè˜¿è””ç¡«ç´ èƒ½ç›´æ¥çµåˆä¸¦æŠ‘åˆ¶STAT3çš„ç£·é…¸åŒ–ï¼Œå¾è€Œé™ä½å…¶è½‰éŒ„æ´»æ€§ï¼Œé€™äº›ç™¼ç¾ç‚ºèƒƒç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„æ½›åœ¨é¶é»ã€‚",
    "fb_post": "ğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘æ—¥å¸¸åƒçš„è˜¿è””å’Œé’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾å®ƒå°èƒƒç™Œå¯èƒ½æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼\n\né€™é …ç ”ç©¶ä¸»è¦åœ¨æ¢è¨è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿èƒƒç™Œç´°èƒçš„å¢é•·å’Œæ“´æ•£ã€‚ç ”ç©¶åœ˜éšŠé€²è¡Œäº†å¤šç¨®å¯¦é©—ï¼Œè©¦åœ–æ‰¾å‡ºè˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œé€™æ¨£æœªä¾†æˆ–è¨±èƒ½é–‹ç™¼å‡ºæ›´å¥½çš„æ²»ç™‚æ–¹æ³•ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘ä¸åƒ…åˆ†æäº†ç´°èƒçš„åŸºå› ï¼Œé‚„é€²ä¸€æ­¥é©—è­‰äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„è¡Œç‚ºã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆæŠ‘åˆ¶èƒƒç™Œç´°èƒçš„ç”Ÿé•·ï¼Œä¸¦ä¸”èƒ½é™ä½ä¸€ç¨®åç‚ºCKMT2-AS1çš„ç‰©è³ªçš„è¡¨é”ï¼Œé€™ç¨®ç‰©è³ªåœ¨èƒƒç™Œæ‚£è€…ä¸­é€šå¸¸è¡¨ç¾è¼ƒé«˜ï¼Œèˆ‡ç”Ÿå­˜ç‡æœ‰é—œã€‚\n\nç°¡å–®ä¾†èªªï¼Œé€™é …ç ”ç©¶è®“æˆ‘å€‘äº†è§£ï¼š\n1ï¸âƒ£ è˜¿è””ç¡«ç´ å°èƒƒç™Œæœ‰æŠ‘åˆ¶æ•ˆæœã€‚\n2ï¸âƒ£ æŠ‘åˆ¶CKMT2-AS1èƒ½æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚\n3ï¸âƒ£ STAT3é€™å€‹å› å­åœ¨é€™å€‹éç¨‹ä¸­æ‰®æ¼”äº†é‡è¦è§’è‰²ã€‚\n\né€™äº›ç™¼ç¾å¯èƒ½ç‚ºæœªä¾†çš„èƒƒç™Œæ²»ç™‚æä¾›æ–°çš„æ€è·¯ï¼Œè®“æˆ‘å€‘ä¸€èµ·æœŸå¾…æ›´å¤šçš„ç ”ç©¶æˆæœå§ï¼",
    "image_prompt": "Create a flat design infographic with a light background that illustrates the research on the anti-cancer effects of sulforaphane from broccoli and radishes. Include simplified icons of broccoli and radishes, and represent experimental subjects such as human cells. Use arrows or flow lines to depict the experimental steps. Include a section labeled 'Key Findings' that highlights the protective effects observed, such as reduced cancer cell growth and the role of CKMT2-AS1 and STAT3.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41135276/"
  },
  {
    "id": "41275316",
    "title_en": "Investigating the clinical efficacy, safety and molecular mechanism of sulforaphane in autism spectrum disorder: an integrated study combining meta-analysis, network pharmacology, and computational biology.",
    "pub_date": "2025 Nov",
    "abstract_en": "Sulforaphane, a natural antioxidant rich in cruciferous vegetables, has emerged as a promising dietary supplement for autism spectrum disorder (ASD). However, its therapeutic efficacy remains controversial, and the pharmacological mechanisms are not fully elucidated. Eligible randomized controlled trials were retrieved from PubMed, Web of Science, Embase, and Cochrane Library databases. Review Manager 5.4 was used for meta-analysis and bias risk assessment. Network pharmacology, Mendelian randomization, GEO data analyses, molecular docking, and molecular dynamics simulation were employed to explore the mechanisms of sulforaphane in ASD. Six trials involving 333 participants were included in the meta-analysis. Pooled results demonstrated that both 4-5 weeks and 8-10 weeks of sulforaphane supplementation significantly decreased the scores on the Social Responsiveness Scale compared to placebo controls. No significant difference was observed in the incidence of adverse events. Network pharmacology identified 10 core targets of sulforaphane in ASD, including AKT1, EGFR, HSP90AA1, SRC, CASP3, STAT1, MAPK1, MMP9, MAPK8, and JAK2. These targets were implicated in the PI3K-Akt signaling pathway, MAPK signaling pathway, Chemokine signaling pathway, Chemical carcinogenesis - reactive oxygen species, TNF signaling pathway, Th17 cell differentiation, mTOR signaling pathway, and IL-17 signaling pathway. Mendelian randomization further revealed an inverse association between STAT1 levels and ASD risk. GEO transcriptomic data provided independent validation for the network pharmacology predictions. The binding energies between sulforaphane and the top 10 core targets are all â‰¤ -4.0Â kcal/mol. Molecular dynamics simulations further validated the stable interaction between MMP-9 and sulforaphane. Sulforaphane may serve as an efficacious and safe adjunctive therapy for ASD, mediated by its anti-oxidant and anti-inflammatory effects along with the modulation of autophagy. CRD42025635045.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœã€‚é›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡æœ‰å¹«åŠ©ï¼Œä½†å…¶ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œé€™æ„å‘³è‘—åœ¨è€ƒæ…®å°‡å…¶ä½œç‚ºè£œå……åŠ‘æ™‚ï¼Œä»éœ€è¬¹æ…è©•ä¼°å…¶æ•ˆæœå’Œå®‰å…¨æ€§ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„é£²é£Ÿå¹²é æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨è‡ªé–‰ç—‡çš„è¼”åŠ©æ²»ç™‚æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚ç”±æ–¼è‡ªé–‰ç—‡çš„ç—‡ç‹€å¤šæ¨£ä¸”è¤‡é›œï¼Œäº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†çš„æ½›åœ¨ç›Šè™•å’Œä½œç”¨æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—ã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•é€²è¡Œåˆ†æï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…çš„ç¤¾äº¤åæ‡‰é‡è¡¨å¾—åˆ†é¡¯è‘—ä¸‹é™ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚ç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€ç¨®å®‰å…¨çš„è¼”åŠ©ç™‚æ³•ã€‚æ­¤å¤–ï¼Œç¶²çµ¡è—¥ç†å­¸åˆ†æè­˜åˆ¥äº†10å€‹èˆ‡è‡ªé–‰ç—‡ç›¸é—œçš„æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯é‡å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¤©ç„¶æŠ—æ°§åŒ–åŠ‘ï¼Œä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœã€‚é›–ç„¶è˜¿è””ç¡«ç´ è¢«èªç‚ºå¯èƒ½å°è‡ªé–‰ç—‡æœ‰å¹«åŠ©ï¼Œä½†å…¶ç™‚æ•ˆä»å­˜åœ¨çˆ­è­°ï¼Œé€™æ„å‘³è‘—åœ¨è€ƒæ…®å°‡å…¶ä½œç‚ºè£œå……åŠ‘æ™‚ï¼Œä»éœ€è¬¹æ…è©•ä¼°å…¶æ•ˆæœå’Œå®‰å…¨æ€§ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½ç‚ºæœªä¾†çš„é£²é£Ÿå¹²é æä¾›æ–°çš„æ–¹å‘ï¼Œå°¤å…¶æ˜¯åœ¨è‡ªé–‰ç—‡çš„è¼”åŠ©æ²»ç™‚æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›ï¼Œä»¥åŠå…¶èƒŒå¾Œçš„è—¥ç†æ©Ÿåˆ¶æ˜¯ä»€éº¼ã€‚ç”±æ–¼è‡ªé–‰ç—‡çš„ç—‡ç‹€å¤šæ¨£ä¸”è¤‡é›œï¼Œäº†è§£é€™ç¨®å¤©ç„¶æˆåˆ†çš„æ½›åœ¨ç›Šè™•å’Œä½œç”¨æ©Ÿåˆ¶å°æ–¼é–‹ç™¼æ–°çš„æ²»ç™‚æ–¹æ³•è‡³é—œé‡è¦ã€‚\n\nåœ¨é€™é …ç ”ç©¶ä¸­ï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æª¢ç´¢äº†ç¬¦åˆæ¢ä»¶çš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæœ€çµ‚ç´å…¥äº†å…­é …æ¶‰åŠ333ååƒèˆ‡è€…çš„è©¦é©—ã€‚ç ”ç©¶ä½¿ç”¨äº†å¤šç¨®æ–¹æ³•é€²è¡Œåˆ†æï¼ŒåŒ…æ‹¬ç¶²çµ¡è—¥ç†å­¸ã€å­Ÿå¾·çˆ¾éš¨æ©ŸåŒ–ã€GEOæ•¸æ“šåˆ†æã€åˆ†å­å°æ¥å’Œåˆ†å­å‹•åŠ›å­¸æ¨¡æ“¬ï¼Œä»¥æ¢è¨è˜¿è””ç¡«ç´ åœ¨è‡ªé–‰ç—‡ä¸­çš„ä½œç”¨æ©Ÿåˆ¶ã€‚é€™äº›æ–¹æ³•å¹«åŠ©ç ”ç©¶è€…æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åœ¨å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç™¼ç¾é¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è˜¿è””ç¡«ç´ è£œå……å¾Œï¼Œåƒèˆ‡è€…çš„ç¤¾äº¤åæ‡‰é‡è¡¨å¾—åˆ†é¡¯è‘—ä¸‹é™ï¼Œé€™æ„å‘³è‘—ä»–å€‘çš„ç¤¾äº¤èƒ½åŠ›æœ‰æ‰€æ”¹å–„ã€‚ç ”ç©¶ä¸­ä¸¦æœªè§€å¯Ÿåˆ°é¡¯è‘—çš„å‰¯ä½œç”¨ç™¼ç”Ÿç‡ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æ˜¯ä¸€ç¨®å®‰å…¨çš„è¼”åŠ©ç™‚æ³•ã€‚æ­¤å¤–ï¼Œç¶²çµ¡è—¥ç†å­¸åˆ†æè­˜åˆ¥äº†10å€‹èˆ‡è‡ªé–‰ç—‡ç›¸é—œçš„æ ¸å¿ƒé¶é»ï¼Œé€™äº›é¶é»æ¶‰åŠå¤šæ¢ä¿¡è™Ÿå‚³å°é€šè·¯ï¼Œé€²ä¸€æ­¥æ”¯æŒäº†è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆã€‚",
    "fb_post": "ğŸ€ è½èªªé’èŠ±æ¤°èœè£¡æœ‰å€‹ç¥ç§˜æˆåˆ†ï¼Œå«åšè˜¿è””ç¡«ç´ ï¼Œå°è‡ªé–‰ç—‡çš„æœ‹å‹å€‘å¯èƒ½æœ‰å¹«åŠ©ï¼é€™é …ç ”ç©¶å°ˆé–€æ¢è¨è˜¿è””ç¡«ç´ å°è‡ªé–‰ç—‡è­œç³»éšœç¤™ï¼ˆASDï¼‰çš„å½±éŸ¿ï¼Œæƒ³çŸ¥é“å®ƒæ˜¯å¦èƒ½æ”¹å–„ç¤¾äº¤èƒ½åŠ›ã€‚ç ”ç©¶è€…å€‘å¾å¤šå€‹è³‡æ–™åº«ä¸­æ‰¾åˆ°å…­é …éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œæ¶‰åŠ333ååƒèˆ‡è€…ï¼Œä¸¦ä½¿ç”¨äº†å¤šç¨®åˆ†ææ–¹æ³•ä¾†æ·±å…¥äº†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ã€‚çµæœé¡¯ç¤ºï¼Œç¶“é4åˆ°10é€±çš„è£œå……å¾Œï¼Œåƒèˆ‡è€…çš„ç¤¾äº¤åæ‡‰èƒ½åŠ›æœ‰é¡¯è‘—æ”¹å–„ï¼Œä¸¦ä¸”æ²’æœ‰è§€å¯Ÿåˆ°æ˜é¡¯çš„å‰¯ä½œç”¨ï¼Œé€™è®“äººæ„Ÿåˆ°æ¬£æ…°ï¼\n\nâœ¨ ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„è‡ªé–‰ç—‡æ‚£è€…çš„ç¤¾äº¤èƒ½åŠ›ã€‚\n2. ç ”ç©¶ä¸­åƒèˆ‡è€…åœ¨è£œå……å¾Œçš„ç¤¾äº¤åæ‡‰å¾—åˆ†é¡¯è‘—ä¸‹é™ã€‚\n3. è˜¿è””ç¡«ç´ çš„å®‰å…¨æ€§å€¼å¾—é—œæ³¨ï¼Œæœªè¦‹æ˜é¡¯å‰¯ä½œç”¨ã€‚\n\né›–ç„¶çµæœä»¤äººé¼“èˆï¼Œä½†åœ¨è€ƒæ…®ä½¿ç”¨æ™‚ï¼Œä»éœ€è¬¹æ…è©•ä¼°å“¦ï¼",
    "image_prompt": "Create a flat design infographic on a light background that explains the study of sulforaphane's effects on autism. Include simple icons representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, and arrows or flow lines to depict the experimental process. Add a section labeled 'Main Results' highlighting key findings such as improvements in social interaction and safety without significant side effects.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "è‡ªé–‰ç—‡è­œç³»éšœç¤™ Autism Spectrum Disorder",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41275316/"
  },
  {
    "id": "41265122",
    "title_en": "Synergistic strategies of sulforaphane biosynthesis and functional properties in broccoli sprouts powder obtained from sucrose stress modulation coupled with vacuum freeze-drying.",
    "pub_date": "2025 Nov",
    "abstract_en": "This study investigated methionine-sucrose stress treatments on glucoraphanin biosynthesis in broccoli sprouts and the impact of vacuum freeze-drying (VFD) on sprout powder quality. Results showed that sucrose treatment elevated glucoraphanin content by 316.30Â % in 4-day sprouts compared to the control (9.72Â mg/g), accompanied by increases of 42.65Â % in total isothiocyanates (ITCs) and 70.00Â % in anthocyanins. The treatment enhanced myrosinase activity and upregulated osmotic regulators. PCA confirmed that sucrose stress optimized the nutritional quality of broccoli sprouts and exhibited potential in sulforaphane enrichment. The VFD broccoli sprout powder exhibited high retention of sulforaphane (6.00Â mg/g dw) and total ITCs (7.00Â mg/g dw), with optimal water-holding capacity, oil-holding capacity, and swelling capacity. The sulforaphane extract exhibited significant antimicrobial activity against E. coli (16.00Â mm inhibition zone) and Staphylococcus aureus (10.02Â mm). The synergistic application of sucrose stress and VFD presents a promising approach for developing functional foods.",
    "para1": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰ä¸€å®šçš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœèŠ½ä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å¯èƒ½å°æ–¼é é˜²æŸäº›ç–¾ç—…æœ‰æ½›åœ¨çš„å¥½è™•ï¼Œå°¤å…¶æ˜¯èˆ‡å…ç–«ç³»çµ±å’ŒæŠ—èŒç›¸é—œçš„å¥åº·å•é¡Œã€‚é€™äº›ç™¼ç¾æé†’æˆ‘å€‘ï¼Œé€éé£²é£Ÿé¸æ“‡å’Œé£Ÿç‰©åŠ å·¥æ–¹æ³•ï¼Œå¯ä»¥æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œä¸»è¦é—œæ³¨é’èŠ±æ¤°èœèŠ½ä¸­è˜¿è””ç¡«ç´ çš„åˆæˆï¼Œä»¥åŠå¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹å¼ä¾†æå‡å…¶ç‡Ÿé¤Šåƒ¹å€¼ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œå¿ƒçš„æ˜¯ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ï¼Œä¸¦æ¢è¨çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚é€™äº›ç ”ç©¶å•é¡Œçš„æ ¸å¿ƒåœ¨æ–¼å¦‚ä½•æé«˜é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œä¸¦é€²ä¸€æ­¥é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦æ–½åŠ äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†å„ç¨®æ¸¬è©¦ä»¥è©•ä¼°å…¶ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶é‚„åŒ…æ‹¬äº†çœŸç©ºå†·å‡ä¹¾ç‡¥çš„éç¨‹ï¼Œä»¥æª¢æ¸¬é€™ç¨®è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªå½±éŸ¿ã€‚æ•´é«”ä¾†èªªï¼Œé€™é …ç ”ç©¶æ—¨åœ¨æ¢ç´¢å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†å„ªåŒ–é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§çš„å«é‡ï¼Œå¢å¹…é”316.30%ã€‚æ­¤å¤–ï¼Œç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰æ˜é¡¯å¢åŠ ã€‚é€™äº›è™•ç†ä¸åƒ…æå‡äº†é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šå“è³ªï¼Œé‚„é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨å¢å¼·æ•ˆæœã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚æœ€å¾Œï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒæœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„å”åŒæ‡‰ç”¨åœ¨é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶çš„çµæœå°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æœ‰ä¸€å®šçš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœèŠ½ä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ è¢«èªç‚ºå°å¥åº·æœ‰ç›Šï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±å’ŒæŠ—èŒèƒ½åŠ›ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éç‰¹å®šçš„è™•ç†æ–¹æ³•ï¼Œå¯ä»¥æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è˜¿è””ç¡«ç´ çš„å«é‡ï¼Œé€™å¯èƒ½å°æ–¼é é˜²æŸäº›ç–¾ç—…æœ‰æ½›åœ¨çš„å¥½è™•ï¼Œå°¤å…¶æ˜¯èˆ‡å…ç–«ç³»çµ±å’ŒæŠ—èŒç›¸é—œçš„å¥åº·å•é¡Œã€‚é€™äº›ç™¼ç¾æé†’æˆ‘å€‘ï¼Œé€éé£²é£Ÿé¸æ“‡å’Œé£Ÿç‰©åŠ å·¥æ–¹æ³•ï¼Œå¯ä»¥æ”¹å–„æˆ‘å€‘çš„å¥åº·ç‹€æ³ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œä¸»è¦é—œæ³¨é’èŠ±æ¤°èœèŠ½ä¸­è˜¿è””ç¡«ç´ çš„åˆæˆï¼Œä»¥åŠå¦‚ä½•é€éä¸åŒçš„è™•ç†æ–¹å¼ä¾†æå‡å…¶ç‡Ÿé¤Šåƒ¹å€¼ã€‚ç ”ç©¶è€…ç‰¹åˆ¥é—œå¿ƒçš„æ˜¯ç”²ç¡«æ°¨é…¸-è”—ç³–å£“åŠ›è™•ç†å°é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§åˆæˆçš„å½±éŸ¿ï¼Œä¸¦æ¢è¨çœŸç©ºå†·å‡ä¹¾ç‡¥å°é’èŠ±æ¤°èœèŠ½ç²‰å“è³ªçš„å½±éŸ¿ã€‚é€™äº›ç ”ç©¶å•é¡Œçš„æ ¸å¿ƒåœ¨æ–¼å¦‚ä½•æé«˜é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ï¼Œä¸¦é€²ä¸€æ­¥é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½ä½œç‚ºå°è±¡ï¼Œä¸¦æ–½åŠ äº†ç”²ç¡«æ°¨é…¸å’Œè”—ç³–çš„å£“åŠ›è™•ç†ã€‚é€™äº›èŠ½åœ¨ç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†å„ç¨®æ¸¬è©¦ä»¥è©•ä¼°å…¶ç‡Ÿé¤Šæˆåˆ†çš„è®ŠåŒ–ã€‚ç ”ç©¶é‚„åŒ…æ‹¬äº†çœŸç©ºå†·å‡ä¹¾ç‡¥çš„éç¨‹ï¼Œä»¥æª¢æ¸¬é€™ç¨®è™•ç†å°é’èŠ±æ¤°èœèŠ½ç²‰çš„å“è³ªå½±éŸ¿ã€‚æ•´é«”ä¾†èªªï¼Œé€™é …ç ”ç©¶æ—¨åœ¨æ¢ç´¢å¦‚ä½•é€éç‰¹å®šçš„è™•ç†æ–¹æ³•ä¾†å„ªåŒ–é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè”—ç³–è™•ç†èƒ½é¡¯è‘—æé«˜é’èŠ±æ¤°èœèŠ½ä¸­è‘¡è„ç³–æ‹‰æ³•å¯§çš„å«é‡ï¼Œå¢å¹…é”316.30%ã€‚æ­¤å¤–ï¼Œç¸½ç•°ç¡«æ°°é…¸é¹½å’ŒèŠ±é’ç´ çš„å«é‡ä¹Ÿæœ‰æ˜é¡¯å¢åŠ ã€‚é€™äº›è™•ç†ä¸åƒ…æå‡äº†é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šå“è³ªï¼Œé‚„é¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ çš„æ½›åœ¨å¢å¼·æ•ˆæœã€‚çœŸç©ºå†·å‡ä¹¾ç‡¥å¾Œçš„é’èŠ±æ¤°èœèŠ½ç²‰ä¿ç•™äº†é«˜æ¿ƒåº¦çš„è˜¿è””ç¡«ç´ å’Œç¸½ç•°ç¡«æ°°é…¸é¹½ï¼Œä¸¦å±•ç¾å‡ºè‰¯å¥½çš„æ°´åˆ†ä¿æŒèƒ½åŠ›å’Œæ²¹è„‚ä¿æŒèƒ½åŠ›ã€‚æœ€å¾Œï¼Œè˜¿è””ç¡«ç´ æå–ç‰©å°å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒæœ‰é¡¯è‘—çš„æŠ—èŒæ´»æ€§ï¼Œé€™äº›çµæœé¡¯ç¤ºå‡ºè”—ç³–å£“åŠ›å’ŒçœŸç©ºå†·å‡ä¹¾ç‡¥çš„å”åŒæ‡‰ç”¨åœ¨é–‹ç™¼åŠŸèƒ½æ€§é£Ÿå“æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "ä½ çŸ¥é“é’èŠ±æ¤°èœèŠ½è£¡æœ‰ä»€éº¼ç§˜å¯†æ­¦å™¨å—ï¼Ÿé€™æ¬¡çš„ç ”ç©¶ç™¼ç¾ï¼Œé’èŠ±æ¤°èœèŠ½ä¸­å«æœ‰çš„è˜¿è””ç¡«ç´ å°æˆ‘å€‘çš„å¥åº·å¯æœ‰å¾ˆå¤§çš„å¹«åŠ©ï¼ç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼å¦‚ä½•æå‡é€™äº›èŠ½çš„ç‡Ÿé¤Šåƒ¹å€¼ï¼Œå°¤å…¶æ˜¯é€éä¸€äº›ç‰¹åˆ¥çš„è™•ç†æ–¹æ³•ä¾†å¢åŠ è£¡é¢çš„ç‡Ÿé¤Šæˆåˆ†ã€‚  \n  \nä»–å€‘ç”¨ç”²ç¡«æ°¨é…¸å’Œè”—ç³–å°é’èŠ±æ¤°èœèŠ½æ–½åŠ å£“åŠ›ï¼Œç¶“éå››å¤©çš„ç”Ÿé•·å¾Œï¼Œé€²è¡Œäº†å„ç¨®æ¸¬è©¦ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè”—ç³–çš„è™•ç†èƒ½è®“é’èŠ±æ¤°èœèŠ½ä¸­çš„ä¸€ç¨®é‡è¦æˆåˆ†â€”â€”è‘¡è„ç³–æ‹‰æ³•å¯§ï¼Œå¢åŠ äº†316.30%ï¼è€Œä¸”ï¼Œé€™äº›èŠ½çš„æŠ—èŒèƒ½åŠ›ä¹Ÿå¾—åˆ°äº†æå‡ï¼Œå°æŠ—å¤§è…¸æ¡¿èŒå’Œé‡‘é»ƒè‰²è‘¡è„çƒèŒçš„æ•ˆæœç›¸ç•¶é¡¯è‘—ã€‚  \n  \né€™äº›ç™¼ç¾å‘Šè¨´æˆ‘å€‘ï¼Œé€éé©ç•¶çš„é£²é£Ÿé¸æ“‡å’Œé£Ÿç‰©è™•ç†æ–¹å¼ï¼Œæˆ‘å€‘å¯ä»¥æ›´å¥½åœ°ç…§é¡§è‡ªå·±çš„å¥åº·ï¼  \n  \nâœ¨ ä¸»è¦é‡é»ï¼š  \n1. é’èŠ±æ¤°èœèŠ½ä¸­çš„è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼å¢å¼·å…ç–«ç³»çµ±ã€‚  \n2. è”—ç³–è™•ç†é¡¯è‘—æé«˜äº†é’èŠ±æ¤°èœèŠ½çš„ç‡Ÿé¤Šæˆåˆ†ã€‚  \n3. é€™äº›èŠ½å°æŠ—èŒçš„æ•ˆæœå€¼å¾—æœŸå¾…ï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on broccoli sprouts. Include simplified icons of broccoli and sulforaphane, along with simplified representations of the experiment subjects (such as humans or cells). Use arrows or flow lines to show the steps of the experiment. Dedicate a section to highlight the main results, such as the increase in a specific protective effect or nutrient levels. Use a light background with soft colors for a scientific and informative style.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41265122/"
  },
  {
    "id": "41159773",
    "title_en": "Sulforaphane-Loaded Hydrogel Prolongs Fully MHC-Mismatched Skin Allograft Survival.",
    "pub_date": "2025 Nov",
    "abstract_en": "Despite immunosuppression, acute rejection (AR) is still a common setback among transplantation patients and is a risk factor for graft survival. Sulforaphane (SFN), a phytochemical present in crucifers, has been shown to have anti-inflammatory and immunoregulatory properties, yet its influences on immune cell activation as well as in graft survival are still unknown. Thus, the aim was to evaluate SFN's effect, and to improve efficacy, efficiency, and availability, it was incorporated into thermosensitive polymeric hydrogels, to prevent AR in skin transplant (Tx) model mice. A thermosensitive hydrogel containing SFN (0.1%) and hyaluronic acid (HA) (0.5%) dispersed in a poloxamer matrix (PL407 at 20% w/v) was developed (GS-PL407 20%, HA and SFN) and characterized as a liquid-viscous hydrogel. The fully MHC-incompatible skin Tx procedure was performed by using donor skin Balb/c mice, transplanted into C57BL/6 recipient mice. The cytotoxicity test of GS was performed using in vitro assays with bone marrow-derived dendritic cells (BMDC). Treatment of BMDC with GS for 24 h presents no cytotoxicity. Untreated allograft mice present 100% of graft loss at day 9 post Tx. Remarkably, subcutaneous GS injection every 3 days promoted 80% of allograft survival for more than 14 days when compared with untreated recipients (<i>p</i> < 0.001). Histological analysis showed a lower level of inflammatory cells in the skin Tx of GS-treated mice. Flow cytometry analysis of draining lymph nodes at day 5 post Tx revealed that GS treatment reduced the frequency of DC and subtypes and function of the CD4<sup>+</sup> T cells. In vitro GS-treated lipopolysaccharide-activated BMDC present less activation of costimulatory markers. Taken together, GS treatment reduced immune cell activation, postponing AR onset and prolonging allograft survival in Tx animals. This strategy highlights the role of SFN as a promising candidate for further studies in organ transplantation experiments and being tested combined with current immunosuppression protocols.",
    "para1": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨ç›Šè™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„æœ‰æ•ˆæ–¹æ³•ï¼Œé€²è€Œæé«˜ç§»æ¤æˆåŠŸç‡ï¼Œé€™å°æ–¼éœ€è¦å™¨å®˜ç§»æ¤çš„ç—…äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·å•Ÿç¤ºã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒå°ç§»æ¤ç‰©å­˜æ´»çš„æ½›åœ¨å½±éŸ¿ã€‚é€™å€‹å•é¡Œçš„è§£ç­”ä¸åƒ…èƒ½å¤ å¹«åŠ©æ”¹å–„ç§»æ¤æ‰‹è¡“çš„çµæœï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å…ç–«æŠ‘åˆ¶æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå…·é«”æ–¹æ³•æ˜¯å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…é¦–å…ˆé–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„æ°´å‡è† ï¼Œç„¶å¾Œå°‡å…¶æ³¨å°„åˆ°æ¥å—ç§»æ¤çš„å°é¼ èº«ä¸Šã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ°´å‡è† æ²»ç™‚çš„å°é¼ ï¼Œå…¶ç§»æ¤ç‰©çš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ä»¥ä¸Šï¼Œä¸”æŒçºŒè¶…é14å¤©ã€‚èˆ‡æœªæ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œé€™äº›å°é¼ çš„çš®è†šçµ„ç¹”ä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œé¡¯ç¤ºå‡ºå…ç–«åæ‡‰çš„æ¸›å°‘ã€‚æ­¤å¤–ï¼Œæµå¼ç´°èƒè¡“åˆ†æé¡¯ç¤ºï¼Œæ²»ç™‚å¾Œçš„å°é¼ æ·‹å·´çµä¸­æŸäº›å…ç–«ç´°èƒçš„æ´»åŒ–ç¨‹åº¦é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤ç‰©çš„å­˜æ´»æ™‚é–“ã€‚",
    "explanation_zh": "åœ¨å™¨å®˜ç§»æ¤çš„éç¨‹ä¸­ï¼Œæ€¥æ€§æ’æ–¥åæ‡‰æ˜¯ä¸€å€‹å¸¸è¦‹çš„å•é¡Œï¼Œé€™æœƒå½±éŸ¿ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„æ½›åœ¨ç›Šè™•ï¼Œå› ç‚ºå®ƒå…·æœ‰æŠ—ç™¼ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚é€éé€™é …ç ”ç©¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰çš„æœ‰æ•ˆæ–¹æ³•ï¼Œé€²è€Œæé«˜ç§»æ¤æˆåŠŸç‡ï¼Œé€™å°æ–¼éœ€è¦å™¨å®˜ç§»æ¤çš„ç—…äººä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹é‡è¦çš„å¥åº·å•Ÿç¤ºã€‚\n\né€™é …ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯è©•ä¼°è˜¿è””ç¡«ç´ å°æ–¼æ€¥æ€§æ’æ–¥åæ‡‰çš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯åœ¨çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿å…ç–«ç´°èƒçš„æ´»åŒ–ï¼Œä»¥åŠå®ƒå°ç§»æ¤ç‰©å­˜æ´»çš„æ½›åœ¨å½±éŸ¿ã€‚é€™å€‹å•é¡Œçš„è§£ç­”ä¸åƒ…èƒ½å¤ å¹«åŠ©æ”¹å–„ç§»æ¤æ‰‹è¡“çš„çµæœï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„å…ç–«æŠ‘åˆ¶æ²»ç™‚æä¾›æ–°çš„æ€è·¯ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†å°é¼ ä½œç‚ºå¯¦é©—å°è±¡ï¼Œå…·é«”æ–¹æ³•æ˜¯å°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆç†±æ•èšåˆç‰©æ°´å‡è† ï¼Œä¸¦å°‡å…¶æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ç ”ç©¶è€…é¦–å…ˆé–‹ç™¼äº†ä¸€ç¨®å«æœ‰0.1%è˜¿è””ç¡«ç´ å’Œ0.5%é€æ˜è³ªé…¸çš„æ°´å‡è† ï¼Œç„¶å¾Œå°‡å…¶æ³¨å°„åˆ°æ¥å—ç§»æ¤çš„å°é¼ èº«ä¸Šã€‚å¯¦é©—ä¸­é‚„é€²è¡Œäº†ç´°èƒæ¯’æ€§æ¸¬è©¦ï¼Œä»¥ç¢ºä¿é€™ç¨®æ°´å‡è† å°å…ç–«ç´°èƒä¸æœƒé€ æˆå‚·å®³ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œæ¥å—è˜¿è””ç¡«ç´ æ°´å‡è† æ²»ç™‚çš„å°é¼ ï¼Œå…¶ç§»æ¤ç‰©çš„å­˜æ´»ç‡é¡¯è‘—æé«˜ï¼Œé”åˆ°80%ä»¥ä¸Šï¼Œä¸”æŒçºŒè¶…é14å¤©ã€‚èˆ‡æœªæ²»ç™‚çš„å°é¼ ç›¸æ¯”ï¼Œé€™äº›å°é¼ çš„çš®è†šçµ„ç¹”ä¸­ç‚ç—‡ç´°èƒçš„æ•¸é‡è¼ƒå°‘ï¼Œé¡¯ç¤ºå‡ºå…ç–«åæ‡‰çš„æ¸›å°‘ã€‚æ­¤å¤–ï¼Œæµå¼ç´°èƒè¡“åˆ†æé¡¯ç¤ºï¼Œæ²»ç™‚å¾Œçš„å°é¼ æ·‹å·´çµä¸­æŸäº›å…ç–«ç´°èƒçš„æ´»åŒ–ç¨‹åº¦é™ä½ï¼Œé€™è¡¨æ˜è˜¿è””ç¡«ç´ å¯èƒ½æœ‰æ•ˆå»¶ç·©æ€¥æ€§æ’æ–¥åæ‡‰çš„ç™¼ç”Ÿï¼Œä¸¦å»¶é•·ç§»æ¤ç‰©çš„å­˜æ´»æ™‚é–“ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ä¸åªæ˜¯ç¾å‘³çš„è”¬èœï¼Œå®ƒé‚„å¯èƒ½å°å™¨å®˜ç§»æ¤æœ‰å¹«åŠ©ï¼ğŸ¤”é€™ç¯‡ç ”ç©¶èšç„¦æ–¼æ€¥æ€§æ’æ–¥åæ‡‰ï¼Œé€™æ˜¯ç§»æ¤éç¨‹ä¸­å¸¸è¦‹çš„å•é¡Œï¼Œæœƒå½±éŸ¿åˆ°ç§»æ¤ç‰©çš„å­˜æ´»ç‡ã€‚ç ”ç©¶äººå“¡ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼Œæ“æœ‰æŠ—ç™¼ç‚å’Œèª¿ç¯€å…ç–«çš„ç‰¹æ€§ï¼Œæˆ–è¨±èƒ½æˆç‚ºæ”¹å–„ç§»æ¤çµæœçš„é—œéµã€‚  \n  \né€™é …ç ”ç©¶ä¸»è¦åœ¨å°é¼ èº«ä¸Šé€²è¡Œï¼Œé€éå°‡è˜¿è””ç¡«ç´ èˆ‡é€æ˜è³ªé…¸è£½æˆæ°´å‡è† ï¼Œä¸¦æ‡‰ç”¨æ–¼çš®è†šç§»æ¤æ¨¡å‹ä¸­ã€‚ä»–å€‘ç™¼ç¾ï¼Œæ¥å—é€™ç¨®æ°´å‡è† æ²»ç™‚çš„å°é¼ ï¼Œå…¶ç§»æ¤ç‰©å­˜æ´»ç‡é”åˆ°80%ä»¥ä¸Šï¼Œä¸”æŒçºŒè¶…é14å¤©ï¼  \n  \nä¸åƒ…å¦‚æ­¤ï¼Œé€™äº›å°é¼ çš„ç‚ç—‡ç´°èƒæ•¸é‡æ¸›å°‘ï¼Œé¡¯ç¤ºå…ç–«åæ‡‰æœ‰æ‰€é™ä½ã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„å™¨å®˜ç§»æ¤å’Œå…ç–«æ²»ç™‚å……æ»¿å¸Œæœ›ï¼  \n  \nğŸ” ç ”ç©¶é‡é»ï¼š  \n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ¸›å°‘æ€¥æ€§æ’æ–¥åæ‡‰ã€‚  \n2. å¯¦é©—å°é¼ çš„ç§»æ¤ç‰©å­˜æ´»ç‡é¡¯è‘—æé«˜ã€‚  \n3. é€™é …ç ”ç©¶æˆ–è¨±ç‚ºæœªä¾†çš„å…ç–«æ²»ç™‚æä¾›æ–°æ€è·¯ã€‚",
    "image_prompt": "Create a simple and clear infographic explaining the experimental method and main results of a study on the effects of sulforaphane on acute rejection in organ transplantation. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like mice or cells, arrows or flow lines indicating the experimental steps, and a section highlighting the main results, such as increased survival rates and reduced inflammation. Use a flat design style with a white or light background and soft color palette.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "å™¨å®˜ç§»æ¤ Organ Transplantation",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41159773/"
  },
  {
    "id": "41196460",
    "title_en": "Sulforaphane: a natural organosulfur having potential to modulate apoptosis and survival signalling in cancer.",
    "pub_date": "2025 Nov",
    "abstract_en": "Owing to its ever-growing range of pharmacological advantages, sulforaphane, an isothiocyanate from cruciferous vegetables such as broccoli, is becoming increasingly popular. This review aims to provide a thorough understanding and a current update on the application of sulforaphane in cancer treatment. Sulforaphane interacts with many signaling molecules that control various pathways in malignant cells, including angiogenesis, apoptosis, cell cycle arrest, metastasis, and inflammation pathways. This review examines the effects of this isothiocyanate on inflammatory mediators, caspases, MMPs, cytokines, and the proteins Bax and Bcl-2. Furthermore, the advantages of nanotechnology and synergistic effects in sulforaphane applications are also reviewed. As per evidence, sulforaphane is a shining example of how ethno-pharmacological expertise can be used to create modern medications.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½åœ¨å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æ–¹é¢çš„æ½›åŠ›ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©é€”å¾‘ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼æå‡å…¬å…±å¥åº·å’Œæ¸›å°‘ç–¾ç—…è² æ“”å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™ç¯‡ç¶œè¿°çš„ç ”ç©¶ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¿ƒç‚ä»‹è³ªã€å‡‹äº¡ç›¸é—œè›‹ç™½å’Œç´°èƒé€±æœŸèª¿æ§å› å­ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­é‡è¦çš„èª¿æ§å› ç´ ã€‚",
    "para3": "é€™é …ç ”ç©¶ä¸»è¦æ˜¯é€šéæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…æª¢è¦–äº†ç›¸é—œçš„å¯¦é©—æ•¸æ“šï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªçš„è¡¨ç¾ã€‚é€™äº›ç ”ç©¶å¹«åŠ©æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨å…¶æ‡‰ç”¨ä¸­çš„å„ªå‹¢ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œé€™å¯èƒ½å°ç™Œç—‡çš„æ²»ç™‚æœ‰æ­£é¢çš„å½±éŸ¿ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ å½±éŸ¿ç‚ç—‡åæ‡‰å’Œç´°èƒå‡‹äº¡ç­‰éç¨‹ï¼Œä¸¦ä¸”åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œèˆ‡å…¶ä»–æ²»ç™‚æ–¹æ³•çµåˆä½¿ç”¨æ™‚å¯èƒ½æœƒå¢å¼·æ•ˆæœã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®ä¾†è‡ªé’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„åŒ–åˆç‰©ï¼Œå› å…¶æ½›åœ¨çš„è—¥ç†å„ªå‹¢è€Œå—åˆ°è¶Šä¾†è¶Šå¤šçš„é—œæ³¨ã€‚é€™é …ç ”ç©¶æä¾›äº†å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­æ‡‰ç”¨çš„æ·±å…¥äº†è§£ï¼Œé¡¯ç¤ºå‡ºå®ƒå¯èƒ½åœ¨å¥åº·ä¿ƒé€²å’Œç–¾ç—…é é˜²æ–¹é¢çš„æ½›åŠ›ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ä¸åŒç”Ÿç‰©é€”å¾‘ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†å°æŠ—ç™Œç—‡ï¼Œé€™å°æ–¼æå‡å…¬å…±å¥åº·å’Œæ¸›å°‘ç–¾ç—…è² æ“”å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™ç¯‡ç¶œè¿°çš„ç ”ç©¶ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ‡‰ç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡ç™Œç´°èƒä¸­çš„å¤šç¨®ä¿¡è™Ÿåˆ†å­äº’å‹•ï¼Œä¸¦å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç‰¹åˆ¥æ˜¯ï¼Œé€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å°æ–¼å¤šç¨®ç”Ÿç‰©æ¨™è¨˜ç‰©çš„å½±éŸ¿ï¼ŒåŒ…æ‹¬ä¿ƒç‚ä»‹è³ªã€å‡‹äº¡ç›¸é—œè›‹ç™½å’Œç´°èƒé€±æœŸèª¿æ§å› å­ï¼Œé€™äº›éƒ½æ˜¯ç™Œç—‡ç™¼å±•éç¨‹ä¸­é‡è¦çš„èª¿æ§å› ç´ ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€šéæ–‡ç»å›é¡§çš„æ–¹å¼é€²è¡Œï¼Œåˆ†æäº†è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ã€‚ç ”ç©¶è€…æª¢è¦–äº†ç›¸é—œçš„å¯¦é©—æ•¸æ“šï¼Œç‰¹åˆ¥æ˜¯è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç‚ç—‡ä»‹è³ªã€å‡‹äº¡é…¶ã€åŸºè³ªé‡‘å±¬è›‹ç™½é…¶ã€ç´°èƒå› å­ä»¥åŠBaxå’ŒBcl-2ç­‰è›‹ç™½è³ªçš„è¡¨ç¾ã€‚é€™äº›ç ”ç©¶å¹«åŠ©æˆ‘å€‘ç†è§£è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ï¼Œä¸¦æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œå”åŒæ•ˆæ‡‰åœ¨å…¶æ‡‰ç”¨ä¸­çš„å„ªå‹¢ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œé€™å¯èƒ½å°ç™Œç—‡çš„æ²»ç™‚æœ‰æ­£é¢çš„å½±éŸ¿ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ å½±éŸ¿ç‚ç—‡åæ‡‰å’Œç´°èƒå‡‹äº¡ç­‰éç¨‹ï¼Œä¸¦ä¸”åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œèˆ‡å…¶ä»–æ²»ç™‚æ–¹æ³•çµåˆä½¿ç”¨æ™‚å¯èƒ½æœƒå¢å¼·æ•ˆæœã€‚é›–ç„¶é€™äº›çµæœä»¤äººé¼“èˆï¼Œä½†ä»éœ€é€²ä¸€æ­¥çš„ç ”ç©¶ä¾†ç¢ºèªå…¶å…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚",
    "fb_post": "ğŸ€ ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘å—åˆ°ç§‘å­¸å®¶çš„é—œæ³¨ï¼é€™é …ç ”ç©¶è®“æˆ‘å€‘å°è˜¿è””ç¡«ç´ åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›æœ‰äº†æ›´æ·±çš„äº†è§£ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ï¼Œä¸¦ä¸”æ¢ç´¢å®ƒèˆ‡ç™Œç´°èƒå…§éƒ¨çš„ä¿¡è™Ÿåˆ†å­ä¹‹é–“çš„äº’å‹•ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯é€šéå›é¡§æ–‡ç»ä¾†é€²è¡Œçš„ï¼Œç§‘å­¸å®¶å€‘åˆ†æäº†è˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿ä¸€äº›èˆ‡ç™Œç—‡ç™¼å±•æœ‰é—œçš„è›‹ç™½è³ªå’Œä»‹è³ªã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘æ›´æ¸…æ¥šè˜¿è””ç¡«ç´ å¯èƒ½åœ¨ç™Œç—‡æ²»ç™‚ä¸­ç™¼æ®çš„ä½œç”¨ï¼Œä¸¦æ¢è¨äº†ç´ç±³æŠ€è¡“å’Œå…¶ä»–æ²»ç™‚æ–¹æ³•çš„å”åŒæ•ˆæœã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨èª¿æ§ç™Œç´°èƒçš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ä¸­æ‰®æ¼”è‘—é‡è¦è§’è‰²ï¼Œå°ç™Œç—‡æ²»ç™‚æœ‰æ­£é¢çš„å½±éŸ¿ã€‚ä¸éï¼Œé€™äº›çµæœé‚„éœ€è¦é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…·é«”çš„ç™‚æ•ˆå’Œæ‡‰ç”¨æ–¹å¼ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡æ²»ç™‚ã€‚\n2. å½±éŸ¿ç™Œç´°èƒç”Ÿé•·å’Œæ“´æ•£çš„å¤šå€‹ç”Ÿç‰©é€”å¾‘ã€‚\n3. ä»éœ€æ›´å¤šç ”ç©¶ä¾†ç¢ºèªå…¶ç™‚æ•ˆã€‚",
    "image_prompt": "Create a flat design infographic with a light background that explains the experimental approach and main findings of a study on sulforaphane from broccoli. Include simple illustrations of broccoli or sulforaphane, simplified representations of experimental subjects like cells or animals, arrows or flow lines showing the experimental steps, and a section labeled 'Main Findings' that highlights protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41196460/"
  },
  {
    "id": "41184790",
    "title_en": "Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.",
    "pub_date": "2025 Nov",
    "abstract_en": "Sulforaphane, an isothiocyanate derived from cruciferous vegetables (e.g., broccoli sprouts), has been explored for its antioxidant and anti-inflammatory properties. This is the first systematic review and meta-analysis to explore the therapeutic potentials of sulforaphane in schizophrenia. We searched PubMed, Scopus, Web of Science, and Cochrane Central for studies from inception to April 2025. We included randomized controlled trials (RCTs) evaluating the efficacy of sulforaphane in schizophrenia. The primary outcomes were changes in the Positive and Negative Syndrome Scale (PANSS) total and its subscales. Secondary outcomes included cognitive measures, metabolic markers, and safety. Four RCTs with 369 schizophrenia patients were included. Sulforaphane did not significantly improve PANSS total or positive symptom scores at the latest follow-up (ranging from 24 weeks to 18 weeks) or at a consistent 12-week time point. However, a modest improvement in negative symptoms was found at 12 week- time point (MD= -1.06; 95% CI: -1.95 to -0.16; pâ€‰=â€‰0.02), which was not maintained at the latest follow-up. General psychopathology scores improved significantly (MD= -1.5; 95% CI: -2.78 to -0.23; pâ€‰=â€‰0.02). No cognitive benefits were observed. Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol. Discontinuation rates were lower in the sulforaphane group (RRâ€‰=â€‰0.68; 95% CI: 0.49 to 0.95; pâ€‰=â€‰0.02). The study provides initial insights into sulforaphane's potential therapeutic effects in schizophrenia, showing modest improvements in general psychopathology and negative symptoms, with favorable metabolic changes and lower discontinuation rates. Due to limited data and heterogeneity, the study findings should be interpreted with caution. Not applicable.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰ä¸­æå–çš„åŒ–åˆç‰©ï¼Œéå»å·²ç¶“è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºçš„ç²¾ç¥ç–¾ç—…ã€‚é›–ç„¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ï¼Œä½†é€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å¯¦éš›æ•ˆæœï¼Œå°¤å…¶æ˜¯åœ¨ç²¾ç¥å¥åº·çš„é é˜²å’Œæ²»ç™‚æ–¹é¢ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…é€²è¡Œäº†ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­é—œæ³¨çš„ä¸»è¦å•é¡Œæ˜¯è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯æ­£å‘å’Œè² å‘ç—‡ç‹€çš„è®ŠåŒ–ã€‚é€™æ˜¯ç¬¬ä¸€å€‹é‡å°é€™ä¸€ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§åˆ†æï¼Œå°æ–¼æœªä¾†çš„ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦é¸å–äº†å¾é–‹å§‹åˆ°2025å¹´4æœˆçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ã€‚é€™äº›ç ”ç©¶çš„å°è±¡ç‚º369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ï¼Œä¸»è¦è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚ç ”ç©¶çš„ä¸»è¦çµæœæŒ‡æ¨™åŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨çš„è®ŠåŒ–ï¼Œæ¬¡è¦çµæœå‰‡åŒ…æ‹¬èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é»ä¸Šï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ­¤å¤–ï¼Œæ•´é«”ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢çš„æ½›åŠ›ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æ¨™è¨˜ï¼ˆå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—çš„é™ä½æ•ˆæœï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›æœ‰è¶£çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾ç¥å¥åº·æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘è”¬èœï¼ˆå¦‚é’èŠ±æ¤°èœï¼‰ä¸­æå–çš„åŒ–åˆç‰©ï¼Œéå»å·²ç¶“è¢«ç ”ç©¶å…¶æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ç‰¹æ€§ã€‚é€™é …ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ²»ç™‚ä¸­çš„æ½›åŠ›ï¼Œé€™æ˜¯ä¸€ç¨®å½±éŸ¿æ€ç¶­ã€æƒ…æ„Ÿå’Œè¡Œç‚ºçš„ç²¾ç¥ç–¾ç—…ã€‚é›–ç„¶çµæœé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç—‡ç‹€æœ‰è¼•å¾®çš„æ”¹å–„ï¼Œä½†é€™äº›ç™¼ç¾ä»éœ€é€²ä¸€æ­¥ç ”ç©¶ä¾†ç¢ºèªå…¶å¯¦éš›æ•ˆæœï¼Œå°¤å…¶æ˜¯åœ¨ç²¾ç¥å¥åº·çš„é é˜²å’Œæ²»ç™‚æ–¹é¢ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ä¸­çš„ç™‚æ•ˆã€‚ç ”ç©¶è€…é€²è¡Œäº†ç³»çµ±æ€§å›é¡§å’Œçµ±åˆåˆ†æï¼Œæ—¨åœ¨è©•ä¼°è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡çš„å½±éŸ¿ã€‚ç ”ç©¶ä¸­é—œæ³¨çš„ä¸»è¦å•é¡Œæ˜¯è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ”¹å–„ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€ï¼Œç‰¹åˆ¥æ˜¯æ­£å‘å’Œè² å‘ç—‡ç‹€çš„è®ŠåŒ–ã€‚é€™æ˜¯ç¬¬ä¸€å€‹é‡å°é€™ä¸€ä¸»é¡Œé€²è¡Œçš„ç³»çµ±æ€§åˆ†æï¼Œå°æ–¼æœªä¾†çš„ç ”ç©¶å’Œè‡¨åºŠæ‡‰ç”¨å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—è¨­è¨ˆä¸Šï¼Œç ”ç©¶è€…å¾å¤šå€‹è³‡æ–™åº«ä¸­æœå°‹ç›¸é—œæ–‡ç»ï¼Œä¸¦é¸å–äº†å¾é–‹å§‹åˆ°2025å¹´4æœˆçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆRCTsï¼‰ã€‚é€™äº›ç ”ç©¶çš„å°è±¡ç‚º369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ï¼Œä¸»è¦è©•ä¼°è˜¿è””ç¡«ç´ çš„ç™‚æ•ˆã€‚ç ”ç©¶çš„ä¸»è¦çµæœæŒ‡æ¨™åŒ…æ‹¬æ­£è² ç—‡ç‹€é‡è¡¨ï¼ˆPANSSï¼‰çš„ç¸½åˆ†åŠå…¶å­é‡è¡¨çš„è®ŠåŒ–ï¼Œæ¬¡è¦çµæœå‰‡åŒ…æ‹¬èªçŸ¥æ¸¬é‡ã€ä»£è¬æ¨™è¨˜å’Œå®‰å…¨æ€§ã€‚é€™æ¨£çš„è¨­è¨ˆä½¿å¾—ç ”ç©¶èƒ½å¤ å…¨é¢è©•ä¼°è˜¿è””ç¡«ç´ çš„æ½›åœ¨ç™‚æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨æ”¹å–„PANSSç¸½åˆ†å’Œæ­£å‘ç—‡ç‹€æ–¹é¢ä¸¦æœªé¡¯è‘—æœ‰æ•ˆï¼Œä½†åœ¨12é€±çš„æ™‚é»ä¸Šï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚æ­¤å¤–ï¼Œæ•´é«”ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿé¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨æŸäº›æ–¹é¢çš„æ½›åŠ›ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ å°ä»£è¬æ¨™è¨˜ï¼ˆå¦‚ä½å¯†åº¦è„‚è›‹ç™½ã€ä¸‰é…¸ç”˜æ²¹è„‚å’Œè†½å›ºé†‡ï¼‰æœ‰é¡¯è‘—çš„é™ä½æ•ˆæœï¼Œä¸”åœ¨è˜¿è””ç¡«ç´ çµ„çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚å„˜ç®¡å¦‚æ­¤ï¼Œç”±æ–¼æ•¸æ“šæœ‰é™ä¸”å­˜åœ¨ç•°è³ªæ€§ï¼Œé€™äº›çµæœæ‡‰è¬¹æ…è§£è®€ã€‚",
    "fb_post": "ä½ çŸ¥é“é’èŠ±æ¤°èœé™¤äº†å¥½åƒï¼Œé‚„æœ‰å¯èƒ½å¹«åŠ©æ”¹å–„å¿ƒç†å¥åº·å—ï¼Ÿæœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆé–€æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„åŒ–åˆç‰©ï¼Œé€™æ˜¯å¾åå­—èŠ±ç§‘çš„è”¬èœä¸­æå–çš„ï¼Œåƒæ˜¯é’èŠ±æ¤°èœã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“è˜¿è””ç¡«ç´ å°ç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…çš„ç—‡ç‹€æœ‰æ²’æœ‰å¹«åŠ©ã€‚  \n  \né€™é …ç ”ç©¶é€²è¡Œäº†ç³»çµ±æ€§çš„åˆ†æï¼Œæ¶µè“‹äº†369åç²¾ç¥åˆ†è£‚ç—‡æ‚£è€…ï¼Œä¸»è¦è§€å¯Ÿè˜¿è””ç¡«ç´ å°ä»–å€‘çš„å½±éŸ¿ï¼Œå°¤å…¶æ˜¯æ­£å‘ï¼ˆä¾‹å¦‚å¹»è¦ºï¼‰å’Œè² å‘ï¼ˆä¾‹å¦‚æƒ…æ„Ÿå¹³æ·¡ï¼‰ç—‡ç‹€çš„è®ŠåŒ–ã€‚çµæœé¡¯ç¤ºï¼Œåœ¨12é€±å¾Œï¼Œè² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ï¼Œæ•´é«”ç²¾ç¥ç—…ç†å­¸çš„è©•åˆ†ä¹Ÿæœ‰é¡¯è‘—æ”¹å–„ã€‚ä¸éï¼Œå°æ–¼æ­£å‘ç—‡ç‹€çš„æ”¹å–„å‰‡æ²’æœ‰æ˜é¡¯æ•ˆæœã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½é™ä½ä¸€äº›ä»£è¬æ¨™è¨˜ï¼Œå¦‚è†½å›ºé†‡ï¼Œä¸¦ä¸”åœ¨è©¦é©—ä¸­å‡ºç¾çš„ä¸­æ­¢ç‡è¼ƒä½ã€‚  \n  \nç¸½çµä¸€ä¸‹ï¼š  \n- è˜¿è””ç¡«ç´ å¯èƒ½å°æŸäº›ç²¾ç¥åˆ†è£‚ç—‡çš„è² å‘ç—‡ç‹€æœ‰è¼•å¾®æ”¹å–„ã€‚  \n- æ•´é«”ç²¾ç¥ç—…ç†å­¸è©•åˆ†é¡¯è‘—æ”¹å–„ï¼Œé¡¯ç¤ºå‡ºæ½›åŠ›ã€‚  \n- å°ä»£è¬æ¨™è¨˜æœ‰é™ä½æ•ˆæœï¼Œä¸”è©¦é©—ä¸­æ­¢ç‡è¼ƒä½ã€‚  \n  \nä¸éï¼Œé€™äº›çµæœé‚„éœ€è¦æ›´å¤šç ”ç©¶ä¾†ç¢ºèªï¼Œæ‰€ä»¥æˆ‘å€‘é‚„æ˜¯è¦ä¿æŒè¬¹æ…å“¦ï¼",
    "image_prompt": "Create a flat design infographic with a light background, illustrating the experiment and main results of a study on sulforaphane. Include symbols representing broccoli and sulforaphane. Simplified figures of human subjects should be present. Use arrows or flow lines to show the experimental steps. Include a section labeled 'Main Results' highlighting slight improvements in negative symptoms and reductions in metabolic markers.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç²¾ç¥åˆ†è£‚ç—‡ Schizophrenia",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41184790/"
  },
  {
    "id": "40992247",
    "title_en": "Assessing the transplacental passage and breastmilk levels of broccoli sprout-derived sulforaphane.",
    "pub_date": "2025 Nov",
    "abstract_en": "Preeclampsia is characterised by hypertension with maternal end-organ dysfunction and/or fetal growth restriction. Sulforaphane, an antioxidant found in broccoli sprouts, has potential as a future therapeutic. With its ability to attenuate the injurious impacts of endothelial dysfunction in vitro, sulforaphane is uniquely positioned to protect against the harmful effects of preeclampsia. However, the transferability of sulforaphane from mother to fetus/baby remains unknown in humans. Uncomplicated pregnant patients (nÂ =Â 8) scheduled for elective caesarean sections (>37 weeks gestation) provided written and informed consent. A single oral dose of EnduraCell, a broccoli sprout extract (equivalent to 21Â mg of sulforaphane), was administered prior to caesarean section. Baseline blood pressure, blood and urine were collected and again at time of operation, alongside umbilical cord blood (vein and artery) and placental samples. 2-4 days post-delivery, a second dose was administered. Two hours later, maternal bloods and breast milk were collected. Samples were processed and analysed by liquid-chromatography mass-spectrometry to measure sulforaphane. Besides an increase in peripheral diastolic blood pressure on the day of caesarean section (pÂ =Â 0.028), there were no changes in maternal blood pressure or heart rate after ingestion of EnduraCell. Sulforaphane was found in maternal serum (70.10Â ng/mlÂ Â±Â 11.90), umbilical cord blood (vein: 25.18Â ng/mLÂ Â±Â 3.11, artery: 18.81Â ng/mLÂ Â±Â 2.36), urine (5726.00Â ng/mLÂ Â±Â 1175.00), placental tissue (10.99Â ng/mgÂ Â±Â 2.11) and breast milk (1.33Â ng/mLÂ Â±Â 2.29). Sulforaphane is present in the umbilical cord and breast milk, providing the world's first evidence of sulforaphane maternal-fetal transfer in humans, and opening avenues for future research into relevant fetal implications.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æŠ—æ°§åŒ–åŠ‘å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™²å‰ç—‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„é«˜è¡€å£“ç–¾ç—…ï¼Œå¯èƒ½æœƒå°æ¯é«”å’Œèƒå…’é€ æˆå‚·å®³ã€‚é€™é …ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æœ‰å®³å½±éŸ¿ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¦Šå¨ æœŸé–“çš„å¥åº·ç‹€æ³ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»æƒ…æ³ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£ï¼Œç•¶å­•å©¦æ”å–è˜¿è””ç¡«ç´ å¾Œï¼Œé€™ç¨®ç‰©è³ªæ˜¯å¦èƒ½å¤ é€šéèƒç›¤å‚³éçµ¦èƒå…’ï¼Œä¸¦åœ¨æ¯ä¹³ä¸­å‡ºç¾ï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å’Œå¥åº·æŒ‡å°å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—å°è±¡ç‚º8åè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨å¦Šå¨ 37é€±ä»¥ä¸Šï¼Œä¸¦å·²ç°½ç½²çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆå¥¹å€‘ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“æœŸé–“æ”¶é›†åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä»¥åŠè‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œç ”ç©¶è€…å†æ¬¡çµ¦äºˆç¬¬äºŒåŠ‘è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©æ¯é«”çš„èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¾†èªªï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªå› æ”å–è˜¿è””ç¡«ç´ è€Œç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ é€™ç¨®æŠ—æ°§åŒ–åŠ‘å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“ç—‡ï¼ˆå³å­ç™²å‰ç—‡ï¼‰æœ‰æ½›åœ¨çš„ä¿è­·ä½œç”¨ã€‚å­ç™²å‰ç—‡æ˜¯ä¸€ç¨®å¦Šå¨ æœŸé–“çš„é«˜è¡€å£“ç–¾ç—…ï¼Œå¯èƒ½æœƒå°æ¯é«”å’Œèƒå…’é€ æˆå‚·å®³ã€‚é€™é …ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•å…§çš®åŠŸèƒ½éšœç¤™çš„æœ‰å®³å½±éŸ¿ï¼Œé€™æ„å‘³è‘—å®ƒå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¦Šå¨ æœŸé–“çš„å¥åº·ç‹€æ³ï¼Œä¸¦ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡ä¸­çš„æ½›åœ¨æ‡‰ç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“çš„è½‰ç§»æƒ…æ³ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£ï¼Œç•¶å­•å©¦æ”å–è˜¿è””ç¡«ç´ å¾Œï¼Œé€™ç¨®ç‰©è³ªæ˜¯å¦èƒ½å¤ é€šéèƒç›¤å‚³éçµ¦èƒå…’ï¼Œä¸¦åœ¨æ¯ä¹³ä¸­å‡ºç¾ï¼Œé€™å°æ–¼æœªä¾†çš„è‡¨åºŠæ‡‰ç”¨å’Œå¥åº·æŒ‡å°å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—å°è±¡ç‚º8åè¨ˆåŠƒé€²è¡Œå‰–è…¹ç”¢çš„å­•å©¦ï¼Œé€™äº›å­•å©¦åœ¨å¦Šå¨ 37é€±ä»¥ä¸Šï¼Œä¸¦å·²ç°½ç½²çŸ¥æƒ…åŒæ„æ›¸ã€‚ç ”ç©¶è€…åœ¨å‰–è…¹ç”¢å‰çµ¦äºˆå¥¹å€‘ä¸€åŠ‘è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œä¸¦åœ¨æ‰‹è¡“æœŸé–“æ”¶é›†åŸºç·šè¡€å£“ã€è¡€æ¶²å’Œå°¿æ¶²æ¨£æœ¬ï¼Œä»¥åŠè‡å¸¶è¡€å’Œèƒç›¤æ¨£æœ¬ã€‚ç”¢å¾Œ2è‡³4å¤©ï¼Œç ”ç©¶è€…å†æ¬¡çµ¦äºˆç¬¬äºŒåŠ‘è˜¿è””ç¡«ç´ ï¼Œä¸¦åœ¨å…©å°æ™‚å¾Œæ”¶é›†æ¯é«”è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ï¼Œé€²è¡Œåˆ†æä»¥æ¸¬é‡è˜¿è””ç¡«ç´ çš„å«é‡ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ åœ¨æ¯é«”è¡€æ¸…ã€è‡å¸¶è¡€ã€å°¿æ¶²ã€èƒç›¤çµ„ç¹”å’Œæ¯ä¹³ä¸­å‡æœ‰æª¢æ¸¬åˆ°ï¼Œé€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½å¤ åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šã€‚é›–ç„¶åœ¨å‰–è…¹ç”¢ç•¶å¤©æ¯é«”çš„èˆ’å¼µå£“æœ‰æ‰€ä¸Šå‡ï¼Œä½†æ•´é«”ä¾†èªªï¼Œæ¯é«”çš„è¡€å£“å’Œå¿ƒç‡ä¸¦æœªå› æ”å–è˜¿è””ç¡«ç´ è€Œç™¼ç”Ÿé¡¯è‘—è®ŠåŒ–ã€‚é€™äº›çµæœç‚ºæœªä¾†ç ”ç©¶è˜¿è””ç¡«ç´ å°èƒå…’çš„å½±éŸ¿æä¾›äº†æ–°çš„ç ”ç©¶æ–¹å‘ã€‚",
    "fb_post": "ğŸŒ± æœ‰è½éè˜¿è””ç¡«ç´ å—ï¼Ÿé€™ç¨®ä¾†è‡ªé’èŠ±æ¤°èœçš„å¤©ç„¶æˆåˆ†ï¼Œæœ€è¿‘åœ¨å¦Šå¨ é«˜è¡€å£“ç—‡çš„ç ”ç©¶ä¸­å¼•èµ·äº†å¤§å®¶çš„æ³¨æ„ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œå¿ƒçš„æ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½åœ¨å­•å©¦é«”å…§å°æŠ—å¦Šå¨ é«˜è¡€å£“ï¼ˆä¹Ÿå°±æ˜¯å­ç™²å‰ç—‡ï¼‰ï¼Œé€™æ˜¯ä¸€ç¨®å¯èƒ½å°åª½åª½å’Œå¯¶å¯¶éƒ½é€ æˆå±éšªçš„ç–¾ç—…ã€‚ç ”ç©¶è€…é‚€è«‹äº†8ä½å³å°‡å‰–è…¹ç”¢çš„å­•å©¦ï¼Œçµ¦å¥¹å€‘æ”å–è˜¿è””ç¡«ç´ æå–ç‰©ï¼Œç„¶å¾Œåœ¨æ‰‹è¡“å’Œç”¢å¾Œæ”¶é›†å¥¹å€‘çš„è¡€æ¶²å’Œæ¯ä¹³æ¨£æœ¬ã€‚\n\nçµæœç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…åœ¨å­•å©¦çš„è¡€æ¶²ä¸­èƒ½è¢«æª¢æ¸¬åˆ°ï¼Œé‚„èƒ½é€šéèƒç›¤å‚³éåˆ°å¯¶å¯¶èº«ä¸Šï¼Œç”šè‡³åœ¨æ¯ä¹³ä¸­ä¹Ÿæœ‰ï¼é€™æ˜¯å…¨çƒé¦–æ¬¡è­‰å¯¦è˜¿è””ç¡«ç´ èƒ½åœ¨æ¯é«”èˆ‡èƒå…’ä¹‹é–“è½‰ç§»çš„è­‰æ“šï¼Œé›–ç„¶æ¯é«”çš„è¡€å£“åœ¨æ‰‹è¡“ç•¶å¤©æœ‰äº›ä¸Šå‡ï¼Œä½†æ•´é«”ä¸Šä¸¦æ²’æœ‰é¡¯è‘—è®ŠåŒ–ã€‚\n\nğŸ’¡ ç¸½çµä¸€ä¸‹ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å°å¦Šå¨ é«˜è¡€å£“æœ‰ä¿è­·ä½œç”¨ã€‚\n2. å®ƒèƒ½å¤ ç©¿éèƒç›¤ï¼Œå½±éŸ¿èƒå…’å¥åº·ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·æŒ‡å°å’Œè‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°æ–¹å‘ï¼",
    "image_prompt": "Create an infographic that explains the research on sulforaphane in pregnancy. Include simple icons representing broccoli and sulforaphane, a simplified illustration of pregnant women as study subjects, arrows or flow lines showing the steps of the experiment (intake of sulforaphane, sample collection), and a section highlighting the main results, such as the transfer of sulforaphane from mother to fetus and effects on blood pressure.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¦Šå¨ é«˜è¡€å£“ç—‡ Preeclampsia",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40992247/"
  },
  {
    "id": "40633511",
    "title_en": "Synthesis and biological evaluation of Sulforaphane derivatives with dual functions: Ischemia-reperfusion injury protection and antitumor effects.",
    "pub_date": "2025 Nov",
    "abstract_en": "Reperfusion therapy for the treatment of acute myocardial infarction (AMI) often leads to ischemia-reperfusion (I/R) injuries, characterized by excessive ROS. Sulforaphane (SFN) homologous, known for their anti-inflammatory and antioxidant properties, activate the nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway and reduce mitochondrial ROS but are limited by poor stability and short half-life. SFN derivatives were synthesized through structural modifications of the dithiocarbamate and thiourea moieties at the isothiocyanate group, aiming to enhance stability and maintain therapeutic efficacy. Compound 3g emerged as a promising candidate, demonstrating superior protection against hypoxia-reoxygenation (H/R) injury in cardiac microvascular endothelial cells (CMECs) and exhibiting good antitumor activity. Specifically, 3g reduced ROS levels by 24.5Â % (compared to nifedipine at 17.8Â %), increased NO production to 48.0Â Î¼M (vs. 44.0Â Î¼M), lowered TNF-Î± secretion to 22.6Â pg/mL (vs. 23.9Â pg/mL). Concurrently, 3g showed potent antiproliferative activity (IC<sub>50</sub>Â =Â 7.5Â Î¼M), with 3.8-fold greater potency than 5-fluorouracil (IC<sub>50</sub>Â =Â 28.2Â Î¼M). Stability studies showed enhanced resistance in both protic and aprotic solvents. Density functional theory (DFT) was applied to characterize the molecular properties of the optimal compounds. Molecular docking and ADMET analysis revealed that aromatic substitution and sulfur oxidation significantly improved Nrf2/Keap1 pathway targeting, highlighting the derivative's potential for stability and therapeutic efficacy. These findings suggest that 3g is a promising candidate for treating I/R-induced injury and oxidative stress-related cardiovascular conditions.",
    "para1": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ï¼Œå¯èƒ½æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ã€‚é€™ç¨®æå‚·é€šå¸¸ä¼´éš¨è‘—éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿï¼Œé€™å°å¿ƒè‡Ÿç´°èƒé€ æˆå‚·å®³ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é€™äº›æƒ…æ³ï¼Œå¾è€Œä¿ƒé€²å¿ƒè¡€ç®¡å¥åº·ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­å°ç¼ºæ°§å†çŒæ³¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€šéæ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†å¢å¼·å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ï¼Œé€™äº›è¡ç”Ÿç‰©æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·å’Œæ°§åŒ–å£“åŠ›ã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«æ°¨åŸºç”²é…¸é¹½å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä»¥æé«˜å…¶ç©©å®šæ€§ã€‚ç ”ç©¶å°è±¡æ˜¯å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œä¸¦ä½¿ç”¨ç¼ºæ°§å†çŒæ³¨çš„æ¨¡å‹ä¾†æ¨¡æ“¬å¿ƒè‡Ÿæå‚·ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†é€™äº›è¡ç”Ÿç‰©å°ç´°èƒçš„ä¿è­·æ•ˆæœï¼Œä¸¦è©•ä¼°äº†å…¶æŠ—è…«ç˜¤æ´»æ€§å’Œå°æ´»æ€§æ°§çš„æŠ‘åˆ¶èƒ½åŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œåˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³å’Œæé«˜ä¸€æ°§åŒ–æ°®ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨æŠ—å¢æ®–æ´»æ€§ä¸Šæ¯”å‚³çµ±è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å…·æ•ˆåŠ›ã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼Œä¸¦é¡¯è‘—æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œç©©å®šæ€§ç ”ç©¶é¡¯ç¤ºï¼Œé€™äº›è¡ç”Ÿç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­å…·æœ‰æ›´å¥½çš„ç©©å®šæ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·å’Œæ°§åŒ–å£“åŠ›ç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°æ–¼å¿ƒè¡€ç®¡å¥åº·å’Œç–¾ç—…é é˜²æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ï¼Œå¯èƒ½æœƒå°è‡´ç¼ºè¡€å†çŒæ³¨æå‚·ã€‚é€™ç¨®æå‚·é€šå¸¸ä¼´éš¨è‘—éé‡çš„æ´»æ€§æ°§ï¼ˆROSï¼‰ç”¢ç”Ÿï¼Œé€™å°å¿ƒè‡Ÿç´°èƒé€ æˆå‚·å®³ã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ æ¸›å°‘é€™äº›æå‚·çš„æ²»ç™‚æ–¹æ³•æ˜¯éå¸¸é‡è¦çš„ã€‚ç ”ç©¶ä¸­æåˆ°çš„è˜¿è””ç¡«ç´ åŠå…¶è¡ç”Ÿç‰©ï¼Œå› å…¶æŠ—ç™¼ç‚å’ŒæŠ—æ°§åŒ–çš„ç‰¹æ€§ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„é€™äº›æƒ…æ³ï¼Œå¾è€Œä¿ƒé€²å¿ƒè¡€ç®¡å¥åº·ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©åœ¨å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒä¸­å°ç¼ºæ°§å†çŒæ³¨æå‚·çš„ä¿è­·ä½œç”¨ã€‚ç ”ç©¶è€…é—œå¿ƒçš„æ˜¯å¦‚ä½•é€šéæ”¹è‰¯è˜¿è””ç¡«ç´ çš„çµæ§‹ä¾†å¢å¼·å…¶ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ï¼Œé€™äº›è¡ç”Ÿç‰©æ˜¯å¦èƒ½æœ‰æ•ˆæ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·å’Œæ°§åŒ–å£“åŠ›ã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©ï¼Œç‰¹åˆ¥æ˜¯é€šéå°äºŒç¡«æ°¨åŸºç”²é…¸é¹½å’Œç¡«è„²åŸºåœ˜é€²è¡Œçµæ§‹ä¿®é£¾ï¼Œä»¥æé«˜å…¶ç©©å®šæ€§ã€‚ç ”ç©¶å°è±¡æ˜¯å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒï¼Œä¸¦ä½¿ç”¨ç¼ºæ°§å†çŒæ³¨çš„æ¨¡å‹ä¾†æ¨¡æ“¬å¿ƒè‡Ÿæå‚·ã€‚ç ”ç©¶è€…æ¸¬è©¦äº†é€™äº›è¡ç”Ÿç‰©å°ç´°èƒçš„ä¿è­·æ•ˆæœï¼Œä¸¦è©•ä¼°äº†å…¶æŠ—è…«ç˜¤æ´»æ€§å’Œå°æ´»æ€§æ°§çš„æŠ‘åˆ¶èƒ½åŠ›ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œåˆæˆçš„åŒ–åˆç‰©3gåœ¨æ¸›å°‘æ´»æ€§æ°§æ°´å¹³å’Œæé«˜ä¸€æ°§åŒ–æ°®ç”¢ç”Ÿæ–¹é¢è¡¨ç¾å‡ºè‰²ï¼Œä¸¦ä¸”åœ¨æŠ—å¢æ®–æ´»æ€§ä¸Šæ¯”å‚³çµ±è—¥ç‰©5-æ°Ÿå°¿å˜§å•¶æ›´å…·æ•ˆåŠ›ã€‚å…·é«”ä¾†èªªï¼Œ3gèƒ½å°‡æ´»æ€§æ°§æ°´å¹³é™ä½24.5%ï¼Œä¸¦é¡¯è‘—æé«˜ä¸€æ°§åŒ–æ°®çš„ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œç©©å®šæ€§ç ”ç©¶é¡¯ç¤ºï¼Œé€™äº›è¡ç”Ÿç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­å…·æœ‰æ›´å¥½çš„ç©©å®šæ€§ï¼Œé¡¯ç¤ºå‡ºå…¶åœ¨æ²»ç™‚ç¼ºè¡€å†çŒæ³¨æå‚·å’Œæ°§åŒ–å£“åŠ›ç›¸é—œå¿ƒè¡€ç®¡ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„å¿ƒè‡Ÿåœ¨é¢å°å‚·å®³æ™‚ï¼Œå¯èƒ½æœƒå—åˆ°æ°§åŒ–å£“åŠ›çš„å½±éŸ¿ï¼Œé€™å°å¥åº·éå¸¸ä¸åˆ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„ç‰©è³ªï¼Œç™¼ç¾å®ƒå¯èƒ½å¹«åŠ©æˆ‘å€‘çš„å¿ƒè‡Ÿæ›´å¥½åœ°æ‡‰å°é€™äº›æŒ‘æˆ°ã€‚\n\nç ”ç©¶çš„é‡é»æ˜¯è˜¿è””ç¡«ç´ çš„è¡ç”Ÿç‰©å°å¿ƒè‡Ÿå¾®è¡€ç®¡å…§çš®ç´°èƒçš„ä¿è­·ä½œç”¨ã€‚ç§‘å­¸å®¶å€‘é€éæ”¹è‰¯é€™äº›è¡ç”Ÿç‰©çš„çµæ§‹ï¼Œå¸Œæœ›èƒ½å¢å¼·å®ƒå€‘çš„ç©©å®šæ€§å’Œç™‚æ•ˆï¼Œç‰¹åˆ¥æ˜¯åœ¨æ€¥æ€§å¿ƒè‚Œæ¢—å¡å¾Œçš„å†çŒæ³¨æ²»ç™‚ä¸­ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†å¹¾ç¨®æ–°çš„è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©ï¼Œä¸¦ä½¿ç”¨ç¼ºæ°§å†çŒæ³¨çš„æ¨¡å‹ä¾†æ¨¡æ“¬å¿ƒè‡Ÿæå‚·ã€‚ä»–å€‘ç™¼ç¾ï¼ŒæŸäº›åŒ–åˆç‰©åœ¨æ¸›å°‘æ´»æ€§æ°§ï¼ˆå°ç´°èƒæœ‰å®³çš„åˆ†å­ï¼‰å’Œå¢åŠ ä¸€æ°§åŒ–æ°®ï¼ˆæœ‰åŠ©æ–¼è¡€ç®¡æ“´å¼µçš„åˆ†å­ï¼‰æ–¹é¢è¡¨ç¾éå¸¸å‡ºè‰²ã€‚\n\né€™é …ç ”ç©¶çš„å¹¾å€‹é‡é»æ˜¯ï¼š\n1. è˜¿è””ç¡«ç´ è¡ç”Ÿç‰©å¯èƒ½æœ‰åŠ©æ–¼æ¸›å°‘å¿ƒè‡Ÿç´°èƒçš„æå‚·ã€‚\n2. æ–°åˆæˆçš„åŒ–åˆç‰©åœ¨æŠ—æ°§åŒ–æ–¹é¢æ•ˆæœé¡¯è‘—ã€‚\n3. é€™äº›è¡ç”Ÿç‰©åœ¨ä¸åŒæº¶åŠ‘ä¸­é¡¯ç¤ºå‡ºæ›´å¥½çš„ç©©å®šæ€§ï¼Œæœªä¾†å¯èƒ½æˆç‚ºå¿ƒè¡€ç®¡ç–¾ç—…çš„æ½›åœ¨æ²»ç™‚é¸æ“‡ã€‚",
    "image_prompt": "Create a flat design infographic that illustrates the experiment and main results of a study on the protective effects of a compound called sulforaphane on heart microvascular endothelial cells. The image should include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans or cells, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting the protective effects and changes observed, all set against a light background with soft colors.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¿ƒè‚Œæ¢—å¡ Myocardial Infarction",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40633511/"
  },
  {
    "id": "40617372",
    "title_en": "Antioxidant effect of esculin and sulforaphane in zebrafish larvae: A comparative study.",
    "pub_date": "2025 Nov",
    "abstract_en": "Antioxidants are crucial for maintaining cellular redox homeostasis by neutralizing free radicals, including reactive oxygen species (ROS). Nuclear factor erythroid-2-related factor 2 (Nrf2) is a transcription factor that activates various cytoprotective genes to counteract oxidative damage. The present study aimed to compare the antioxidant potential of natural phytochemicals, esculin (ESC), and sulforaphane (SFN) in zebrafish larvae, focusing on Nrf2 activation. Zebrafish larvae were treated with ESC (100Â Î¼M) and SFN (40Â Î¼M) along with control for 6Â h. The levels of ROS, lipid peroxidation (LPO), nitric oxide (NO), glutathione S-transferase (GST), glutathione peroxidase (GPx), catalase (CAT), and reduced glutathione (GSH) were measured. Further, RT-PCR and Western blotting methods were employed to determine the antioxidant genes and protein levels, respectively. In addition, Nrf2 localization within the cell was assessed using nuclear/cytosolic fractionation assay and wholemount immunohistochemistry method. Our results demonstrate that ESC treatment significantly increased antioxidant enzyme activities (GST, GPx, CAT), similar to the effects observed with SFN. Further, ESC enhanced the mRNA levels of antioxidant genes expression, such as nrf2, gstp1, hmox1a, prdx1, nqo1, gss, gsr, sqstm1, hsp90aa1.2 than SFN. Antioxidant proteins Nrf2, Gstp1, Cat, and Sod2 were upregulated in the ESC-treated groups. Subsequently, nuclear localization of Nrf2 was detected in both SFN- and ESC-treated groups, confirming Nrf2 translocation into the nucleus. Our findings suggest that ESC possesses potent antioxidant activity as SFN in 72-hpf zebrafish larvae through the Keap1-Nrf2 signaling pathway.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶ä¸­æåˆ°çš„Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·æ€§åŸºå› ï¼Œå¹«åŠ©æŠµæŠ—æ°§åŒ–æå‚·ã€‚é€™æ„å‘³è‘—é€éå¢åŠ æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç´°èƒï¼Œé€²è€Œé™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼Œç‰¹åˆ¥æ˜¯èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°Nrf2çš„æ¿€æ´»æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„æ°§åŒ–å£“åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å®ƒå€‘çš„æŠ—æ°§åŒ–æ©Ÿåˆ¶ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„æŠ—æ°§åŒ–åŠ‘ä¾†æºå’Œæ”¹å–„å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "å¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºå¹¾çµ„ï¼Œåˆ†åˆ¥æ¥å—esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ä½¿ç”¨äº†RT-PCRå’ŒWestern blottingç­‰æ–¹æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”æ°´å¹³ï¼Œä¸¦è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­ä¹Ÿç¢ºèªäº†Nrf2åœ¨ç´°èƒæ ¸ä¸­çš„å®šä½ï¼Œé€™è¡¨æ˜é€™å…©ç¨®åŒ–åˆç‰©éƒ½èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœæç¤ºesculinåœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œä½†ä¸¦ä¸è¡¨ç¤ºä¸€å®šèƒ½æ²»ç™’æˆ–å®Œå…¨é˜²æ­¢ç›¸é—œç–¾ç—…ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æŠ—æ°§åŒ–åŠ‘çš„ä½œç”¨ä¸Šã€‚æŠ—æ°§åŒ–åŠ‘èƒ½å¤ ä¸­å’Œè‡ªç”±åŸºï¼Œé€™å°æ–¼ç¶­æŒç´°èƒçš„å¥åº·è‡³é—œé‡è¦ã€‚ç ”ç©¶ä¸­æåˆ°çš„Nrf2æ˜¯ä¸€ç¨®è½‰éŒ„å› å­ï¼Œèƒ½å•Ÿå‹•å¤šç¨®ä¿è­·æ€§åŸºå› ï¼Œå¹«åŠ©æŠµæŠ—æ°§åŒ–æå‚·ã€‚é€™æ„å‘³è‘—é€éå¢åŠ æŠ—æ°§åŒ–åŠ‘çš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿è­·ç´°èƒï¼Œé€²è€Œé™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªï¼Œç‰¹åˆ¥æ˜¯èˆ‡æ°§åŒ–å£“åŠ›ç›¸é—œçš„ç–¾ç—…ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¯”è¼ƒå…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªâ€”â€”è˜¿è””ç¡«ç´ å’Œesculinåœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯å®ƒå€‘å°Nrf2çš„æ¿€æ´»æ•ˆæœã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„æ°§åŒ–å£“åŠ›ï¼Œä¸¦é€²ä¸€æ­¥æ¢è¨å®ƒå€‘çš„æŠ—æ°§åŒ–æ©Ÿåˆ¶ã€‚é€™å°æ–¼å°‹æ‰¾æ–°çš„æŠ—æ°§åŒ–åŠ‘ä¾†æºå’Œæ”¹å–„å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nå¯¦é©—ä¸­ä½¿ç”¨äº†72å°æ™‚çš„æ–‘é¦¬é­šå¹¼é«”ä½œç‚ºç ”ç©¶å°è±¡ï¼Œä¸¦å°‡å…¶åˆ†ç‚ºå¹¾çµ„ï¼Œåˆ†åˆ¥æ¥å—esculinï¼ˆ100Î¼Mï¼‰å’Œè˜¿è””ç¡«ç´ ï¼ˆ40Î¼Mï¼‰çš„è™•ç†ï¼ŒæŒçºŒ6å°æ™‚ã€‚ç ”ç©¶è€…æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼ŒåŒ…æ‹¬æ´»æ€§æ°§ï¼ˆROSï¼‰ã€è„‚è³ªéæ°§åŒ–ï¼ˆLPOï¼‰ã€ä¸€æ°§åŒ–æ°®ï¼ˆNOï¼‰ã€ä»¥åŠå¹¾ç¨®æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„ä½¿ç”¨äº†RT-PCRå’ŒWestern blottingç­‰æ–¹æ³•ä¾†æª¢æ¸¬æŠ—æ°§åŒ–åŸºå› å’Œè›‹ç™½è³ªçš„è¡¨é”æ°´å¹³ï¼Œä¸¦è©•ä¼°Nrf2åœ¨ç´°èƒå…§çš„å®šä½ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œesculinçš„è™•ç†é¡¯è‘—æé«˜äº†æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œèˆ‡è˜¿è””ç¡«ç´ çš„æ•ˆæœç›¸ä¼¼ã€‚æ­¤å¤–ï¼Œesculiné‚„ä¿ƒé€²äº†å¤šå€‹æŠ—æ°§åŒ–åŸºå› çš„mRNAè¡¨é”æ°´å¹³ï¼Œé¡¯ç¤ºå‡ºå…¶å¼·å¤§çš„æŠ—æ°§åŒ–æ´»æ€§ã€‚ç ”ç©¶ä¸­ä¹Ÿç¢ºèªäº†Nrf2åœ¨ç´°èƒæ ¸ä¸­çš„å®šä½ï¼Œé€™è¡¨æ˜é€™å…©ç¨®åŒ–åˆç‰©éƒ½èƒ½æœ‰æ•ˆæ¿€æ´»Nrf2ä¿¡è™Ÿé€šè·¯ã€‚é€™äº›çµæœæç¤ºesculinåœ¨æŠ—æ°§åŒ–æ–¹é¢çš„æ½›åŠ›ï¼Œèˆ‡è˜¿è””ç¡«ç´ ç›¸ç•¶ï¼Œä½†ä¸¦ä¸è¡¨ç¤ºä¸€å®šèƒ½æ²»ç™’æˆ–å®Œå…¨é˜²æ­¢ç›¸é—œç–¾ç—…ã€‚",
    "fb_post": "ğŸ€ å¤§å®¶å¥½ï¼ä»Šå¤©ä¾†èŠèŠä¸€å€‹æœ‰è¶£çš„ç ”ç©¶ï¼Œé—œæ–¼æˆ‘å€‘èº«é«”è£¡çš„æŠ—æ°§åŒ–åŠ‘ï¼ä½ çŸ¥é“å—ï¼ŸæŠ—æ°§åŒ–åŠ‘èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—è‡ªç”±åŸºçš„å‚·å®³ï¼Œé€™å°ç¶­æŒå¥åº·éå¸¸é‡è¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨å…©ç¨®å¤©ç„¶æ¤ç‰©åŒ–å­¸ç‰©è³ªï¼šè˜¿è””ç¡«ç´ å’Œesculinï¼Œæƒ³çœ‹çœ‹å®ƒå€‘åœ¨æ–‘é¦¬é­šå¹¼é«”ä¸­çš„æŠ—æ°§åŒ–æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“é€™äº›åŒ–åˆç‰©å¦‚ä½•å½±éŸ¿ç´°èƒå…§çš„æ°§åŒ–å£“åŠ›ï¼Œä¸¦äº†è§£å®ƒå€‘çš„æŠ—æ°§åŒ–æ©Ÿåˆ¶ã€‚ç‚ºäº†é€²è¡Œå¯¦é©—ï¼Œä»–å€‘ç”¨72å°æ™‚å¤§çš„æ–‘é¦¬é­šå¹¼é«”ï¼Œåˆ†åˆ¥çµ¦äºˆé€™å…©ç¨®åŒ–åˆç‰©ï¼Œä¸¦æ¸¬é‡äº†å¤šç¨®æŒ‡æ¨™ï¼Œæ¯”å¦‚æ´»æ€§æ°§å’ŒæŠ—æ°§åŒ–é…¶çš„æ´»æ€§ã€‚\n\nçµæœé¡¯ç¤ºï¼Œesculinå’Œè˜¿è””ç¡«ç´ éƒ½èƒ½æœ‰æ•ˆæé«˜æŠ—æ°§åŒ–é…¶çš„æ´»æ€§ï¼Œä¸¦ä¿ƒé€²æŠ—æ°§åŒ–åŸºå› çš„è¡¨é”ï¼Œé€™æ„å‘³è‘—å®ƒå€‘éƒ½èƒ½å•Ÿå‹•Nrf2é€™å€‹ä¿è­·æ€§åŸºå› ï¼Œå¹«åŠ©æˆ‘å€‘æŠµæŠ—æ°§åŒ–æå‚·ã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. æŠ—æ°§åŒ–åŠ‘èƒ½å¹«åŠ©æˆ‘å€‘æŠµæŠ—è‡ªç”±åŸºï¼Œç¶­æŒç´°èƒå¥åº·ã€‚\n2. è˜¿è””ç¡«ç´ å’Œesculinåœ¨æŠ—æ°§åŒ–æ–¹é¢è¡¨ç¾ç›¸ä¼¼ï¼Œèƒ½å•Ÿå‹•ä¿è­·æ€§åŸºå› ã€‚\n3. é€™äº›ç™¼ç¾æœ‰åŠ©æ–¼æœªä¾†å°‹æ‰¾æ–°çš„æŠ—æ°§åŒ–åŠ‘ä¾†æºï¼",
    "image_prompt": "Create a flat design infographic showing the experiment and main results of the study. Include symbols representing broccoli or sulforaphane, simplified illustrations of zebrafish or cells as experimental subjects, arrows or flow lines indicating the experimental steps, and a section labeled 'Main Results' highlighting protective effects and changes observed during the experiment. Use a light background with soft colors to create an informative and easy-to-understand visual.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40617372/"
  },
  {
    "id": "40533430",
    "title_en": "Monovalent glycoconjugates of sulforaphane prevent inflammation induced by lipopolysaccharide in human dendritic cells by inhibiting NF-Ä¸B signalling pathway.",
    "pub_date": "2025 Nov",
    "abstract_en": "Sulforaphane (SFN) has notable health benefits but faces challenges due to its poor solubility and delivery. This study investigates SFN-glycoconjugates effects on lipopolysaccharide (LPS)-induced inflammation in dendritic cells (DCs). With the aiming to enhance their therapeutic potential against inflammatory diseases. Novel monovalent SFN-glycoconjugates with mannose (Man) and fucose (0Fuc) were developed and tested for their anti-inflammatory and immune-modulatory properties in DCs from healthy donors under chronic LPS exposure. By leveraging therapeutic strategies, SFN-glycoconjugates significantly improved the solubility and bioavailability of SFN, thereby overcoming the limitations of traditional delivery methods. Monocyte-derived DCs were treated with SFN-glycoconjugates and subsequently exposed to a chronic inflammatory environment induced by LPS. Our results showed that SFN-glycoconjugates enhance effectiveness in suppressing inflammation by targeting the p65 NF-ÎºB pathway, without affecting MAPK signalling. SFN-glycoconjugates induce a tolerogenic immune response, characterized by increased IL-10 production and enhanced regulatory T- and B-cell proliferation. These effects surpass those of p65 NF-ÎºB inhibition alone, highlighting a distinct and potent regulatory mechanism independent of MAPK pathways. The integration of food therapeutic strategies not only enhances the stability and delivery of bioactive compounds but also broadens their potential applications in functional foods and therapeutic approaches. In particular, SFN-glycoconjugates represent a promising option as biologically active compounds for inflammatory diseases, offering enhanced anti-inflammatory and immunomodulatory effects through optimized delivery systems and the activation of specific molecular pathways.",
    "para1": "è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£åº¦å·®å’Œå‚³éå›°é›£ï¼Œä½¿ç”¨ä¸Šé¢è‡¨æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—ç‚ç—‡ç›¸é—œç–¾ç—…æ–¹é¢ã€‚é€éæ”¹é€²è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œå¯èƒ½èƒ½å¤ æ›´æœ‰æ•ˆåœ°ç™¼æ®å…¶æŠ—ç‚ä½œç”¨ï¼Œé€™å°æ–¼è¨±å¤šæ…¢æ€§ç–¾ç—…çš„é é˜²å’Œæ²»ç™‚éƒ½æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚",
    "para2": "é€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼ˆSFN-glycoconjugatesï¼‰å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„åŒ–åˆç‰©ä¾†å¢å¼·è˜¿è””ç¡«ç´ åœ¨æ²»ç™‚ç‚ç—‡ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ¨¹çªç´°èƒï¼ˆDCsï¼‰çš„ä½œç”¨ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾å¥åº·æè´ˆè€…ç²å–äº†å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç‚ç—‡æƒ…æ³ã€‚æ¥è‘—ï¼Œé€™äº›æ¨¹çªç´°èƒè¢«è™•ç†ä»¥è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œç ”ç©¶å…¶æŠ—ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚é€™é …ç ”ç©¶çš„è¨­è¨ˆæ—¨åœ¨å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ï¼Œæå‡è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©åˆ©ç”¨åº¦ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œä¸»è¦æ˜¯é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›åŒ–åˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œé€™å°æ–¼ç‚ç—‡ç–¾ç—…çš„æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰æ˜¯ä¸€ç¨®å…·æœ‰é¡¯è‘—å¥åº·ç›Šè™•çš„åŒ–åˆç‰©ï¼Œä½†ç”±æ–¼å…¶æº¶è§£åº¦å·®å’Œå‚³éå›°é›£ï¼Œä½¿ç”¨ä¸Šé¢è‡¨æŒ‘æˆ°ã€‚é€™é …ç ”ç©¶çš„çµæœå¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æä¾›æ–°çš„å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨å°æŠ—ç‚ç—‡ç›¸é—œç–¾ç—…æ–¹é¢ã€‚é€éæ”¹é€²è˜¿è””ç¡«ç´ çš„å‚³éæ–¹å¼ï¼Œå¯èƒ½èƒ½å¤ æ›´æœ‰æ•ˆåœ°ç™¼æ®å…¶æŠ—ç‚ä½œç”¨ï¼Œé€™å°æ–¼è¨±å¤šæ…¢æ€§ç–¾ç—…çš„é é˜²å’Œæ²»ç™‚éƒ½æœ‰æ½›åœ¨çš„å¹«åŠ©ã€‚\n\né€™é …ç ”ç©¶ä¸»è¦é—œæ³¨è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼ˆSFN-glycoconjugatesï¼‰å°æ–¼ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰å¼•èµ·çš„ç‚ç—‡åæ‡‰çš„å½±éŸ¿ã€‚ç ”ç©¶è€…å¸Œæœ›é€éé€™äº›æ–°å‹çš„åŒ–åˆç‰©ä¾†å¢å¼·è˜¿è””ç¡«ç´ åœ¨æ²»ç™‚ç‚ç—‡ç–¾ç—…æ–¹é¢çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯é‡å°æ¨¹çªç´°èƒï¼ˆDCsï¼‰çš„ä½œç”¨ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œä¹Ÿå¯èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚æ–¹æ³•æä¾›æ–°çš„æ–¹å‘ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å¾å¥åº·æè´ˆè€…ç²å–äº†å–®æ ¸ç´°èƒè¡ç”Ÿçš„æ¨¹çªç´°èƒï¼Œä¸¦å°‡å…¶æš´éœ²æ–¼æ…¢æ€§LPSç’°å¢ƒä¸­ï¼Œä»¥æ¨¡æ“¬ç‚ç—‡æƒ…æ³ã€‚æ¥è‘—ï¼Œé€™äº›æ¨¹çªç´°èƒè¢«è™•ç†ä»¥è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©ï¼Œç ”ç©¶å…¶æŠ—ç‚å’Œå…ç–«èª¿ç¯€çš„ç‰¹æ€§ã€‚é€™é …ç ”ç©¶çš„è¨­è¨ˆæ—¨åœ¨å…‹æœå‚³çµ±å‚³éæ–¹æ³•çš„é™åˆ¶ï¼Œæå‡è˜¿è””ç¡«ç´ çš„æº¶è§£åº¦å’Œç”Ÿç‰©åˆ©ç”¨åº¦ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„æ•ˆæœé¡¯è‘—ï¼Œä¸»è¦æ˜¯é€éé‡å°p65 NF-ÎºBé€”å¾‘ä¾†å¯¦ç¾ï¼Œè€Œä¸å½±éŸ¿MAPKä¿¡è™Ÿå‚³éã€‚é€™äº›åŒ–åˆç‰©èƒ½å¤ èª˜å°è€å—æ€§å…ç–«åæ‡‰ï¼Œå¢åŠ IL-10çš„ç”¢ç”Ÿï¼Œä¸¦ä¿ƒé€²èª¿ç¯€æ€§Tç´°èƒå’ŒBç´°èƒçš„å¢æ®–ã€‚é€™äº›æ•ˆæœè¶…éäº†å–®ç´”æŠ‘åˆ¶p65 NF-ÎºBçš„ä½œç”¨ï¼Œé¡¯ç¤ºå‡ºä¸€ç¨®ç¨ç‰¹ä¸”å¼·æ•ˆçš„èª¿ç¯€æ©Ÿåˆ¶ï¼Œé€™å°æ–¼ç‚ç—‡ç–¾ç—…çš„æ²»ç™‚å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "fb_post": "ğŸ½ï¸ä½ çŸ¥é“è˜¿è””ç¡«ç´ å°å¥åº·æœ‰å¤šé‡è¦å—ï¼Ÿé€™æ˜¯ä¸€ç¨®èƒ½å¹«åŠ©æˆ‘å€‘å°æŠ—ç‚ç—‡çš„ç¥å¥‡æˆåˆ†ï¼Œä½†éå»å› ç‚ºå®ƒä¸å®¹æ˜“è¢«èº«é«”å¸æ”¶ï¼Œä½¿ç”¨ä¸Šæœ‰é»å›°é›£ã€‚æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾äº†ä¸€ç¨®æ–°æ–¹æ³•ï¼Œå¯ä»¥è®“è˜¿è””ç¡«ç´ æ›´æœ‰æ•ˆåœ°ç™¼æ®ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç‚ç—‡ç›¸é—œç–¾ç—…æ–¹é¢ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ¢è¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©çš„åŒ–åˆç‰©ï¼Œç ”ç©¶è€…å¸Œæœ›é€éé€™ç¨®æ–°å‹åŒ–åˆç‰©ä¾†å¢å¼·è˜¿è””ç¡«ç´ çš„æ•ˆæœã€‚å¯¦é©—ä¸­ï¼Œä»–å€‘å¾å¥åº·æè´ˆè€…é‚£è£¡å–å¾—äº†æ¨¹çªç´°èƒï¼ˆé€™æ˜¯ä¸€ç¨®å…ç–«ç´°èƒï¼‰ï¼Œä¸¦å°‡å…¶æš´éœ²åœ¨æ¨¡æ“¬çš„ç‚ç—‡ç’°å¢ƒä¸­ï¼Œç„¶å¾Œå†ç”¨é€™äº›æ–°åŒ–åˆç‰©ä¾†è§€å¯Ÿæ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©åœ¨æŠ‘åˆ¶ç‚ç—‡æ–¹é¢çš„è¡¨ç¾éå¸¸äº®çœ¼ï¼å®ƒä¸»è¦é€šéä¸€æ¢ç‰¹å®šçš„ä¿¡è™Ÿé€šè·¯ä¾†ç™¼æ®ä½œç”¨ï¼Œé‚„èƒ½ä¿ƒé€²å…ç–«ç³»çµ±çš„å¥åº·åæ‡‰ï¼Œé€™å°æ–¼æ”¹å–„ç‚ç—‡ç–¾ç—…æœ‰å¾ˆå¤§çš„æ½›åŠ›ã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š\n1. è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®æœ‰åŠ©æ–¼æŠ—ç‚çš„å¥åº·æˆåˆ†ã€‚\n2. æ–°å‹è˜¿è””ç¡«ç´ -ç³–è‹·çµåˆç‰©èƒ½æå‡æ•ˆæœï¼Œå…‹æœå‚³éå›°é›£ã€‚\n3. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æœ‰æ•ˆæŠ‘åˆ¶ç‚ç—‡ï¼Œä¿ƒé€²å…ç–«å¥åº·ï¼",
    "image_prompt": "Create a flat design infographic that explains the experimental method and main results of a study on sulforaphane-glycoconjugates. Use a light-colored background with soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like human cells, and arrows or flow lines to indicate the experimental steps. Add a section highlighting the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç‚ç—‡æ€§ç–¾ç—… Inflammatory Diseases",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40533430/"
  },
  {
    "id": "41171476",
    "title_en": "Online solid-phase extraction of glucoraphanin and sulforaphane from non-edible plants based on amino acid-functionalized covalent organic frameworks.",
    "pub_date": "2025 Oct",
    "abstract_en": "Glucoraphanin (GR) and sulforaphane (SFN) are sulfur-containing compounds with diverse medicinal applications. However, cruciferous vegetables are a single source of GR and SFN, which limits development and utilization in natural resources. Herein, amino acid covalent organic framework (COF-Cys) was synthesized via click reactions and employed as an adsorbent in online solid-phase extraction (online SPE) to determine GR and SFN in non-edible plant samples. The adsorption mechanism was analyzed using density functional theory, revealing that adsorption occurred via electrostatic interaction and hydrogen bonding. Under the optimum conditions, good linearity (4-2500Â ng/mL; R<sup>2</sup>â€‰=â€‰0.9922 and 0.9968) and lower limits of detection (1.0Â ng/mL and 0.6Â ng/mL) were observed. GR and SFN were found in 18 non-edible plant samples, and recoveries of spiked samples were 89.1-109.3% with RSDâ€‰â‰¤â€‰6.9%. The COF-Cys-online SPE-UPLC-MS/MS approach displays great potential for application to detect GR and SFN in non-edible plants and provide valuable support for the development of functional products.",
    "para1": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šæ¤ç‰©ä¸­å­˜åœ¨ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†é–‹ç™¼æ–°å‹å¥åº·ç”¢å“æä¾›äº†æ©Ÿæœƒã€‚é€™äº›åŒ–åˆç‰©èˆ‡å¤šç¨®å¥åº·ç›Šè™•ç›¸é—œï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç‚æ–¹é¢ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„ä¾†æºå’Œæª¢æ¸¬æ–¹æ³•å°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢ç´¢å¦‚ä½•æœ‰æ•ˆæª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†æºæ–¼åå­—èŠ±ç§‘è”¬èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚",
    "para3": "å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµå½¢æˆçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œå¯¦é©—é¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œä½æª¢æ¸¬é™ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬ä¸­çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆè¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨æŠ€è¡“çš„æª¢æ¸¬æ–¹æ³•å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œå¯ä»¥æ‡‰ç”¨æ–¼éå¯é£Ÿç”¨æ¤ç‰©ä¸­è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©çš„æª¢æ¸¬ï¼Œä¸¦ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œè˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©åœ¨è¨±å¤šæ¤ç‰©ä¸­å­˜åœ¨ï¼Œé€™å¯èƒ½ç‚ºæœªä¾†é–‹ç™¼æ–°å‹å¥åº·ç”¢å“æä¾›äº†æ©Ÿæœƒã€‚é€™äº›åŒ–åˆç‰©èˆ‡å¤šç¨®å¥åº·ç›Šè™•ç›¸é—œï¼Œå°¤å…¶æ˜¯åœ¨æŠ—æ°§åŒ–å’ŒæŠ—ç‚æ–¹é¢ï¼Œå› æ­¤äº†è§£å®ƒå€‘çš„ä¾†æºå’Œæª¢æ¸¬æ–¹æ³•å°æ–¼ä¿ƒé€²å¥åº·å’Œé é˜²ç–¾ç—…å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢ç´¢å¦‚ä½•æœ‰æ•ˆæª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ã€‚ç”±æ–¼é€™äº›åŒ–åˆç‰©ä¸»è¦ä¾†æºæ–¼åå­—èŠ±ç§‘è”¬èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘çš„é–‹ç™¼å’Œåˆ©ç”¨ã€‚å› æ­¤ï¼Œç ”ç©¶è€…å¸Œæœ›æ‰¾åˆ°æ–°çš„æ–¹æ³•ä¾†æª¢æ¸¬é€™äº›åŒ–åˆç‰©ï¼Œä¸¦æ“´å¤§å…¶æ‡‰ç”¨ç¯„åœã€‚\n\nå¯¦é©—ä¸­ï¼Œç ”ç©¶è€…åˆæˆäº†ä¸€ç¨®æ°¨åŸºé…¸å…±åƒ¹æœ‰æ©Ÿæ¡†æ¶ï¼ˆCOF-Cysï¼‰ï¼Œä¸¦å°‡å…¶ç”¨ä½œåœ¨ç·šå›ºç›¸èƒå–çš„å¸é™„åŠ‘ï¼Œä»¥æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ã€‚ç ”ç©¶è€…ä½¿ç”¨å¯†åº¦æ³›å‡½ç†è«–åˆ†æäº†å¸é™„æ©Ÿåˆ¶ï¼Œç™¼ç¾å¸é™„ä¸»è¦æ˜¯é€šééœé›»ç›¸äº’ä½œç”¨å’Œæ°«éµå½¢æˆçš„ã€‚åœ¨æœ€ä½³æ¢ä»¶ä¸‹ï¼Œå¯¦é©—é¡¯ç¤ºå‡ºè‰¯å¥½çš„ç·šæ€§é—œä¿‚å’Œä½æª¢æ¸¬é™ã€‚\n\nä¸»è¦ç™¼ç¾æ˜¯ï¼Œåœ¨18ç¨®éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æª¢æ¸¬åˆ°äº†è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©ï¼Œä¸¦ä¸”åœ¨æ·»åŠ æ¨£æœ¬ä¸­çš„å›æ”¶ç‡é”åˆ°89.1%åˆ°109.3%ä¹‹é–“ï¼Œè®Šç•°ä¿‚æ•¸å°æ–¼6.9%ã€‚é€™è¡¨æ˜COF-Cysåœ¨ç·šå›ºç›¸èƒå–çµåˆè¶…é«˜æ•ˆæ¶²ç›¸è‰²è­œ-è³ªè­œè¯ç”¨æŠ€è¡“çš„æª¢æ¸¬æ–¹æ³•å…·æœ‰å¾ˆå¤§çš„æ½›åŠ›ï¼Œå¯ä»¥æ‡‰ç”¨æ–¼éå¯é£Ÿç”¨æ¤ç‰©ä¸­è˜¿è””ç¡«ç´ å’Œå…¶å‰é«”åŒ–åˆç‰©çš„æª¢æ¸¬ï¼Œä¸¦ç‚ºåŠŸèƒ½æ€§ç”¢å“çš„é–‹ç™¼æä¾›æœ‰åƒ¹å€¼çš„æ”¯æŒã€‚",
    "fb_post": "ğŸŒ± ä½ çŸ¥é“å—ï¼Ÿè˜¿è””ç¡«ç´ ä¸åƒ…åƒ…å­˜åœ¨æ–¼æˆ‘å€‘çš„é¤æ¡Œä¸Šï¼Œé‚„éš±è—åœ¨è¨±å¤šéå¯é£Ÿç”¨çš„æ¤ç‰©ä¸­ï¼é€™é …ç ”ç©¶çš„é‡é»å°±æ˜¯æƒ³è¦æ‰¾å‡ºé€™äº›ç¥ç§˜åŒ–åˆç‰©ï¼Œä¸¦çœ‹çœ‹å®ƒå€‘èƒ½å¸¶ä¾†ä»€éº¼å¥åº·ç›Šè™•ã€‚\n\nç ”ç©¶è€…å€‘å°ˆæ³¨æ–¼å¦‚ä½•æœ‰æ•ˆæª¢æ¸¬é€™äº›è˜¿è””ç¡«ç´ åŠå…¶å‰é«”åŒ–åˆç‰©ï¼Œå› ç‚ºå®ƒå€‘ä¸»è¦ä¾†è‡ªåå­—èŠ±ç§‘çš„è”¬èœï¼Œå¦‚é’èŠ±æ¤°èœï¼Œé€™é™åˆ¶äº†å®ƒå€‘çš„æ‡‰ç”¨ã€‚ç‚ºäº†è§£æ±ºé€™å€‹å•é¡Œï¼Œä»–å€‘åˆæˆäº†ä¸€ç¨®ç‰¹æ®Šçš„æ°¨åŸºé…¸æ¡†æ¶ï¼Œä¸¦åˆ©ç”¨é€™å€‹æ¡†æ¶ä¾†æª¢æ¸¬éå¯é£Ÿç”¨æ¤ç‰©ä¸­çš„è˜¿è””ç¡«ç´ ã€‚\n\nå¯¦é©—çµæœé¡¯ç¤ºï¼Œä»–å€‘æˆåŠŸåœ¨18ç¨®ä¸åŒçš„éå¯é£Ÿç”¨æ¤ç‰©æ¨£æœ¬ä¸­æ‰¾åˆ°äº†è˜¿è””ç¡«ç´ ï¼Œä¸¦ä¸”æª¢æ¸¬çš„æº–ç¢ºåº¦éå¸¸é«˜ï¼é€™ä¸åƒ…è®“æˆ‘å€‘å°é€™äº›åŒ–åˆç‰©æœ‰äº†æ›´æ·±çš„äº†è§£ï¼Œä¹Ÿç‚ºæœªä¾†é–‹ç™¼åŠŸèƒ½æ€§ç”¢å“é‹ªå¹³äº†é“è·¯ã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å­˜åœ¨æ–¼è¨±å¤šéå¯é£Ÿç”¨æ¤ç‰©ä¸­ï¼Œå¯èƒ½æœ‰åŠ©æ–¼å¥åº·ã€‚\n2. ç ”ç©¶è€…é–‹ç™¼äº†æ–°æ–¹æ³•ä¾†æª¢æ¸¬é€™äº›åŒ–åˆç‰©ã€‚\n3. å¯¦é©—çµæœé¡¯ç¤ºæª¢æ¸¬æº–ç¢ºä¸”å¯é ï¼Œæœªä¾†å¯æœ›æ‡‰ç”¨æ–¼å¥åº·ç”¢å“çš„é–‹ç™¼ï¼",
    "image_prompt": "Create an infographic that explains the experimental method and main results of a study on sulforaphane. Use a flat design style with a white or light-colored background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects (such as humans, animals, or cells), arrows or flow lines indicating the experimental steps, and a section clearly labeled 'Main Results' showing recovery rates and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41171476/"
  },
  {
    "id": "41246347",
    "title_en": "Sulforaphane in cancer precision medicine: from biosynthetic origins to multiscale mechanisms and clinical translation.",
    "pub_date": "2025",
    "abstract_en": "Sulforaphane (SFN), an isothiocyanate derived from glucoraphanin in cruciferous vegetables, has evolved from a dietary antioxidant to a sophisticated multi-target agent in oncology. While its roles in nuclear factor erythroid 2-related factor 2 (Nrf2) activation and histone deacetylase (HDAC) inhibition are well-established, this review provides a novel synthesis by integrating disparate research scales-a multiscale perspective that spans from the genetic and epigenetic regulation of glucoraphanin biosynthesis in plants to SFN's recently elucidated effects on ferroptosis, cancer stem cells (CSCs), and the tumor immune microenvironment in humans. We critically evaluate how key host factors, such as gut microbiota composition and glutathione S-transferase (GST) polymorphisms, dictate SFN bioavailability and efficacy, thereby framing a precision nutrition paradigm for its application. Furthermore, we move beyond generic claims of synergy to detail SFN's specific mechanisms in enhancing conventional therapies, including the modulation of drug transporters and immune checkpoints. By integrating advances from plant biochemistry to molecular oncology, this review establishes an updated and mechanism-oriented framework for realizing SFN's compelling potential in cancer prevention and therapy through a precision medicine approach.",
    "para1": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘è”¬èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå°å¥åº·æœ‰æ½›åœ¨çš„ç›Šè™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é é˜²æ–¹é¢ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿äººé«”å…§çš„å¤šç¨®ç”Ÿç‰©éç¨‹ï¼Œä¸¦ä¸”å¼·èª¿äº†å®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„å¤šé‡ä½œç”¨ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²ç–¾ç—…ï¼Œä¸¦æ”¹å–„ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•ï¼Œé€™å°æ–¼æå‡äººé¡å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©å­¸éç¨‹ä¸­ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒï¼Œä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æ¶‰åŠè˜¿è””ç¡«ç´ çš„åŸºæœ¬ç”Ÿç‰©å­¸ï¼Œé‚„åŒ…æ‹¬å…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾æº–ç‡Ÿé¤Šçš„èƒŒæ™¯ä¸‹ã€‚",
    "para3": "ç ”ç©¶è€…æ¡ç”¨å¤šå±¤æ¬¡çš„ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€åŸºå› èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œç„¶å¾Œå»¶ä¼¸åˆ°å…¶åœ¨äººé«”å…§çš„ä½œç”¨ã€‚é€™åŒ…æ‹¬åˆ†æè…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œå€‹é«”çš„åŸºå› å¤šæ¨£æ€§å¦‚ä½•å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§ã€‚ç ”ç©¶é‚„è©•ä¼°äº†è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡å‚³çµ±æ²»ç™‚ç›¸çµåˆï¼Œæå‡ç™‚æ•ˆï¼Œé€™æ¨£çš„å¤šè§’åº¦åˆ†ææœ‰åŠ©æ–¼æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰å¤šé‡æ©Ÿåˆ¶ï¼Œé€™äº›æ©Ÿåˆ¶åŒ…æ‹¬èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»çš„åŠŸèƒ½ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœå—åˆ°å®¿ä¸»å› ç´ çš„å½±éŸ¿ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆå’ŒåŸºå› å¤šæ¨£æ€§ï¼Œé€™æ„å‘³è‘—å…¶ç™‚æ•ˆå¯èƒ½å› äººè€Œç•°ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„è¦–è§’ï¼Œä¸¦å¼·èª¿äº†ç²¾æº–é†«ç™‚åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„é‡è¦æ€§ã€‚",
    "explanation_zh": "è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å¾åå­—èŠ±ç§‘è”¬èœä¸­æå–çš„åŒ–åˆç‰©ï¼Œè¿‘å¹´ä¾†è¢«èªç‚ºå°å¥åº·æœ‰æ½›åœ¨çš„ç›Šè™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡é é˜²æ–¹é¢ã€‚é€™é …ç ”ç©¶æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿äººé«”å…§çš„å¤šç¨®ç”Ÿç‰©éç¨‹ï¼Œä¸¦ä¸”å¼·èª¿äº†å®ƒåœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„å¤šé‡ä½œç”¨ã€‚é€éäº†è§£è˜¿è””ç¡«ç´ çš„æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ–¹å¼ä¾†é é˜²ç–¾ç—…ï¼Œä¸¦æ”¹å–„ç¾æœ‰çš„æ²»ç™‚æ–¹æ³•ï¼Œé€™å°æ–¼æå‡äººé¡å¥åº·å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯è˜¿è””ç¡«ç´ çš„å¤šé‡ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡ç›¸é—œçš„ç”Ÿç‰©å­¸éç¨‹ä¸­ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒã€è…«ç˜¤å…ç–«å¾®ç’°å¢ƒï¼Œä»¥åŠå…¶åœ¨äººé«”å…§çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§å’Œç™‚æ•ˆã€‚é€™äº›å•é¡Œçš„æ¢è¨ä¸åƒ…æ¶‰åŠè˜¿è””ç¡«ç´ çš„åŸºæœ¬ç”Ÿç‰©å­¸ï¼Œé‚„åŒ…æ‹¬å…¶åœ¨è‡¨åºŠæ‡‰ç”¨ä¸­çš„æ½›åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç²¾æº–ç‡Ÿé¤Šçš„èƒŒæ™¯ä¸‹ã€‚\n\nç ”ç©¶è€…æ¡ç”¨å¤šå±¤æ¬¡çš„ç ”ç©¶æ–¹æ³•ï¼Œå¾æ¤ç‰©çš„åŸºå› å’Œè¡¨è§€åŸºå› èª¿æ§é–‹å§‹ï¼Œæ¢è¨è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œç„¶å¾Œå»¶ä¼¸åˆ°å…¶åœ¨äººé«”å…§çš„ä½œç”¨ã€‚é€™åŒ…æ‹¬åˆ†æè…¸é“å¾®ç”Ÿç‰©çµ„çš„çµ„æˆå’Œå€‹é«”çš„åŸºå› å¤šæ¨£æ€§å¦‚ä½•å½±éŸ¿è˜¿è””ç¡«ç´ çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§ã€‚ç ”ç©¶é‚„è©•ä¼°äº†è˜¿è””ç¡«ç´ å¦‚ä½•èˆ‡å‚³çµ±æ²»ç™‚ç›¸çµåˆï¼Œæå‡ç™‚æ•ˆï¼Œé€™æ¨£çš„å¤šè§’åº¦åˆ†ææœ‰åŠ©æ–¼æ›´å…¨é¢åœ°ç†è§£è˜¿è””ç¡«ç´ çš„æ½›åŠ›ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­å…·æœ‰å¤šé‡æ©Ÿåˆ¶ï¼Œé€™äº›æ©Ÿåˆ¶åŒ…æ‹¬èª¿ç¯€è—¥ç‰©é‹è¼¸å’Œå…ç–«æª¢æŸ¥é»çš„åŠŸèƒ½ã€‚ç ”ç©¶æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ çš„æ•ˆæœå—åˆ°å®¿ä¸»å› ç´ çš„å½±éŸ¿ï¼Œä¾‹å¦‚è…¸é“å¾®ç”Ÿç‰©çš„çµ„æˆå’ŒåŸºå› å¤šæ¨£æ€§ï¼Œé€™æ„å‘³è‘—å…¶ç™‚æ•ˆå¯èƒ½å› äººè€Œç•°ã€‚é€™äº›çµæœç‚ºæœªä¾†çš„è‡¨åºŠæ‡‰ç”¨æä¾›äº†æ–°çš„è¦–è§’ï¼Œä¸¦å¼·èª¿äº†ç²¾æº–é†«ç™‚åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„é‡è¦æ€§ã€‚",
    "fb_post": "ğŸ€ å¤§å®¶çŸ¥é“å—ï¼Ÿè˜¿è””è£¡é¢æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„æˆåˆ†ï¼Œæœ€è¿‘ç§‘å­¸å®¶å€‘ç™¼ç¾å®ƒå°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤šæ½›åœ¨çš„å¥½è™•ï¼Œç‰¹åˆ¥æ˜¯åœ¨ç™Œç—‡çš„é é˜²ä¸Šï¼é€™ç¯‡ç ”ç©¶å°±æ·±å…¥æ¢è¨äº†è˜¿è””ç¡«ç´ æ˜¯å¦‚ä½•å½±éŸ¿æˆ‘å€‘èº«é«”çš„ã€‚\n\nç ”ç©¶è€…å€‘é—œå¿ƒçš„å•é¡ŒåŒ…æ‹¬ï¼šè˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç—‡å¹¹ç´°èƒå’Œè…«ç˜¤çš„å…ç–«ç’°å¢ƒï¼Œé‚„æœ‰å®ƒåœ¨æˆ‘å€‘èº«é«”è£¡çš„å¸æ”¶æ•ˆæœã€‚ä»–å€‘å¾æ¤ç‰©çš„åŸºå› é–‹å§‹ï¼Œé€æ­¥ç ”ç©¶è˜¿è””ç¡«ç´ çš„åˆæˆéç¨‹ï¼Œä¸¦äº†è§£è…¸é“å¾®ç”Ÿç‰©å’Œå€‹é«”åŸºå› å¦‚ä½•å½±éŸ¿å®ƒçš„æ•ˆæœã€‚\n\næœ€çµ‚çš„çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ä¸­æœ‰å¤šé‡ä½œç”¨ï¼Œé€™äº›ä½œç”¨å¯èƒ½æœƒå› ç‚ºæ¯å€‹äººçš„è…¸é“å¾®ç”Ÿç‰©å’ŒåŸºå› ä¸åŒè€Œæœ‰æ‰€ä¸åŒã€‚é€™äº›ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„ç™Œç—‡æ²»ç™‚æœ‰äº†æ–°çš„æƒ³åƒã€‚\n\nğŸ” ä¸»è¦é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡é é˜²ã€‚\n2. å…¶æ•ˆæœå—åˆ°è…¸é“å¾®ç”Ÿç‰©å’ŒåŸºå› å½±éŸ¿ã€‚\n3. ç ”ç©¶å¼·èª¿äº†ç²¾æº–é†«ç™‚åœ¨ç™Œç—‡æ²»ç™‚ä¸­çš„é‡è¦æ€§ã€‚",
    "image_prompt": "Create a flat design infographic illustrating the research on glucosinolates. Include symbols representing broccoli or glucosinolates. Add simplified icons of experimental subjects like humans, animals, or cells. Use arrows or flow lines to show the experimental process. Include a section labeled 'Main Findings' that highlights protective effects or changes observed in the study. Use a soft color palette on a white or light background.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41246347/"
  },
  {
    "id": "41056875",
    "title_en": "Sulforaphane inhibits gastric cancer progression by regulating the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis.",
    "pub_date": "2025 Oct",
    "abstract_en": "Sulforaphane (SFN) plays a vital role in many types of cancer as a natural extract from plants. However, whether SFN can inhibit gastric carcinogenesis by regulating the lncRNA-miRNA-mRNA axis is unclear. In the current work, the significantly differentially expressed lncRNA PSMB8AS1 was obtained by performing high-throughput sequencing of gastric cancer cells treated with SFN. The qRT-PCR assay results confirmed the inhibitory effect of SFN on PSM8AS1. Subsequently, using gastric cancer data from TCGA and 11 pairs of clinical samples from gastric and paracancerous tissues, we found that PSMB8-AS1 was upregulated in gastric cancer, and high expression of PSMB8-AS1 was associated with low survival of patients with gastric cancer. MTT, cell colony formation, scratch healing, flow cytometry, and qRT-PCR assays showed that the knockdown of PSMB8-AS1 significantly reduced the proliferation and migration of gastric cancer cells as well as promoted apoptosis. Dual luciferase reporter gene and RNA immunoprecipitation (RIP) assay confirmed that PSMB8-AS1 can function as the molecular sponge for miR-888-5p. Meanwhile, bioinformatics analysis and dual-luciferase reporter gene assay showed that miR-888-5p regulates SLC4A7. Overexpression of miR-888-5p or knockdown of SLC4A7 reduced the proliferation and migration of gastric cancer cells. In addition, rescue experiments confirmed that the inhibitory effects of the knockdown of PSMB8-AS1 or the knockdown of SLC4A7 on the proliferation and migration of gastric cancer cells could be reversed by miR-888-5p inhibitor treatment. Subcutaneous tumor formation experiments in nude mice demonstrated that the tumor volume of nude mice transplanted with PSMB8-AS1-knockdown gastric cancer cells was significantly reduced compared with that of the control group. Transcription factors can usually bind to the promoter regions of lncRNAs and regulate the transcription of lncRNAs. We demonstrated through website prediction and experiments that SFN can inhibit the level of PSMB8-AS1 by regulating the transcription factor YY1. These results suggest that SFN inhibits gastric cancer growth through the YY1/PSMB8-AS1/miR-888-5p/SLC4A7 axis. Therefore, SFN might be a promising therapeutical agent for GC prevention and therapy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é é˜²æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é€™å°æ–¼å¸Œæœ›é é˜²ç™Œç—‡çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›æœ‰å®¶æ—ç—…å²æˆ–å…¶ä»–é¢¨éšªå› ç´ çš„äººä¾†èªªï¼Œé€™æ¨£çš„é£²é£Ÿèª¿æ•´å¯èƒ½æœƒæœ‰æ½›åœ¨çš„å¥½è™•ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€šéèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ä¾†å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç ”ç©¶è€…é—œå¿ƒçš„ä¸»è¦å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿï¼Œä¸¦ä¸”å…·é«”æ˜¯é€éå“ªç¨®åˆ†å­æ©Ÿåˆ¶ä¾†é”æˆé€™ä¸€æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ½›åŠ›ï¼Œé‚„æ·±å…¥åˆ†æäº†èˆ‡èƒƒç™Œç›¸é—œçš„åˆ†å­è®ŠåŒ–ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚å’Œé é˜²ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥è­˜åˆ¥è¡¨é”é¡¯è‘—ä¸åŒçš„lncRNAã€‚æ¥è‘—ï¼Œä»–å€‘ä½¿ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªäº†è˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶é‚„åˆ©ç”¨ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œåˆ†æï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦ä¸”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡å‘ˆè² ç›¸é—œã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†å¤šç¨®ç´°èƒå¯¦é©—ï¼ŒåŒ…æ‹¬MTTã€ç´°èƒå…‹éš†å½¢æˆã€åˆ®ç—•ç™’åˆã€æµå¼ç´°èƒè¡“ç­‰ï¼Œä»¥æ¢è¨PSMB8-AS1çš„åŠŸèƒ½åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚",
    "para4": "ä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—è­‰å¯¦ï¼Œéè¡¨é”miR-888-5pæˆ–æŠ‘åˆ¶SLC4A7éƒ½èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚æ­¤å¤–ï¼Œä½¿ç”¨è£¸é¼ é€²è¡Œçš„çš®ä¸‹è…«ç˜¤å½¢æˆå¯¦é©—é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„èƒƒç™Œç´°èƒç§»æ¤å¾Œï¼Œè…«ç˜¤é«”ç©é¡¯è‘—æ¸›å°‘ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€é€”å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œç‚ºèƒƒç™Œçš„é é˜²å’Œæ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†æœ‰é—œå¥åº·å’Œç–¾ç—…é é˜²çš„é‡è¦å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨èƒƒç™Œçš„é é˜²æ–¹é¢ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€éèª¿ç¯€ç‰¹å®šçš„åˆ†å­è·¯å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç™¼å±•ã€‚é€™æ„å‘³è‘—ï¼Œé€éé£²é£Ÿä¸­å¢åŠ å¯Œå«è˜¿è””ç¡«ç´ çš„é£Ÿç‰©ï¼Œå¦‚é’èŠ±æ¤°èœï¼Œå¯èƒ½æœ‰åŠ©æ–¼é™ä½èƒƒç™Œçš„é¢¨éšªï¼Œé€²è€Œä¿ƒé€²æ•´é«”å¥åº·ã€‚é€™å°æ–¼å¸Œæœ›é é˜²ç™Œç—‡çš„äººä¾†èªªï¼Œæä¾›äº†ä¸€å€‹æ–°çš„æ€è·¯ï¼Œå°¤å…¶æ˜¯å°æ–¼é‚£äº›æœ‰å®¶æ—ç—…å²æˆ–å…¶ä»–é¢¨éšªå› ç´ çš„äººä¾†èªªï¼Œé€™æ¨£çš„é£²é£Ÿèª¿æ•´å¯èƒ½æœƒæœ‰æ½›åœ¨çš„å¥½è™•ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨èƒƒç™Œä¸­çš„ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•é€šéèª¿ç¯€é•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰ä¾†å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·å’Œæ“´æ•£ã€‚ç ”ç©¶è€…é—œå¿ƒçš„ä¸»è¦å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ æŠ‘åˆ¶èƒƒç™Œçš„ç™¼ç”Ÿï¼Œä¸¦ä¸”å…·é«”æ˜¯é€éå“ªç¨®åˆ†å­æ©Ÿåˆ¶ä¾†é”æˆé€™ä¸€æ•ˆæœã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ½›åŠ›ï¼Œé‚„æ·±å…¥åˆ†æäº†èˆ‡èƒƒç™Œç›¸é—œçš„åˆ†å­è®ŠåŒ–ï¼Œé€™å°æ–¼æœªä¾†çš„ç™Œç—‡æ²»ç™‚å’Œé é˜²ç­–ç•¥å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…é¦–å…ˆå°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œé«˜é€šé‡æ¸¬åºï¼Œä»¥è­˜åˆ¥è¡¨é”é¡¯è‘—ä¸åŒçš„lncRNAã€‚æ¥è‘—ï¼Œä»–å€‘ä½¿ç”¨qRT-PCRç­‰æ–¹æ³•ç¢ºèªäº†è˜¿è””ç¡«ç´ å°PSMB8-AS1çš„æŠ‘åˆ¶ä½œç”¨ã€‚ç ”ç©¶é‚„åˆ©ç”¨ä¾†è‡ªTCGAçš„èƒƒç™Œæ•¸æ“šä»¥åŠ11å°è‡¨åºŠæ¨£æœ¬é€²è¡Œåˆ†æï¼Œç™¼ç¾PSMB8-AS1åœ¨èƒƒç™Œä¸­è¡¨é”ä¸Šèª¿ï¼Œä¸¦ä¸”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡å‘ˆè² ç›¸é—œã€‚æ­¤å¤–ï¼Œç ”ç©¶è€…é‚„é€²è¡Œäº†å¤šç¨®ç´°èƒå¯¦é©—ï¼ŒåŒ…æ‹¬MTTã€ç´°èƒå…‹éš†å½¢æˆã€åˆ®ç—•ç™’åˆã€æµå¼ç´°èƒè¡“ç­‰ï¼Œä»¥æ¢è¨PSMB8-AS1çš„åŠŸèƒ½åŠå…¶å°ç™Œç´°èƒå¢æ®–å’Œé·ç§»çš„å½±éŸ¿ã€‚\n\nä¸»è¦çš„ç ”ç©¶ç™¼ç¾é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1èƒ½é¡¯è‘—æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œä¸¦ä¿ƒé€²ç´°èƒå‡‹äº¡ã€‚ç ”ç©¶é‚„ç™¼ç¾ï¼ŒPSMB8-AS1å¯ä»¥ä½œç‚ºmiR-888-5pçš„åˆ†å­æµ·ç¶¿ï¼Œä¸¦ä¸”miR-888-5pèƒ½èª¿æ§SLC4A7çš„è¡¨é”ã€‚é€²ä¸€æ­¥çš„å¯¦é©—è­‰å¯¦ï¼Œéè¡¨é”miR-888-5pæˆ–æŠ‘åˆ¶SLC4A7éƒ½èƒ½æ¸›å°‘èƒƒç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ã€‚æ­¤å¤–ï¼Œä½¿ç”¨è£¸é¼ é€²è¡Œçš„çš®ä¸‹è…«ç˜¤å½¢æˆå¯¦é©—é¡¯ç¤ºï¼ŒæŠ‘åˆ¶PSMB8-AS1çš„èƒƒç™Œç´°èƒç§»æ¤å¾Œï¼Œè…«ç˜¤é«”ç©é¡¯è‘—æ¸›å°‘ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéYY1/PSMB8-AS1/miR-888-5p/SLC4A7é€™ä¸€é€”å¾‘ä¾†æŠ‘åˆ¶èƒƒç™Œçš„ç”Ÿé•·ï¼Œç‚ºèƒƒç™Œçš„é é˜²å’Œæ²»ç™‚æä¾›äº†æ–°çš„å¯èƒ½æ€§ã€‚",
    "fb_post": "ğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿåƒé’èŠ±æ¤°èœå¯èƒ½å°ä½ çš„èƒƒæœ‰æ„æƒ³ä¸åˆ°çš„å¥½è™•ï¼\n\næœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšã€Œè˜¿è””ç¡«ç´ ã€çš„ç‰©è³ªï¼Œé€™ç¨®ç‰©è³ªå­˜åœ¨æ–¼é’èŠ±æ¤°èœç­‰è”¬èœä¸­ï¼Œç ”ç©¶è€…ç™¼ç¾å®ƒå¯èƒ½æœ‰åŠ©æ–¼é é˜²èƒƒç™Œã€‚ä»–å€‘æ¢è¨äº†è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç™Œç´°èƒçš„ç”Ÿé•·ï¼Œç‰¹åˆ¥æ˜¯é€šéèª¿ç¯€ä¸€ç¨®å«åšé•·éˆéç·¨ç¢¼RNAï¼ˆlncRNAï¼‰çš„åˆ†å­ä¾†é”æˆé€™å€‹æ•ˆæœã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å°æ¥å—è˜¿è””ç¡«ç´ è™•ç†çš„èƒƒç™Œç´°èƒé€²è¡Œäº†åˆ†æï¼Œç™¼ç¾ä¸€ç¨®å«åšPSMB8-AS1çš„lncRNAåœ¨ç™Œç´°èƒä¸­çš„è¡¨é”é‡ä¸Šå‡ï¼Œä¸¦ä¸”èˆ‡æ‚£è€…çš„ç”Ÿå­˜ç‡æœ‰é—œã€‚é€²ä¸€æ­¥çš„å¯¦é©—é¡¯ç¤ºï¼ŒæŠ‘åˆ¶é€™ç¨®lncRNAèƒ½é¡¯è‘—æ¸›å°‘ç™Œç´°èƒçš„å¢æ®–å’Œé·ç§»ï¼Œç”šè‡³ä¿ƒé€²ç´°èƒå‡‹äº¡ï¼\n\né€™é …ç ”ç©¶çš„çµæœè®“æˆ‘å€‘äº†è§£åˆ°ï¼š\n1ï¸âƒ£ è˜¿è””ç¡«ç´ æœ‰æ½›åŠ›æˆç‚ºèƒƒç™Œé é˜²çš„é£²é£Ÿé¸æ“‡ã€‚\n2ï¸âƒ£ PSMB8-AS1å¯èƒ½æ˜¯èƒƒç™Œæ²»ç™‚çš„æ–°é¶é»ã€‚\n3ï¸âƒ£ å¥åº·çš„é£²é£Ÿç¿’æ…£å°æ–¼é™ä½ç™Œç—‡é¢¨éšªè‡³é—œé‡è¦ï¼\n\nè®“æˆ‘å€‘ä¸€èµ·é—œæ³¨é£²é£Ÿå¥åº·ï¼Œç‚ºæœªä¾†çš„å¥åº·æ‰“ä¸‹åŸºç¤ï¼",
    "image_prompt": "Create an infographic that explains the experiment and main findings of a study on sulforaphane. Include simple illustrations of broccoli and sulforaphane as symbols. Show simplified icons representing experimental subjects like cells or animals. Use arrows or flow lines to depict the steps of the experiment. Include a section that highlights the main results, such as protective effects against cancer and changes in cell behavior. The style should be flat design, with a white or light-colored background and soft color palette.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "èƒƒç™Œ Gastric Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41056875/"
  },
  {
    "id": "41235157",
    "title_en": "Novel magnolol-sulforaphane hybrids as potent antitumor agents: synthesis and biological characterization.",
    "pub_date": "2025 Oct",
    "abstract_en": "The natural product-based hybrid strategy is a promising approach for innovative drug discovery. Leveraging the privileged architecture of sulforaphane-a prominent anticancer natural product-we engineered a novel library of magnolol-sulforaphane molecular hybrids for antitumor evaluation through a concise synthetic strategy for the pharmacophore of sulforaphane (SFN), culminating in the identification of CTNPC8 as a promising anticancer compound. Notably, CTNPC8 not only displays exceptional broad-spectrum anticancer activity with potency surpassing both parent compounds and cisplatin, but also exhibits potent <i>in vitro</i> efficacy against the challenging nasopharyngeal carcinoma (NPC) cell model. Mechanistic studies in nasopharyngeal carcinoma models reveal that CTNPC8 triggers mitochondrial-mediated apoptosis through regulating ROS generation and induces G<sub>2</sub>/M phase arrest. Transcriptomic profiling coupled with validation experiments reveals that CTNPC8 exerts its anti-NPC activity primarily by modulating the Akt/mTOR pathway. The present study provided a valuable strategy for discovering new antitumor agents through hybrid molecular design, nominating CTNPC8 as a promising hit compound for anti-NPC research.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œè—¥ç‰©çš„é–‹ç™¼ä¸Šã€‚é€éçµåˆå¤©ç„¶ç”¢å“çš„ç‰¹æ€§ï¼Œç ”ç©¶äººå“¡å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ï¼Œé€™å°æ–¼é¢å°å„ç¨®ç™Œç—‡çš„æ²»ç™‚ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—æœŸå¾…çš„æ–¹å‘ã€‚ç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œé€™ç¨®é›£æ²»çš„ç™Œç—‡ï¼Œè‹¥èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°‡æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°å‹çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å·²çŸ¥çš„æŠ—ç™Œå¤©ç„¶ç”¢å“ï¼Œè¨­è¨ˆå‡ºä¸€ç³»åˆ—æ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤æ´»æ€§è©•ä¼°ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…é—œæ³¨è—¥ç‰©çš„æ•ˆæœï¼Œé‚„æ¢ç´¢äº†å…¶ä½œç”¨æ©Ÿåˆ¶ï¼ŒæœŸæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘åˆæˆäº†ä¸€ç¨®åç‚ºCTNPC8çš„æ–°åŒ–åˆç‰©ï¼Œä¸¦å°å…¶é€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§æ¸¬è©¦ã€‚å¯¦é©—ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œé€šéä¸€ç³»åˆ—çš„æ©Ÿåˆ¶ç ”ç©¶ï¼Œæ¢è¨CTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ã€‚ç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£CTNPC8çš„ä½œç”¨è·¯å¾‘ï¼Œé€™äº›æ–¹æ³•æœ‰åŠ©æ–¼æ­ç¤ºå…¶æŠ—ç™Œæ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶åŸæ–™åŒ–åˆç‰©å’Œé †é‰‘ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒCTNPC8èƒ½å¤ é€šéèª¿æ§æ´»æ€§æ°§çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒé€²å…¥G2/MæœŸåœæ»¯ã€‚æ­¤å¤–ï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœç‚ºæœªä¾†æŠ—è…«ç˜¤è—¥ç‰©çš„é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦å•Ÿç¤ºï¼Œå°¤å…¶æ˜¯åœ¨æŠ—ç™Œè—¥ç‰©çš„é–‹ç™¼ä¸Šã€‚é€éçµåˆå¤©ç„¶ç”¢å“çš„ç‰¹æ€§ï¼Œç ”ç©¶äººå“¡å¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æŠ—ç™Œè—¥ç‰©ï¼Œé€™å°æ–¼é¢å°å„ç¨®ç™Œç—‡çš„æ²»ç™‚ä¾†èªªï¼Œç„¡ç–‘æ˜¯ä¸€å€‹å€¼å¾—æœŸå¾…çš„æ–¹å‘ã€‚ç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œé€™ç¨®é›£æ²»çš„ç™Œç—‡ï¼Œè‹¥èƒ½æ‰¾åˆ°æ–°çš„æ²»ç™‚æ–¹æ³•ï¼Œå°‡æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„ç”Ÿå­˜ç‡å’Œç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯é–‹ç™¼ä¸€ç¨®æ–°å‹çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œç‰¹åˆ¥æ˜¯é‡å°é¼»å’½ç™Œçš„æ²»ç™‚ã€‚ç ”ç©¶è€…å€‘åˆ©ç”¨è˜¿è””ç¡«ç´ é€™ç¨®å·²çŸ¥çš„æŠ—ç™Œå¤©ç„¶ç”¢å“ï¼Œè¨­è¨ˆå‡ºä¸€ç³»åˆ—æ–°çš„åˆ†å­æ··åˆç‰©ï¼Œä¸¦é€²è¡ŒæŠ—è…«ç˜¤æ´»æ€§è©•ä¼°ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…é—œæ³¨è—¥ç‰©çš„æ•ˆæœï¼Œé‚„æ¢ç´¢äº†å…¶ä½œç”¨æ©Ÿåˆ¶ï¼ŒæœŸæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…å€‘åˆæˆäº†ä¸€ç¨®åç‚ºCTNPC8çš„æ–°åŒ–åˆç‰©ï¼Œä¸¦å°å…¶é€²è¡Œäº†æŠ—è…«ç˜¤æ´»æ€§æ¸¬è©¦ã€‚å¯¦é©—ä¸»è¦é‡å°é¼»å’½ç™Œç´°èƒæ¨¡å‹ï¼Œé€šéä¸€ç³»åˆ—çš„æ©Ÿåˆ¶ç ”ç©¶ï¼Œæ¢è¨CTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ã€‚ç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†è½‰éŒ„çµ„åˆ†æï¼Œä»¥äº†è§£CTNPC8çš„ä½œç”¨è·¯å¾‘ï¼Œé€™äº›æ–¹æ³•æœ‰åŠ©æ–¼æ­ç¤ºå…¶æŠ—ç™Œæ©Ÿåˆ¶ã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ï¼Œç”šè‡³è¶…éäº†å…¶åŸæ–™åŒ–åˆç‰©å’Œé †é‰‘ã€‚ç ”ç©¶çµæœé¡¯ç¤ºï¼ŒCTNPC8èƒ½å¤ é€šéèª¿æ§æ´»æ€§æ°§çš„ç”Ÿæˆä¾†èª˜å°ç·šç²’é«”ä»‹å°çš„ç´°èƒå‡‹äº¡ï¼Œä¸¦ä½¿ç´°èƒé€²å…¥G2/MæœŸåœæ»¯ã€‚æ­¤å¤–ï¼ŒCTNPC8çš„æŠ—é¼»å’½ç™Œæ´»æ€§ä¸»è¦æ˜¯é€šéèª¿ç¯€Akt/mTORé€šè·¯ä¾†å¯¦ç¾çš„ã€‚é€™äº›çµæœç‚ºæœªä¾†æŠ—è…«ç˜¤è—¥ç‰©çš„é–‹ç™¼æä¾›äº†æ–°çš„æ€è·¯ã€‚",
    "fb_post": "ğŸ‰ å¤§å®¶çŸ¥é“å—ï¼Ÿç§‘å­¸å®¶å€‘æœ€è¿‘ç™¼ç¾äº†ä¸€ç¨®æ–°çš„æŠ—ç™ŒåŒ–åˆç‰©ï¼Œå¯èƒ½å°é¼»å’½ç™Œçš„æ²»ç™‚æœ‰é‡å¤§å½±éŸ¿ï¼é€™é …ç ”ç©¶åˆ©ç”¨äº†ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œè¨­è¨ˆå‡ºæ–°çš„åˆ†å­ä¾†å°æŠ—ç™Œç´°èƒã€‚ç ”ç©¶åœ˜éšŠä¸åƒ…æ¸¬è©¦äº†é€™äº›æ–°åŒ–åˆç‰©çš„æ•ˆæœï¼Œé‚„æ·±å…¥æ¢ç´¢å®ƒå€‘çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œå¸Œæœ›èƒ½æ‰¾åˆ°æ›´æœ‰æ•ˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚  \n\nåœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘åˆæˆäº†ä¸€ç¨®åç‚ºCTNPC8çš„æ–°åŒ–åˆç‰©ï¼Œä¸¦å°å…¶åœ¨é¼»å’½ç™Œç´°èƒæ¨¡å‹ä¸­çš„æŠ—è…«ç˜¤æ´»æ€§é€²è¡Œäº†æ¸¬è©¦ã€‚é€éè§€å¯ŸCTNPC8å¦‚ä½•å½±éŸ¿ç´°èƒçš„ç”Ÿé•·å’Œæ­»äº¡ï¼Œç ”ç©¶è€…å€‘é‚„é€²è¡Œäº†æ·±å…¥çš„åˆ†æï¼Œæ­ç¤ºäº†é€™å€‹åŒ–åˆç‰©çš„æŠ—ç™Œæ©Ÿåˆ¶ã€‚  \n\næœ€é‡è¦çš„æ˜¯ï¼ŒCTNPC8å±•ç¾äº†è¶…è¶Šå‚³çµ±æ²»ç™‚çš„æŠ—ç™Œæ½›åŠ›ï¼å®ƒèƒ½å¤ èª¿æ§ç´°èƒå…§çš„æ´»æ€§æ°§ï¼Œèª˜å°ç™Œç´°èƒå‡‹äº¡ï¼Œä¸¦å½±éŸ¿ç´°èƒçš„ç”Ÿé•·é€±æœŸã€‚é€™äº›ç ”ç©¶çµæœç‚ºæœªä¾†çš„æŠ—è…«ç˜¤è—¥ç‰©é–‹ç™¼æä¾›äº†æ–°çš„æ–¹å‘ã€‚  \n\nğŸ” ä¸»è¦é‡é»ï¼š  \n1. CTNPC8é¡¯ç¤ºå‡ºå„ªç•°çš„æŠ—ç™Œæ´»æ€§ã€‚  \n2. å®ƒé€éèª¿æ§ç´°èƒå…§æ´»æ€§æ°§ä¾†èª˜å°ç™Œç´°èƒæ­»äº¡ã€‚  \n3. é€™é …ç ”ç©¶ç‚ºé¼»å’½ç™Œçš„æ²»ç™‚æä¾›äº†æ–°çš„å¸Œæœ›ï¼",
    "image_prompt": "Create a flat design infographic on the experimental methods and main results of a study on a new anti-cancer compound called CTNPC8. The image should have a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified representations of experimental subjects like cells or humans, and arrows or flow lines indicating the experimental steps. Also, include a section labeled 'Main Results' highlighting the protective effects and changes observed in the study.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "é¼»å’½ç™Œ Nasopharyngeal Carcinoma",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41235157/"
  },
  {
    "id": "41181585",
    "title_en": "Sulforaphane alleviates hepatocyte pyroptosis via activating Nrf2-HO-1 signaling during septic acute liver injury.",
    "pub_date": "2025",
    "abstract_en": "Acute liver injury (ALI) caused by sepsis is a fatal disease with a high mortality rate and poor prognosis. Sulforaphane (SFN) is a natural isothiocyanate that has robust antioxidant and anti-inflammatory properties. The aim of this study was to identify the pharmacological effects and therapeutic mechanisms of SFN in lipopolysaccharide (LPS)-induced ALI. The role of SFN in ALI was investigated using a mouse model of LPS-induced ALI. Briefly, eighteen mice were divided into three groups: control, LPS, and LPS + SFN, which were intraperitoneally injected for 2Â days before LPS treatment. 24Â h after the LPS injection, blood and liver tissues were collected for further analysis. The hematoxylin and eosin (HE) staining showed a lot of visible necrosis areas, inflammatory cell infiltration, and congestion in liver. Meanwhile, Ly6G and F4/80 staining showed increased infiltration of neutrophils and macrophages in liver, these results indicated that LPS induced sever ALI. As inflammatory response plays a vital role in the pathogenesis of LPS-induced ALI, we detected the occurrence of pyroptosis in liver by ribonucleic acid (RNA) sequencing. The results showed that pyroptosis was significantly promoted by LPS, as indicated by gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analyses, revealing the activation of pyroptosis, interleukin (IL)-1 production, IL-18 production, and inflammatory signaling pathways. Then, we explored the effect of SFN on LPS-induced ALI. The results showed that SFN obviously reduced LPS-induced plasma alanine aminotransferase and aspartate aminotransferase level, pathological injuries and TdT-mediated dUTP nick-end labeling (TUNEL) positive cells, indicating protective effect of SFN on ALI. Furthermore, SFN also showed robust effect on LPS-induced inflammatory response in liver, as reflected by suppressing the infiltration of neutrophils and macrophages, and downregulating mRNA levels of C-X-C motif chemokine ligand 9, IL-6, monocyte chemoattractant protein-1, and tumor necrosis factor-Î± in liver of LPS treated mice. Furthermore, SFN blocked hepatocyte pyroptosis, and suppressed plasma IL-1Î² and IL-18 levels of LPS treated mice. Mechanistically, SFN selectively activated nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling to mediate pyroptotic cell death. SFN also reversed the inhibited superoxide dismutase activity and induced malondialdehyde content in liver of LPS exposed mice. SFN ameliorated liver injury and inflammation during LPS-induced ALI by suppressing hepatocyte pyroptosis via the activation of Nrf2/HO-1 signaling. This study provides new evidence for the potential treatment of ALI with SFN.",
    "para1": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™å¯èƒ½ä½¿å…¶æˆç‚ºæ²»ç™‚æ€¥æ€§è‚æå‚·çš„æ½›åœ¨é¸æ“‡ã€‚é€™é …ç ”ç©¶çš„çµæœæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æ¸›å°‘è‚æå‚·çš„ç™¼ç”Ÿï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰èª˜å°çš„æ€¥æ€§è‚æå‚·ä¸­çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿçš„ç‚ç—‡åæ‡‰åŠç´°èƒæ­»äº¡ï¼Œç‰¹åˆ¥æ˜¯èˆ‡æ€¥æ€§è‚æå‚·ç›¸é—œçš„ç—…ç†è®ŠåŒ–ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œé‚„èƒ½ç‚ºæ€¥æ€§è‚æå‚·çš„æ²»ç™‚æä¾›æ–°çš„è¦‹è§£ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬ç”±LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚ä»–å€‘å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œä»¥è©•ä¼°è‚è‡Ÿçš„ç—…ç†è®ŠåŒ–å’Œç‚ç—‡åæ‡‰ã€‚",
    "para4": "ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSèª˜å°çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶å°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶è‚è‡Ÿçš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦ä¸‹èª¿å¤šç¨®ç‚ç—‡ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSèª˜å°çš„è‚æå‚·å’Œç‚ç—‡ã€‚é€™é …ç ”ç©¶ç‚ºè˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·æ²»ç™‚ä¸­çš„æ½›åŠ›æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "explanation_zh": "æ€¥æ€§è‚æå‚·ï¼ˆALIï¼‰æ˜¯ä¸€ç¨®ç”±æ•—è¡€ç—‡å¼•èµ·çš„è‡´å‘½ç–¾ç—…ï¼Œæ­»äº¡ç‡é«˜ä¸”é å¾Œä¸ä½³ã€‚å› æ­¤ï¼Œå°‹æ‰¾æœ‰æ•ˆçš„é é˜²å’Œæ²»ç™‚æ–¹æ³•å°æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³è‡³é—œé‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å…·æœ‰å¼·å¤§çš„æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ï¼Œé€™å¯èƒ½ä½¿å…¶æˆç‚ºæ²»ç™‚æ€¥æ€§è‚æå‚·çš„æ½›åœ¨é¸æ“‡ã€‚é€™é …ç ”ç©¶çš„çµæœæˆ–è¨±èƒ½ç‚ºæœªä¾†çš„æ²»ç™‚ç­–ç•¥æä¾›æ–°çš„æ€è·¯ï¼Œå¹«åŠ©æ¸›å°‘è‚æå‚·çš„ç™¼ç”Ÿï¼Œä¸¦æ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ åœ¨ç”±è„‚å¤šé†£ï¼ˆLPSï¼‰èª˜å°çš„æ€¥æ€§è‚æå‚·ä¸­çš„è—¥ç†ä½œç”¨åŠå…¶æ²»ç™‚æ©Ÿåˆ¶ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿è‚è‡Ÿçš„ç‚ç—‡åæ‡‰åŠç´°èƒæ­»äº¡ï¼Œç‰¹åˆ¥æ˜¯èˆ‡æ€¥æ€§è‚æå‚·ç›¸é—œçš„ç—…ç†è®ŠåŒ–ã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼ç†è§£è˜¿è””ç¡«ç´ çš„ä½œç”¨ï¼Œé‚„èƒ½ç‚ºæ€¥æ€§è‚æå‚·çš„æ²»ç™‚æä¾›æ–°çš„è¦‹è§£ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†å°é¼ æ¨¡å‹ä¾†æ¨¡æ“¬ç”±LPSå¼•èµ·çš„æ€¥æ€§è‚æå‚·ã€‚ä»–å€‘å°‡18éš»å°é¼ åˆ†ç‚ºä¸‰çµ„ï¼šå°ç…§çµ„ã€LPSçµ„å’ŒLPS + è˜¿è””ç¡«ç´ çµ„ã€‚åœ¨LPSè™•ç†å‰ï¼Œé€™ä¸‰çµ„å°é¼ æ¥å—äº†ç‚ºæœŸå…©å¤©çš„è…¹è…”æ³¨å°„ã€‚LPSæ³¨å°„å¾Œ24å°æ™‚ï¼Œç ”ç©¶è€…æ”¶é›†äº†å°é¼ çš„è¡€æ¶²å’Œè‚è‡Ÿçµ„ç¹”é€²è¡Œé€²ä¸€æ­¥åˆ†æï¼Œä»¥è©•ä¼°è‚è‡Ÿçš„ç—…ç†è®ŠåŒ–å’Œç‚ç—‡åæ‡‰ã€‚\n\nç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½é¡¯è‘—é™ä½LPSèª˜å°çš„è¡€æ¼¿è½‰æ°¨é…¶æ°´å¹³å’Œè‚è‡Ÿç—…ç†æå‚·ï¼Œé¡¯ç¤ºå‡ºå…¶å°æ€¥æ€§è‚æå‚·çš„ä¿è­·ä½œç”¨ã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½æŠ‘åˆ¶è‚è‡Ÿçš„ç‚ç—‡åæ‡‰ï¼Œæ¸›å°‘ä¸­æ€§ç²’ç´°èƒå’Œå·¨å™¬ç´°èƒçš„æµ¸æ½¤ï¼Œä¸¦ä¸‹èª¿å¤šç¨®ç‚ç—‡ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½é€šéæ¿€æ´»Nrf2/HO-1ä¿¡è™Ÿé€šè·¯ä¾†æŠ‘åˆ¶è‚ç´°èƒçš„ç„¦äº¡ï¼Œå¾è€Œæ”¹å–„LPSèª˜å°çš„è‚æå‚·å’Œç‚ç—‡ã€‚é€™é …ç ”ç©¶ç‚ºè˜¿è””ç¡«ç´ åœ¨æ€¥æ€§è‚æå‚·æ²»ç™‚ä¸­çš„æ½›åŠ›æä¾›äº†æ–°çš„è­‰æ“šã€‚",
    "fb_post": "ğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„è‚è‡Ÿå…¶å¯¦å¾ˆè„†å¼±ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ„ŸæŸ“çš„æ™‚å€™ï¼æœ€è¿‘æœ‰ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ é€™å€‹ç¥å¥‡çš„æˆåˆ†ï¼Œå¯èƒ½å°æ€¥æ€§è‚æå‚·æœ‰ä¿è­·ä½œç”¨å“¦ï¼\n\né€™é …ç ”ç©¶ä¸»è¦æ˜¯æƒ³äº†è§£è˜¿è””ç¡«ç´ å¦‚ä½•å¹«åŠ©è‚è‡Ÿå°æŠ—ç”±ç´°èŒå¼•èµ·çš„ç‚ç—‡ã€‚ç ”ç©¶è€…å€‘ç”¨å°é¼ ä¾†æ¨¡æ“¬é€™ç¨®æƒ…æ³ï¼Œä¸¦çµ¦å®ƒå€‘æ³¨å°„äº†ç‰¹å®šçš„ç‰©è³ªä¾†èª˜ç™¼è‚æå‚·ã€‚æ¥è‘—ï¼Œä»–å€‘è§€å¯Ÿäº†å°é¼ çš„è‚è‡Ÿè®ŠåŒ–ï¼Œçœ‹çœ‹è˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æ¸›è¼•æå‚·ã€‚\n\nçµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½é™ä½è‚è‡Ÿçš„æå‚·ç¨‹åº¦ï¼Œé‚„èƒ½æ¸›å°‘ç‚ç—‡åæ‡‰ï¼Œè®“è‚è‡Ÿæ¢å¾©å¾—æ›´å¿«ï¼é€™æ¨£çš„ç™¼ç¾è®“æˆ‘å€‘å°æœªä¾†çš„æ²»ç™‚æœ‰äº†æ›´å¤šçš„æœŸå¾…ã€‚\n\nğŸ” é‡é»æ•´ç†ï¼š  \n1. è˜¿è””ç¡«ç´ å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚ç‰¹æ€§ã€‚  \n2. ç ”ç©¶é¡¯ç¤ºå®ƒèƒ½æ¸›è¼•æ€¥æ€§è‚æå‚·ã€‚  \n3. é€™å¯èƒ½æˆç‚ºæœªä¾†æ²»ç™‚è‚æå‚·çš„æ–°æ–¹å‘ï¼",
    "image_prompt": "Create a flat design infographic explaining the experimental method and main results of a study on the protective effects of sulforaphane on acute liver injury. Include simple illustrations of broccoli or a symbol representing sulforaphane, simplified depictions of experimental subjects (like mice or cells), arrows or flow lines indicating the experimental steps, and a section highlighting the main results (such as protective effects and changes observed). Use a light background with soft colors.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "æ€¥æ€§è‚æå‚· Acute Liver Injury",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41181585/"
  },
  {
    "id": "41099966",
    "title_en": "Sulforaphane improves exercise-induced NRF2 signaling in older adults: an in vivo-ex vivo approach.",
    "pub_date": "2025 Oct",
    "abstract_en": "Redox signaling is a key mechanism of exercise-induced adaptation. However, studies have demonstrated impaired responses to acute exercise in older organisms. Adjunctive therapies to augment exercise effects may overcome these deficits. Sulforaphane (SFN), a phytochemical from cruciferous vegetables, stimulates NRF2. This study tested the hypothesis that combining acute exercise (in vivo stimulus) with ex vivo SFN treatment would induce greater NRF2 activation and signaling in older adults compared to either treatment alone. Twenty-five older adults (12 men, 13 women; mean age: 67â€‰Â±â€‰5Â years) performed 30-min cycling exercise (AET). Blood was drawn before and immediately after the AET to isolate PBMCs and incubate with and without SFN (5Â ÂµM) treatment (four conditions: DMSO (CON), SFN, exercise (EX), and EXâ€‰+â€‰SFN). PBMCs were harvested after 2-h or 5-h incubation for measures of NRF2 or gene expression for NQO1, HO-1, GR, and GCLC targets, respectively. All treatments (SFN, EX, EXâ€‰+â€‰SFN) increased NRF2 activation compared to CON (pâ€‰<â€‰0.05). The response to EXâ€‰+â€‰SFN was significantly greater than either SFN or EX alone (2.1-fold versus 1.5-fold, pâ€‰=â€‰0.01). SFN stimulation resulted in a significant upregulation of all four genes compared to control (pâ€‰<â€‰0.001). EXâ€‰+â€‰SFN treatment stimulated a greater increase in gene expression compared to EX (pâ€‰<â€‰0.05); however, SFN did not differ statistically from EXâ€‰+â€‰SFN, suggesting a possible ceiling effect of the SFN concentration in terms of gene expression. There were no significant sex differences in any of the responses. These data suggest that combining exercise with SFN may amplify the strength of NRF2/ARE redox signaling in older adults. ClinicalTrials.gov ID: NCT04848792.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¹´é•·è€…ä¾†èªªã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—ä»–å€‘åœ¨é€²è¡Œé‹å‹•æ™‚å¯èƒ½ç„¡æ³•ç²å¾—æœ€ä½³çš„å¥åº·æ•ˆç›Šã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•è®Šå¾—éå¸¸é‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œçµåˆé‹å‹•èˆ‡æŸäº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„ä½¿ç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³ï¼Œé€²è€Œæå‡ä»–å€‘çš„ç”Ÿæ´»å“è³ªã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…å°æ–¼è€å¹´äººçš„é‹å‹•è¨ˆç•«æœ‰å¹«åŠ©ï¼Œä¹Ÿå¯èƒ½å°æ–¼é é˜²èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œæä¾›æ–°çš„æ€è·¯ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•é€šéçµåˆé‹å‹•å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ä¾†å¢å¼·å¹´é•·è€…çš„ç”Ÿç†åæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¹´é•·è€…åœ¨é€²è¡Œæ€¥æ€§é‹å‹•æ™‚ï¼Œèº«é«”çš„åæ‡‰æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä»¥åŠæ˜¯å¦å¯ä»¥é€šéè¼”åŠ©ç™‚æ³•ä¾†æ”¹å–„é€™ç¨®æƒ…æ³ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶å‡è¨­çµåˆé‹å‹•èˆ‡è˜¿è””ç¡«ç´ è™•ç†ï¼Œèƒ½å¤ æ¯”å–®ç¨çš„é‹å‹•æˆ–è˜¿è””ç¡«ç´ è™•ç†æ›´æœ‰æ•ˆåœ°æ¿€æ´»NRF2é€™ä¸€é‡è¦çš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¾è€Œä¿ƒé€²èº«é«”çš„é©æ‡‰èƒ½åŠ›ã€‚",
    "para3": "é€™é …ç ”ç©¶çš„å¯¦é©—å°è±¡æ˜¯25ä½å¹´é•·è€…ï¼ŒåŒ…å«12åç”·æ€§å’Œ13åå¥³æ€§ï¼Œå¹³å‡å¹´é½¡ç‚º67æ­²ã€‚åƒèˆ‡è€…é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ã€‚é€™äº›ç´°èƒåœ¨ä¸åŒçš„æ¢ä»¶ä¸‹é€²è¡Œè™•ç†ï¼ŒåŒ…æ‹¬ä¸æ·»åŠ è˜¿è””ç¡«ç´ çš„å°ç…§çµ„ã€å–®ç¨çš„è˜¿è””ç¡«ç´ è™•ç†ã€å–®ç¨çš„é‹å‹•è™•ç†ï¼Œä»¥åŠé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆã€‚ç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»åŒ–ç¨‹åº¦åŠç›¸é—œåŸºå› çš„è¡¨é”ã€‚",
    "para4": "ç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ‰€æœ‰çš„è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„æœ‰é¡¯è‘—çš„NRF2æ´»åŒ–ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶åæ‡‰å¼·åº¦é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ï¼Œé¡¯ç¤ºå‡º2.1å€çš„å¢å¼·æ•ˆæœã€‚è˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—æé«˜äº†å››å€‹ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„è™•ç†åœ¨åŸºå› è¡¨é”ä¸Šæ¯”å–®ç¨é‹å‹•æœ‰æ›´å¤§çš„å¢å¼·ï¼Œä½†è˜¿è””ç¡«ç´ çš„æ•ˆæœèˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ åœ¨çµ±è¨ˆä¸Šä¸¦ç„¡é¡¯è‘—å·®ç•°ï¼Œé€™å¯èƒ½æš—ç¤ºè‘—è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šå­˜åœ¨æŸç¨®ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶çµæœæœªé¡¯ç¤ºæ€§åˆ¥å°åæ‡‰æœ‰é¡¯è‘—å½±éŸ¿ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯å°æ–¼å¹´é•·è€…ä¾†èªªã€‚éš¨è‘—å¹´é½¡å¢é•·ï¼Œèº«é«”å°é‹å‹•çš„åæ‡‰å¯èƒ½æœƒæ¸›å¼±ï¼Œé€™ä½¿å¾—ä»–å€‘åœ¨é€²è¡Œé‹å‹•æ™‚å¯èƒ½ç„¡æ³•ç²å¾—æœ€ä½³çš„å¥åº·æ•ˆç›Šã€‚å› æ­¤ï¼Œå°‹æ‰¾èƒ½å¤ å¢å¼·é‹å‹•æ•ˆæœçš„è¼”åŠ©ç™‚æ³•è®Šå¾—éå¸¸é‡è¦ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œçµåˆé‹å‹•èˆ‡æŸäº›æ¤ç‰©åŒ–å­¸ç‰©è³ªçš„ä½¿ç”¨ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ”¹å–„å¹´é•·è€…çš„å¥åº·ç‹€æ³ï¼Œé€²è€Œæå‡ä»–å€‘çš„ç”Ÿæ´»å“è³ªã€‚é€™æ¨£çš„ç™¼ç¾ä¸åƒ…å°æ–¼è€å¹´äººçš„é‹å‹•è¨ˆç•«æœ‰å¹«åŠ©ï¼Œä¹Ÿå¯èƒ½å°æ–¼é é˜²èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œæä¾›æ–°çš„æ€è·¯ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•é€šéçµåˆé‹å‹•å’Œè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ä¾†å¢å¼·å¹´é•·è€…çš„ç”Ÿç†åæ‡‰ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¹´é•·è€…åœ¨é€²è¡Œæ€¥æ€§é‹å‹•æ™‚ï¼Œèº«é«”çš„åæ‡‰æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä»¥åŠæ˜¯å¦å¯ä»¥é€šéè¼”åŠ©ç™‚æ³•ä¾†æ”¹å–„é€™ç¨®æƒ…æ³ã€‚å…·é«”ä¾†èªªï¼Œç ”ç©¶å‡è¨­çµåˆé‹å‹•èˆ‡è˜¿è””ç¡«ç´ è™•ç†ï¼Œèƒ½å¤ æ¯”å–®ç¨çš„é‹å‹•æˆ–è˜¿è””ç¡«ç´ è™•ç†æ›´æœ‰æ•ˆåœ°æ¿€æ´»NRF2é€™ä¸€é‡è¦çš„ä¿¡è™Ÿå‚³å°è·¯å¾‘ï¼Œå¾è€Œä¿ƒé€²èº«é«”çš„é©æ‡‰èƒ½åŠ›ã€‚\n\né€™é …ç ”ç©¶çš„å¯¦é©—å°è±¡æ˜¯25ä½å¹´é•·è€…ï¼ŒåŒ…å«12åç”·æ€§å’Œ13åå¥³æ€§ï¼Œå¹³å‡å¹´é½¡ç‚º67æ­²ã€‚åƒèˆ‡è€…é€²è¡Œäº†30åˆ†é˜çš„é¨è‡ªè¡Œè»Šé‹å‹•ï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½å–è¡€æ¶²ï¼Œä»¥åˆ†é›¢å¤–å‘¨è¡€å–®æ ¸ç´°èƒï¼ˆPBMCsï¼‰ã€‚é€™äº›ç´°èƒåœ¨ä¸åŒçš„æ¢ä»¶ä¸‹é€²è¡Œè™•ç†ï¼ŒåŒ…æ‹¬ä¸æ·»åŠ è˜¿è””ç¡«ç´ çš„å°ç…§çµ„ã€å–®ç¨çš„è˜¿è””ç¡«ç´ è™•ç†ã€å–®ç¨çš„é‹å‹•è™•ç†ï¼Œä»¥åŠé‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆã€‚ç ”ç©¶è€…åœ¨2å°æ™‚æˆ–5å°æ™‚å¾Œæ”¶é›†ç´°èƒï¼Œä»¥æ¸¬é‡NRF2çš„æ´»åŒ–ç¨‹åº¦åŠç›¸é—œåŸºå› çš„è¡¨é”ã€‚\n\nç ”ç©¶çš„ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ‰€æœ‰çš„è™•ç†çµ„ï¼ˆè˜¿è””ç¡«ç´ ã€é‹å‹•ã€é‹å‹•åŠ è˜¿è””ç¡«ç´ ï¼‰éƒ½æ¯”å°ç…§çµ„æœ‰é¡¯è‘—çš„NRF2æ´»åŒ–ã€‚ç‰¹åˆ¥æ˜¯é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå…¶åæ‡‰å¼·åº¦é¡¯è‘—é«˜æ–¼å–®ç¨çš„è˜¿è””ç¡«ç´ æˆ–é‹å‹•ï¼Œé¡¯ç¤ºå‡º2.1å€çš„å¢å¼·æ•ˆæœã€‚è˜¿è””ç¡«ç´ çš„åˆºæ¿€ä¹Ÿé¡¯è‘—æé«˜äº†å››å€‹ç›¸é—œåŸºå› çš„è¡¨é”ã€‚é›–ç„¶é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„è™•ç†åœ¨åŸºå› è¡¨é”ä¸Šæ¯”å–®ç¨é‹å‹•æœ‰æ›´å¤§çš„å¢å¼·ï¼Œä½†è˜¿è””ç¡«ç´ çš„æ•ˆæœèˆ‡é‹å‹•åŠ è˜¿è””ç¡«ç´ åœ¨çµ±è¨ˆä¸Šä¸¦ç„¡é¡¯è‘—å·®ç•°ï¼Œé€™å¯èƒ½æš—ç¤ºè‘—è˜¿è””ç¡«ç´ æ¿ƒåº¦åœ¨åŸºå› è¡¨é”ä¸Šå­˜åœ¨æŸç¨®ä¸Šé™æ•ˆæ‡‰ã€‚ç ”ç©¶çµæœæœªé¡¯ç¤ºæ€§åˆ¥å°åæ‡‰æœ‰é¡¯è‘—å½±éŸ¿ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿé‹å‹•å’Œä¸€äº›å¤©ç„¶æˆåˆ†çš„çµåˆï¼Œå¯èƒ½æœƒè®“å¹´é•·è€…çš„å¥åº·è¡¨ç¾æ›´å¥½ï¼é€™é …ç ”ç©¶å°ˆé–€æ¢è¨å¹´é•·è€…åœ¨é‹å‹•æ™‚ï¼Œå¦‚ä½•é€éè˜¿è””ç¡«ç´ ï¼ˆSFNï¼‰ä¾†å¢å¼·èº«é«”çš„åæ‡‰ã€‚ç ”ç©¶è€…å€‘ç™¼ç¾ï¼Œé‹å‹•åŠ ä¸Šè˜¿è””ç¡«ç´ çš„æ­é…ï¼Œèƒ½æ›´æœ‰æ•ˆåœ°æ¿€æ´»ä¸€å€‹å«åšNRF2çš„ä¿¡è™Ÿç³»çµ±ï¼Œé€™å°èº«é«”çš„é©æ‡‰èƒ½åŠ›éå¸¸é‡è¦ã€‚\n\né€™é …ç ”ç©¶é‚€è«‹äº†25ä½å¹´é•·è€…åƒåŠ ï¼Œä»–å€‘é¨äº†30åˆ†é˜çš„è‡ªè¡Œè»Šï¼Œä¸¦åœ¨é‹å‹•å‰å¾ŒæŠ½è¡€é€²è¡Œåˆ†æã€‚ç ”ç©¶è€…å€‘æ¯”è¼ƒäº†ä¸åŒçµ„åˆ¥çš„åæ‡‰ï¼ŒåŒ…æ‹¬åªé‹å‹•ã€åªæœç”¨è˜¿è””ç¡«ç´ ï¼Œä»¥åŠå…©è€…çµåˆçš„æ•ˆæœã€‚\n\nçµæœé¡¯ç¤ºï¼Œé‹å‹•åŠ ä¸Šè˜¿è””ç¡«ç´ çš„çµ„åˆï¼Œå°èº«é«”çš„å½±éŸ¿æœ€ç‚ºé¡¯è‘—ï¼ŒNRF2çš„æ´»åŒ–ç¨‹åº¦æ¯”å–®ç¨çš„é‹å‹•æˆ–è˜¿è””ç¡«ç´ æ›´é«˜ï¼Œç”šè‡³å¢å¼·äº†2.1å€ï¼é€™ä¸åƒ…å°è€å¹´äººçš„å¥åº·æœ‰å¹«åŠ©ï¼Œä¹Ÿçµ¦æˆ‘å€‘æä¾›äº†æ–°çš„æ€è·¯ä¾†é é˜²èˆ‡å¹´é½¡ç›¸é—œçš„å¥åº·å•é¡Œã€‚\n\nğŸ”‘ ç ”ç©¶é‡é»ï¼š\n1. çµåˆé‹å‹•èˆ‡è˜¿è””ç¡«ç´ èƒ½æå‡å¹´é•·è€…çš„å¥åº·åæ‡‰ã€‚\n2. NRF2ä¿¡è™Ÿç³»çµ±åœ¨é‹å‹•èˆ‡å¥åº·ä¸­æ‰®æ¼”é‡è¦è§’è‰²ã€‚\n3. é‹å‹•åŠ è˜¿è””ç¡«ç´ çš„æ•ˆæœé¡¯è‘—é«˜æ–¼å–®ç¨è™•ç†ã€‚  ",
    "image_prompt": "Create a flat design infographic on a light background that explains the experiment and main results of a study on the effects of exercise combined with sulforaphane (SFN) on older adults. Include simplified icons of broccoli or sulforaphane, representations of human participants, and peripheral blood mononuclear cells (PBMCs). Use arrows or flow lines to indicate the experimental steps. Highlight a section labeled 'Main Results' showing the significant activation of NRF2 and the enhanced effects of the combination treatment.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41099966/"
  },
  {
    "id": "40763479",
    "title_en": "Sulforaphane modulates macrophage polarization via JAK1/STAT1 inhibition to promote tendon repair in tendinopathy.",
    "pub_date": "2025 Oct",
    "abstract_en": "Imbalanced M1/M2 macrophage polarization is central to tendinopathy pathogenesis. Sulforaphane (SFN), a natural compound with anti-inflammatory properties, may modulate macrophage polarization. This study utilized a collagenase-induced mouse model of tendinopathy to evaluate the therapeutic effects of local SFN administration on tendinopathy in vivo. Furthermore, the effects of SFN on macrophage polarization were investigated in vitro, and RNA sequencing was used to explore the mechanisms by which SFN regulates macrophage polarization in vivo. Finally, an ex vivo human pathological tendon culture system was employed to explore the therapeutic effects of SFN on tendinopathic lesions. In this study, we found that SFN modulated the polarization of M1 macrophages towards M2 macrophages, thereby effectively modulating the inflammatory response. RNA sequencing and Western blot analyses indicated that the effect of SFN was mediated through the JAK1/STAT1 signaling pathway. In a collagenase-induced mouse model of tendinopathy, local injection of SFN led to a significant improvement in tendon tissue structure, with the collagen matrix restoring its natural dense parallel arrangement. Furthermore, there was an increase in local M2 macrophages and a decrease in M1 macrophages, which promoted the resolution of inflammation. Finally, the immunomodulatory effect of SFN on macrophages was also validated in tendon tissue from patients with tendinopathy. SFN can effectively alleviate tendinopathy by promoting the polarization of M1 macrophages towards M2 macrophages, an effect achieved through the inhibition of the JAK1/STAT1 signaling pathway, thereby providing a promising therapeutic approach for the treatment of tendinopathy.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç–¾ç—…çš„ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸­ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†é”åˆ°æ›´å¥½çš„æ•ˆæœï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œæ™®é€šäººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ä¸­çš„å·¨å™¬ç´°èƒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè‚Œè…±ç—…çš„ç™¼å±•èˆ‡å·¨å™¬ç´°èƒçš„æ¥µåŒ–æœ‰é—œï¼Œè€Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ èª¿ç¯€é€™äº›ç´°èƒçš„åŠŸèƒ½ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—ç‚ç‰¹æ€§ï¼Œé‚„å¸Œæœ›æ­ç¤ºå…¶åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚",
    "para3": "å¯¦é©—æ–¹é¢ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„é¼ é¡æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–é€²è¡Œäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–å¯¦é©—ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ èª¿ç¯€å·¨å™¬ç´°èƒæ¥µåŒ–çš„æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œä»¥é€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„ç™‚æ•ˆã€‚",
    "para4": "ä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆåœ°å°‡M1å‹å·¨å™¬ç´°èƒè½‰è®Šç‚ºM2å‹å·¨å™¬ç´°èƒï¼Œé€™æœ‰åŠ©æ–¼èª¿ç¯€ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªå°è·¡åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„é¼ é¡æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™å°æ–¼ç‚ç—‡çš„ç·©è§£å…·æœ‰é‡è¦æ„ç¾©ã€‚æ­¤å¤–ï¼Œé€™ä¸€å…ç–«èª¿ç¯€æ•ˆæœä¹Ÿåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­å¾—åˆ°äº†é©—è­‰ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å°å¥åº·å’Œç–¾ç—…é é˜²çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸Šã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œé€šå¸¸ä¼´éš¨è‘—ç–¼ç—›å’ŒåŠŸèƒ½éšœç¤™ã€‚ç ”ç©¶é¡¯ç¤ºï¼Œé€éèª¿ç¯€å…ç–«ç´°èƒçš„åŠŸèƒ½ï¼Œå¯èƒ½æœ‰åŠ©æ–¼æ¸›è¼•é€™ç¨®ç–¾ç—…çš„ç‚ç—‡åæ‡‰ï¼Œé€²è€Œæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»å“è³ªã€‚é€™æ„å‘³è‘—ï¼Œæœªä¾†åœ¨è‚Œè…±ç—…çš„æ²»ç™‚ä¸­ï¼Œå¯èƒ½å¯ä»¥è€ƒæ…®ä½¿ç”¨å¤©ç„¶åŒ–åˆç‰©ä¾†é”åˆ°æ›´å¥½çš„æ•ˆæœï¼Œé€™å°æ–¼é‹å‹•å“¡å’Œæ™®é€šäººä¾†èªªéƒ½æ˜¯ä¸€å€‹å€¼å¾—é—œæ³¨çš„æ–¹å‘ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…çš„æ²»ç™‚æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒå¦‚ä½•å½±éŸ¿å…ç–«ç³»çµ±ä¸­çš„å·¨å™¬ç´°èƒã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè‚Œè…±ç—…çš„ç™¼å±•èˆ‡å·¨å™¬ç´°èƒçš„æ¥µåŒ–æœ‰é—œï¼Œè€Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½å¤ èª¿ç¯€é€™äº›ç´°èƒçš„åŠŸèƒ½ï¼Œé€²è€Œæ”¹å–„è‚Œè…±çš„å¥åº·ç‹€æ…‹ã€‚é€™é …ç ”ç©¶ä¸åƒ…é—œæ³¨è˜¿è””ç¡«ç´ çš„æŠ—ç‚ç‰¹æ€§ï¼Œé‚„å¸Œæœ›æ­ç¤ºå…¶åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åœ¨æ©Ÿåˆ¶ã€‚\n\nå¯¦é©—æ–¹é¢ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†ä¸€ç¨®ç”±è† åŸé…¶èª˜å°çš„é¼ é¡æ¨¡å‹ä¾†æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦è©•ä¼°å±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ çš„æ²»ç™‚æ•ˆæœã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„åœ¨é«”å¤–é€²è¡Œäº†å·¨å™¬ç´°èƒçš„æ¥µåŒ–å¯¦é©—ï¼Œä¸¦åˆ©ç”¨RNAæ¸¬åºæŠ€è¡“ä¾†æ¢ç´¢è˜¿è””ç¡«ç´ èª¿ç¯€å·¨å™¬ç´°èƒæ¥µåŒ–çš„æ©Ÿåˆ¶ã€‚æœ€å¾Œï¼Œç ”ç©¶è€…é‚„ä½¿ç”¨äº†äººé¡ç—…ç†è‚Œè…±çš„åŸ¹é¤Šç³»çµ±ï¼Œä»¥é€²ä¸€æ­¥é©—è­‰è˜¿è””ç¡«ç´ å°è‚Œè…±ç—…è®Šçš„ç™‚æ•ˆã€‚\n\nä¸»è¦çš„ç™¼ç¾æ˜¯ï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æœ‰æ•ˆåœ°å°‡M1å‹å·¨å™¬ç´°èƒè½‰è®Šç‚ºM2å‹å·¨å™¬ç´°èƒï¼Œé€™æœ‰åŠ©æ–¼èª¿ç¯€ç‚ç—‡åæ‡‰ã€‚RNAæ¸¬åºå’Œè›‹ç™½è³ªå°è·¡åˆ†æé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ çš„ä½œç”¨æ˜¯é€šéæŠ‘åˆ¶JAK1/STAT1ä¿¡è™Ÿé€šè·¯ä¾†å¯¦ç¾çš„ã€‚åœ¨è† åŸé…¶èª˜å°çš„é¼ é¡æ¨¡å‹ä¸­ï¼Œå±€éƒ¨æ³¨å°„è˜¿è””ç¡«ç´ é¡¯è‘—æ”¹å–„äº†è‚Œè…±çµ„ç¹”çš„çµæ§‹ï¼Œä¸¦ä¿ƒé€²äº†M2å‹å·¨å™¬ç´°èƒçš„å¢åŠ å’ŒM1å‹å·¨å™¬ç´°èƒçš„æ¸›å°‘ï¼Œé€™å°æ–¼ç‚ç—‡çš„ç·©è§£å…·æœ‰é‡è¦æ„ç¾©ã€‚æ­¤å¤–ï¼Œé€™ä¸€å…ç–«èª¿ç¯€æ•ˆæœä¹Ÿåœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­å¾—åˆ°äº†é©—è­‰ï¼Œé¡¯ç¤ºå‡ºè˜¿è””ç¡«ç´ åœ¨è‚Œè…±ç—…æ²»ç™‚ä¸­çš„æ½›åŠ›ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£²é£Ÿä¸­ç«Ÿç„¶æœ‰å¯èƒ½å¹«åŠ©æ”¹å–„é‹å‹•å‚·å®³ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œå®ƒå¯èƒ½å°è‚Œè…±ç—…çš„æ²»ç™‚æœ‰å¾ˆå¤§çš„å¹«åŠ©ã€‚è‚Œè…±ç—…æ˜¯ä¸€ç¨®å¸¸è¦‹çš„é‹å‹•å‚·å®³ï¼Œæœƒè®“äººæ„Ÿåˆ°ç–¼ç—›å’Œä¸é©ã€‚é€™é …ç ”ç©¶çš„ç›®çš„æ˜¯çœ‹çœ‹è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘å…ç–«ç³»çµ±ä¸­çš„ä¸€ç¨®ç´°èƒï¼Œåå«å·¨å™¬ç´°èƒã€‚ç ”ç©¶è€…ç”¨å°é¼ æ¨¡æ“¬è‚Œè…±ç—…ï¼Œä¸¦æ³¨å°„è˜¿è””ç¡«ç´ ä¾†è§€å¯Ÿæ•ˆæœã€‚ä»–å€‘ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ èƒ½æœ‰æ•ˆåœ°èª¿ç¯€é€™äº›å·¨å™¬ç´°èƒçš„åŠŸèƒ½ï¼Œè®“å®ƒå€‘å¾ä¸€ç¨®å¼•èµ·ç‚ç—‡çš„ç‹€æ…‹è½‰è®Šç‚ºæœ‰åŠ©æ–¼ä¿®å¾©çš„ç‹€æ…‹ã€‚é€™ä¸åƒ…åœ¨å°é¼ èº«ä¸Šè§€å¯Ÿåˆ°ï¼Œç”šè‡³åœ¨è‚Œè…±ç—…æ‚£è€…çš„çµ„ç¹”ä¸­ä¹Ÿæœ‰é¡ä¼¼çš„æ•ˆæœï¼\n\nğŸ” ç ”ç©¶é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½å¹«åŠ©æ”¹å–„è‚Œè…±ç—…çš„ç‚ç—‡åæ‡‰ã€‚\n2. å®ƒèƒ½è½‰è®Šå·¨å™¬ç´°èƒçš„åŠŸèƒ½ï¼Œä¿ƒé€²ä¿®å¾©ã€‚\n3. é€™é …ç ”ç©¶ç‚ºæœªä¾†çš„æ²»ç™‚æä¾›äº†æ–°çš„æ–¹å‘ã€‚",
    "image_prompt": "Create an informative illustration that explains the experimental methods and main findings of a study on the effects of sulforaphane on tendon disease. The image should have a flat design style with a light background and soft colors. Include symbols representing broccoli or sulforaphane, simplified illustrations of experimental subjects like humans, animals, or cells, and arrows or flow lines to indicate the experimental steps. Also, include a section that highlights the main results, such as protective effects and changes observed in the study.",
    "is_human_study": true,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "è‚Œè…±ç—… Tendinopathy",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40763479/"
  },
  {
    "id": "41060333",
    "title_en": "Sulforaphane from broccoli, an epigenetic modulator in cancer cells.",
    "pub_date": "2025 Oct",
    "abstract_en": "The consumption of cruciferous vegetables offers several health benefits due to some of their compounds. Sulforaphane (SFN), a compound found in cabbage and broccoli, has received special attention in recent years due to its anticancer activities. The main objective of this systematic review is to examine the epigenetic and genetic effects of SFN on cancers (in vitro and in vivo) which contribute to its anticancer activities. We only analyzed studies that combined its epigenetic effects and anticancer activities due to the multitude of studies on SFN over the past few years. We found that SFN is able to regulate epigenetic mechanisms and promote the prevention and treatment of several cancers. Definitely, it prevents tumor growth and acts as a histone deacetylase (HDAC) inhibitor, a DNA methyltransferase (DNMT) inhibitor, and a microRNA regulator in several cancers. These epigenetic regulations lead indirectly to a hyperregulation or deregulation of the expression of genes involved in carcinogenesis. SFN hasn't any major epigenetic effect on normal cells. This review revealed that the anticancer activities attributable to SFN are largely related to its ability to modulate cancer cell epigenome. These capabilities to modulate the epigenome make SFN a promising anticancer agent with significant therapeutic potential.",
    "para1": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦ä¾†è‡ªæ–¼å®ƒå€‘æ‰€å«çš„æŸäº›åŒ–åˆç‰©ã€‚æœ€è¿‘ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œæ´»æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç™Œç—‡ï¼Œä¸¦ä¿ƒé€²å¥åº·ã€‚é€™è®“æˆ‘å€‘æ€è€ƒï¼Œæ—¥å¸¸é£²é£Ÿä¸­åŠ å…¥æ›´å¤šçš„é’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šå¢å¼·æˆ‘å€‘çš„å¥åº·é˜²è­·åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™Œç—‡æ–¹é¢ã€‚",
    "para2": "é€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†ç™¼æ®æŠ—ç™Œä½œç”¨ã€‚ç”±æ–¼è¿‘å¹´ä¾†æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™ç¯‡å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨é‚£äº›åŒæ™‚æ¢è¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰å’ŒæŠ—ç™Œæ´»æ€§çš„ç ”ç©¶ä¸Šï¼Œè©¦åœ–æ•´åˆé€™äº›è³‡æ–™ä»¥æä¾›æ›´å…¨é¢çš„ç†è§£ã€‚",
    "para3": "é€™é …ç ”ç©¶åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œæ¶µè“‹äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶å°è±¡åŒ…æ‹¬ç™Œç´°èƒå’Œæ­£å¸¸ç´°èƒï¼Œç ”ç©¶æ–¹æ³•å‰‡è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åœ¨ä½œç”¨ï¼Œä¸¦äº†è§£å…¶å°åŸºå› è¡¨é”çš„èª¿æ§æ©Ÿåˆ¶ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚é›–ç„¶é€™é …ç ”ç©¶æŒ‡å‡ºè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿é¡¯è‘—ï¼Œä½†å°æ­£å¸¸ç´°èƒå‰‡æ²’æœ‰æ˜é¡¯çš„è¡¨è§€éºå‚³æ•ˆæ‡‰ã€‚é€™äº›èª¿ç¯€ä½œç”¨å¯èƒ½é–“æ¥å°è‡´èˆ‡ç™Œç—‡ç™¼ç”Ÿæœ‰é—œçš„åŸºå› è¡¨é”çš„éåº¦æˆ–ä¸è¶³èª¿æ§ã€‚ç¸½çš„ä¾†èªªï¼Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ´»æ€§èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæŠ—ç™ŒåŠ‘çš„æ½›åŠ›ã€‚",
    "explanation_zh": "é’èŠ±æ¤°èœç­‰åå­—èŠ±ç§‘è”¬èœçš„æ”å–å°å¥åº·æœ‰è¨±å¤šå¥½è™•ï¼Œé€™ä¸»è¦ä¾†è‡ªæ–¼å®ƒå€‘æ‰€å«çš„æŸäº›åŒ–åˆç‰©ã€‚æœ€è¿‘ï¼Œè˜¿è””ç¡«ç´ å› å…¶æŠ—ç™Œæ´»æ€§è€Œå—åˆ°ç‰¹åˆ¥é—œæ³¨ã€‚é€™é …ç ”ç©¶çš„å•Ÿç¤ºåœ¨æ–¼ï¼Œé€éé£²é£Ÿä¸­å¢åŠ é€™é¡è”¬èœçš„æ”å–ï¼Œå¯èƒ½æœ‰åŠ©æ–¼é é˜²æŸäº›ç™Œç—‡ï¼Œä¸¦ä¿ƒé€²å¥åº·ã€‚é€™è®“æˆ‘å€‘æ€è€ƒï¼Œæ—¥å¸¸é£²é£Ÿä¸­åŠ å…¥æ›´å¤šçš„é’èŠ±æ¤°èœï¼Œæˆ–è¨±èƒ½åœ¨æŸç¨®ç¨‹åº¦ä¸Šå¢å¼·æˆ‘å€‘çš„å¥åº·é˜²è­·åŠ›ï¼Œç‰¹åˆ¥æ˜¯åœ¨å°æŠ—ç™Œç—‡æ–¹é¢ã€‚\n\né€™é …ç³»çµ±æ€§å›é¡§çš„ä¸»è¦ç›®çš„æ˜¯æ¢è¨è˜¿è””ç¡«ç´ å°ç™Œç—‡çš„è¡¨è§€éºå‚³å’Œéºå‚³å½±éŸ¿ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ å¦‚ä½•é€éèª¿ç¯€åŸºå› è¡¨é”ä¾†ç™¼æ®æŠ—ç™Œä½œç”¨ã€‚ç”±æ–¼è¿‘å¹´ä¾†æœ‰è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œé€™ç¯‡å›é¡§ç‰¹åˆ¥é›†ä¸­åœ¨é‚£äº›åŒæ™‚æ¢è¨å…¶è¡¨è§€éºå‚³æ•ˆæ‡‰å’ŒæŠ—ç™Œæ´»æ€§çš„ç ”ç©¶ä¸Šï¼Œè©¦åœ–æ•´åˆé€™äº›è³‡æ–™ä»¥æä¾›æ›´å…¨é¢çš„ç†è§£ã€‚\n\né€™é …ç ”ç©¶åˆ†æäº†å¤šé …é—œæ–¼è˜¿è””ç¡«ç´ çš„ç ”ç©¶ï¼Œæ¶µè“‹äº†é«”å¤–ï¼ˆin vitroï¼‰å’Œé«”å…§ï¼ˆin vivoï¼‰çš„å¯¦é©—ã€‚ç ”ç©¶å°è±¡åŒ…æ‹¬ç™Œç´°èƒå’Œæ­£å¸¸ç´°èƒï¼Œç ”ç©¶æ–¹æ³•å‰‡è‘—é‡æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿ç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ã€‚é€éé€™äº›å¯¦é©—ï¼Œç ”ç©¶è€…å¸Œæœ›èƒ½å¤ æ­ç¤ºè˜¿è””ç¡«ç´ åœ¨ç™Œç—‡é é˜²å’Œæ²»ç™‚ä¸­çš„æ½›åœ¨ä½œç”¨ï¼Œä¸¦äº†è§£å…¶å°åŸºå› è¡¨é”çš„èª¿æ§æ©Ÿåˆ¶ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œä¸¦ä¿ƒé€²å¤šç¨®ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚é›–ç„¶é€™é …ç ”ç©¶æŒ‡å‡ºè˜¿è””ç¡«ç´ å°ç™Œç´°èƒçš„å½±éŸ¿é¡¯è‘—ï¼Œä½†å°æ­£å¸¸ç´°èƒå‰‡æ²’æœ‰æ˜é¡¯çš„è¡¨è§€éºå‚³æ•ˆæ‡‰ã€‚é€™äº›èª¿ç¯€ä½œç”¨å¯èƒ½é–“æ¥å°è‡´èˆ‡ç™Œç—‡ç™¼ç”Ÿæœ‰é—œçš„åŸºå› è¡¨é”çš„éåº¦æˆ–ä¸è¶³èª¿æ§ã€‚ç¸½çš„ä¾†èªªï¼Œè˜¿è””ç¡«ç´ çš„æŠ—ç™Œæ´»æ€§èˆ‡å…¶èª¿ç¯€ç™Œç´°èƒè¡¨è§€åŸºå› çµ„çš„èƒ½åŠ›å¯†åˆ‡ç›¸é—œï¼Œé¡¯ç¤ºå‡ºå…¶ä½œç‚ºæŠ—ç™ŒåŠ‘çš„æ½›åŠ›ã€‚",
    "fb_post": "ğŸŒ±ä½ çŸ¥é“é’èŠ±æ¤°èœè£¡æœ‰å€‹ç¥ç§˜æˆåˆ†å«è˜¿è””ç¡«ç´ å—ï¼Ÿæœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œå®ƒå¯èƒ½å°æŠ—ç™Œç—‡æœ‰å¹«åŠ©ï¼é€™ç¯‡ç ”ç©¶å°ˆæ³¨æ–¼è˜¿è””ç¡«ç´ å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„åŸºå› ï¼Œä¸¦å¯èƒ½å¹«åŠ©é é˜²æŸäº›ç™Œç—‡ã€‚\n\nç ”ç©¶è€…å€‘åˆ†æäº†è¨±å¤šé—œæ–¼è˜¿è””ç¡«ç´ çš„å¯¦é©—ï¼Œå¾ç™Œç´°èƒåˆ°æ­£å¸¸ç´°èƒéƒ½æœ‰æ¶‰åŠã€‚ä»–å€‘æƒ³äº†è§£é€™å€‹æˆåˆ†æ˜¯å¦‚ä½•èª¿ç¯€åŸºå› è¡¨é”çš„ï¼Œä¸¦ä¸”ç™¼ç¾è˜¿è””ç¡«ç´ èƒ½å¤ å½±éŸ¿ç´°èƒçš„è¡¨è§€éºå‚³æ©Ÿåˆ¶ï¼Œé€™å¯èƒ½æ˜¯å®ƒæŠ—ç™Œæ´»æ€§çš„é—œéµï¼\n\nä¸»è¦ç™¼ç¾åŒ…æ‹¬ï¼š\n1. è˜¿è””ç¡«ç´ èƒ½å¤ èª¿ç¯€èˆ‡ç™Œç—‡ç›¸é—œçš„åŸºå› è¡¨é”ã€‚\n2. å°ç™Œç´°èƒçš„å½±éŸ¿é¡¯è‘—ï¼Œä½†å°æ­£å¸¸ç´°èƒçš„å½±éŸ¿ä¸å¤§ã€‚\n3. é€™äº›èª¿ç¯€ä½œç”¨å¯èƒ½æœ‰åŠ©æ–¼ç™Œç—‡çš„é é˜²å’Œæ²»ç™‚ã€‚\n\næ‰€ä»¥ï¼Œè®“æˆ‘å€‘åœ¨æ—¥å¸¸é£²é£Ÿä¸­å¤šåŠ å…¥é’èŠ±æ¤°èœï¼Œç‚ºå¥åº·åŠ åˆ†å§ï¼",
    "image_prompt": "Create an informative illustration that explains the experimental methods and main findings of a study on sulforaphane. The style should be flat design with a white or light-colored background and soft colors. Include symbols for broccoli or sulforaphane, simplified representations of experimental subjects such as humans, animals, or cells. Use arrows or flow lines to indicate the experimental steps. Include a section that clearly states the main results, such as protective effects or changes observed.",
    "is_human_study": false,
    "is_animal_study": true,
    "is_disease_related": true,
    "disease_name": "ç™Œç—‡ Cancer",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41060333/"
  },
  {
    "id": "40553560",
    "title_en": "Antibacterial effects of sulforaphane - AÂ phytonutrient derived from broccoli asÂ promising candidate in the combat ofÂ bacterial infections.",
    "pub_date": "2025 Oct",
    "abstract_en": "Bacterial pathogens, particularly antibiotic-resistant strains may constitute major challenges for the successful treatment of infected patients. Therefore, novel antibiotics or alternative, antibiotics-independent compounds with antimicrobial properties such as phytonutrients are needed. Our systematic literature review summarizes current knowledge on antibacterial effects of sulforaphane (SFN) in vitro and in vivo, including human studies. The isothiocyanate SFN is abundant in plants from the BrassicaceaeÂ family including broccoli. The 28 reports reviewed herein revealed that SFN i.) exerted antimicrobial effects against a variety of Gram-positive and Gram-negative bacteria; ii.) counteracted distinct virulence factors such as biofilm formation and toxin production (e.g. Shiga toxin); iii.)Â enhanced antibacterial immune cell responses mounting in anti-oxidant and anti-inflammatory actions thereby supporting bacterial killing and dampening inflammatory cell and tissue damage; iv.) prevented from aspirin-induced small intestinal cell injury; and v.) alleviated Helicobacter pylori-induced gastritis. In conclusion, given its antibacterial, immune-modulatory, and disease-alleviating effects, SFN constitutesÂ a promising alternative antibiotic-independent candidate for the treatment of bacterial infections, warranting further consideration in clinical trials.",
    "para1": "åœ¨ç•¶å‰æŠ—ç”Ÿç´ æŠ—è—¥æ€§æ—¥ç›Šåš´é‡çš„æƒ…æ³ä¸‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•è®Šå¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ½›åŠ›çš„æ›¿ä»£ç™‚æ³•ï¼Œå¹«åŠ©å°æŠ—ç´°èŒæ„ŸæŸ“ï¼Œå°¤å…¶æ˜¯é‚£äº›å°å‚³çµ±æŠ—ç”Ÿç´ ç„¡æ•ˆçš„ç´°èŒã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³ï¼Œä¹Ÿå¯èƒ½åœ¨ç–¾ç—…é é˜²æ–¹é¢ç™¼æ®ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼é‚£äº›æ˜“å—ç´°èŒæ„ŸæŸ“å½±éŸ¿çš„äººç¾¤ã€‚é€éäº†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´å®‰å…¨ä¸”æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œæ¸›å°‘æŠ—ç”Ÿç´ çš„ä½¿ç”¨ï¼Œå¾è€Œé™ä½æŠ—è—¥æ€§å•é¡Œçš„é¢¨éšªã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°æŠ—ç´°èŒæ„ŸæŸ“æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆå°æŠ—å„ç¨®ç´°èŒï¼ŒåŒ…æ‹¬ä¸€äº›å°æŠ—ç”Ÿç´ æœ‰æŠ—è—¥æ€§çš„ç´°èŒã€‚é€éç³»çµ±æ€§æ–‡ç»å›é¡§ï¼Œç ”ç©¶è€…å½™æ•´äº†ç›®å‰æœ‰é—œè˜¿è””ç¡«ç´ çš„çŸ¥è­˜ï¼Œä¸¦åˆ†æå…¶åœ¨é«”å¤–å’Œé«”å…§çš„æŠ—èŒæ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨äººé«”ç ”ç©¶ä¸­çš„æ‡‰ç”¨ã€‚",
    "para3": "é€™é …ç ”ç©¶æ¡ç”¨äº†ç³»çµ±æ€§æ–‡ç»å›é¡§çš„æ–¹æ³•ï¼Œåˆ†æäº†28ç¯‡ç›¸é—œå ±å‘Šï¼Œé€™äº›å ±å‘Šæ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒç‰¹æ€§ã€‚ç ”ç©¶å°è±¡åŒ…æ‹¬ä¸åŒçš„ç´°èŒé¡å‹ï¼Œæ¶µè“‹äº†å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒã€‚ç ”ç©¶è€…è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼ŒåŒ…æ‹¬å…¶å°ç´°èŒæ¯’æ€§å› å­çš„å½±éŸ¿ã€å…ç–«åæ‡‰çš„å¢å¼·ï¼Œä»¥åŠå°ç´°èƒæå‚·çš„ä¿è­·ä½œç”¨ã€‚é€™äº›ç ”ç©¶ä¸åƒ…é™æ–¼å¯¦é©—å®¤ç’°å¢ƒï¼Œé‚„åŒ…æ‹¬äº†äººé«”çš„ç ”ç©¶çµæœï¼Œæä¾›äº†æ›´å…¨é¢çš„ç†è§£ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤å’Œæ¸›å°‘ç´°èƒåŠçµ„ç¹”çš„æå‚·ã€‚ç ”ç©¶é‚„æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ï¼Œä¸¦é˜²æ­¢é˜¿æ–¯åŒ¹æ—å¼•èµ·çš„å°è…¸ç´°èƒæå‚·ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ›¿ä»£æŠ—ç”Ÿç´ ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "explanation_zh": "åœ¨ç•¶å‰æŠ—ç”Ÿç´ æŠ—è—¥æ€§æ—¥ç›Šåš´é‡çš„æƒ…æ³ä¸‹ï¼Œå°‹æ‰¾æ–°çš„æ²»ç™‚æ–¹æ³•è®Šå¾—å°¤ç‚ºé‡è¦ã€‚é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›å•Ÿç¤ºï¼Œé¡¯ç¤ºè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰æ½›åŠ›çš„æ›¿ä»£ç™‚æ³•ï¼Œå¹«åŠ©å°æŠ—ç´°èŒæ„ŸæŸ“ï¼Œå°¤å…¶æ˜¯é‚£äº›å°å‚³çµ±æŠ—ç”Ÿç´ ç„¡æ•ˆçš„ç´°èŒã€‚é€™ä¸åƒ…æœ‰åŠ©æ–¼æ”¹å–„æ‚£è€…çš„å¥åº·ç‹€æ³ï¼Œä¹Ÿå¯èƒ½åœ¨ç–¾ç—…é é˜²æ–¹é¢ç™¼æ®ä½œç”¨ï¼Œç‰¹åˆ¥æ˜¯å°æ–¼é‚£äº›æ˜“å—ç´°èŒæ„ŸæŸ“å½±éŸ¿çš„äººç¾¤ã€‚é€éäº†è§£é€™äº›å¤©ç„¶æˆåˆ†çš„ä½œç”¨æ©Ÿåˆ¶ï¼Œæˆ‘å€‘æˆ–è¨±èƒ½æ‰¾åˆ°æ›´å®‰å…¨ä¸”æœ‰æ•ˆçš„æ²»ç™‚é¸æ“‡ï¼Œæ¸›å°‘æŠ—ç”Ÿç´ çš„ä½¿ç”¨ï¼Œå¾è€Œé™ä½æŠ—è—¥æ€§å•é¡Œçš„é¢¨éšªã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œç‰¹åˆ¥æ˜¯å®ƒåœ¨å°æŠ—ç´°èŒæ„ŸæŸ“æ–¹é¢çš„æ½›åŠ›ã€‚ç ”ç©¶è€…é—œæ³¨çš„å•é¡Œæ˜¯ï¼Œè˜¿è””ç¡«ç´ æ˜¯å¦èƒ½æœ‰æ•ˆå°æŠ—å„ç¨®ç´°èŒï¼ŒåŒ…æ‹¬ä¸€äº›å°æŠ—ç”Ÿç´ æœ‰æŠ—è—¥æ€§çš„ç´°èŒã€‚é€éç³»çµ±æ€§æ–‡ç»å›é¡§ï¼Œç ”ç©¶è€…å½™æ•´äº†ç›®å‰æœ‰é—œè˜¿è””ç¡«ç´ çš„çŸ¥è­˜ï¼Œä¸¦åˆ†æå…¶åœ¨é«”å¤–å’Œé«”å…§çš„æŠ—èŒæ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨äººé«”ç ”ç©¶ä¸­çš„æ‡‰ç”¨ã€‚\n\né€™é …ç ”ç©¶æ¡ç”¨äº†ç³»çµ±æ€§æ–‡ç»å›é¡§çš„æ–¹æ³•ï¼Œåˆ†æäº†28ç¯‡ç›¸é—œå ±å‘Šï¼Œé€™äº›å ±å‘Šæ¢è¨äº†è˜¿è””ç¡«ç´ çš„æŠ—èŒç‰¹æ€§ã€‚ç ”ç©¶å°è±¡åŒ…æ‹¬ä¸åŒçš„ç´°èŒé¡å‹ï¼Œæ¶µè“‹äº†å¤šç¨®é©è˜­æ°é™½æ€§å’Œé™°æ€§ç´°èŒã€‚ç ”ç©¶è€…è©•ä¼°äº†è˜¿è””ç¡«ç´ çš„ä½œç”¨æ©Ÿåˆ¶ï¼ŒåŒ…æ‹¬å…¶å°ç´°èŒæ¯’æ€§å› å­çš„å½±éŸ¿ã€å…ç–«åæ‡‰çš„å¢å¼·ï¼Œä»¥åŠå°ç´°èƒæå‚·çš„ä¿è­·ä½œç”¨ã€‚é€™äº›ç ”ç©¶ä¸åƒ…é™æ–¼å¯¦é©—å®¤ç’°å¢ƒï¼Œé‚„åŒ…æ‹¬äº†äººé«”çš„ç ”ç©¶çµæœï¼Œæä¾›äº†æ›´å…¨é¢çš„ç†è§£ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ å°å¤šç¨®ç´°èŒå…·æœ‰æŠ—èŒæ•ˆæœï¼Œä¸¦èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¦‚ç”Ÿç‰©è†œå½¢æˆå’Œæ¯’ç´ ç”¢ç”Ÿã€‚æ­¤å¤–ï¼Œè˜¿è””ç¡«ç´ é‚„èƒ½å¢å¼·å…ç–«ç´°èƒçš„åæ‡‰ï¼Œä¸¦å…·æœ‰æŠ—æ°§åŒ–å’ŒæŠ—ç™¼ç‚çš„ä½œç”¨ï¼Œé€™æœ‰åŠ©æ–¼ç´°èŒçš„æ¸…é™¤å’Œæ¸›å°‘ç´°èƒåŠçµ„ç¹”çš„æå‚·ã€‚ç ”ç©¶é‚„æŒ‡å‡ºï¼Œè˜¿è””ç¡«ç´ èƒ½å¤ æ¸›è¼•ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ï¼Œä¸¦é˜²æ­¢é˜¿æ–¯åŒ¹æ—å¼•èµ·çš„å°è…¸ç´°èƒæå‚·ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æœ‰å‰æ™¯çš„æ›¿ä»£æŠ—ç”Ÿç´ ï¼Œå€¼å¾—åœ¨è‡¨åºŠè©¦é©—ä¸­é€²ä¸€æ­¥æ¢è¨ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿæˆ‘å€‘çš„é£Ÿç‰©è£¡ç«Ÿç„¶è—è‘—å°æŠ—ç´°èŒçš„ç§˜å¯†æ­¦å™¨ï¼æœ€è¿‘çš„ç ”ç©¶ç™¼ç¾ï¼Œè˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºä¸€ç¨®æ–°å‹çš„å¤©ç„¶æŠ—ç”Ÿç´ ï¼Œå¹«åŠ©æˆ‘å€‘å°æŠ—é‚£äº›å°å‚³çµ±æŠ—ç”Ÿç´ ç„¡æ•ˆçš„ç´°èŒã€‚é€™é …ç ”ç©¶ä¸»è¦æ¢è¨è˜¿è””ç¡«ç´ çš„æŠ—èŒæ•ˆæœï¼Œå°¤å…¶æ˜¯å®ƒå°æŠ—ä¸€äº›é ‘å›ºç´°èŒçš„æ½›åŠ›ã€‚ç ”ç©¶è€…å€‘é€éç³»çµ±æ€§æ–‡ç»å›é¡§ï¼Œåˆ†æäº†28ç¯‡ç›¸é—œå ±å‘Šï¼Œäº†è§£è˜¿è””ç¡«ç´ åœ¨å¯¦é©—å®¤å’Œäººé«”ä¸­çš„è¡¨ç¾ã€‚çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ ä¸åƒ…èƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§ï¼Œé‚„èƒ½å¢å¼·æˆ‘å€‘å…ç–«ç³»çµ±çš„åæ‡‰ï¼Œå°æŠ—ç‚ç—‡ï¼Œç”šè‡³æœ‰åŠ©æ–¼æ¸›è¼•ç”±å¹½é–€èºæ—‹æ¡¿èŒå¼•èµ·çš„èƒƒç‚ï¼\n\nç¸½çµä¸€ä¸‹é€™é …ç ”ç©¶çš„é‡é»ï¼š\n1. è˜¿è””ç¡«ç´ å¯èƒ½æˆç‚ºå°æŠ—ç´°èŒæ„ŸæŸ“çš„æ½›åœ¨æ›¿ä»£ç™‚æ³•ã€‚\n2. å®ƒèƒ½æŠ‘åˆ¶ç´°èŒçš„æ¯’æ€§å› å­ï¼Œå¢å¼·å…ç–«åæ‡‰ã€‚\n3. ç ”ç©¶çµæœé¡¯ç¤ºï¼Œè˜¿è””ç¡«ç´ æœ‰åŠ©æ–¼æ¸›å°‘ç´°èƒæå‚·åŠç‚ç—‡ã€‚",
    "image_prompt": "Create a flat design infographic that explains the experimental methods and main results of a study on the antimicrobial effects of sulforaphane. Include simplified illustrations of broccoli or sulforaphane, experimental subjects like humans or cells, and arrows or flow lines indicating the experimental steps. Add a section that highlights the main results, such as protective effects and changes observed.",
    "is_human_study": true,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "å¹½é–€èºæ—‹æ¡¿èŒæ„ŸæŸ“ Helicobacter pylori infection",
    "is_clinical_trial": true,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40553560/"
  },
  {
    "id": "40597512",
    "title_en": "In vitro gastrointestinal digestion of broccolis sprout extract: Impact on the bioaccesibility of sulforaphane and total phenolic.",
    "pub_date": "2025 Oct",
    "abstract_en": "Broccoli sprout extract is rich in phenolic compounds and sulforaphane (SFN) and the gastrointestinal digestion process can affect the bioaccessibility of these substances. This study aimed to evaluate the antioxidant capacity and the content of total phenolic compounds (TPC) and SFN in broccoli sprout extract before and during in vitro gastrointestinal digestion (GID). The antioxidant capacity was determined using different assays (FRAP, ABTS and DPPH), and the TPC and sulforaphane content was measured using the Folin-Ciocalteu method and high performance liquid chromatography (HPLC), respectively. The in vitro digestion analyses followed the INFOGEST 2.0 protocol. Additionally, microbiological characterization and chemical composition analysis of broccoli sprouts were conducted. The microbiological analyses indicated that the sprouts were safe for consumption, with high amounts of TPC, antioxidant capacity, and SFN content. The TPC content decreased significantly (pÂ <Â 0.001) after GID, from 1740.0Â Î¼gÂ eq. GAE/g before digestion to 536.5Â Î¼gÂ eq. GAE/g in the gastric phase and 211.0Â Î¼gÂ eq. GAE/g in the enteric phase. The antioxidant capacity also decreased significantly after simulated digestion compared to initial values. A lower (pÂ <Â 0.001) SFN content was identified in the gastric phase (18.6Â mg/g) compared to the intestinal phase (27.8Â mg/g), although both showed lower SFN levels than the undigested sample, which contained 72.2Â mg/g of SFN. In conclusion, simulated digestion significantly reduced the amount of TPC and SFN, likely due to degradation or biotransformation of the compounds under digestion conditions.",
    "para1": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•é€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–é…šé¡åŒ–åˆç‰©è¢«èªç‚ºå…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œé€™äº›ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—è‡ªç”±åŸºï¼Œæ¸›å°‘ç´°èƒæå‚·ï¼Œé€²è€Œé™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚äº†è§£é€™äº›åŒ–åˆç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œå°æ–¼æˆ‘å€‘å¦‚ä½•æœ‰æ•ˆåœ°åˆ©ç”¨é€™äº›å¥åº·æˆåˆ†è‡³é—œé‡è¦ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿æˆ‘å€‘çš„é£²é£Ÿé¸æ“‡å’Œå¥åº·ç®¡ç†ç­–ç•¥ã€‚",
    "para2": "æœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä¸¦é€²ä¸€æ­¥è©•ä¼°å…¶ç”Ÿç‰©å¯åˆ©ç”¨æ€§ï¼Œé€™å°æ–¼ç‡Ÿé¤Šå­¸å’Œé£Ÿå“ç§‘å­¸é ˜åŸŸéƒ½å…·æœ‰é‡è¦æ„ç¾©ã€‚",
    "para3": "ç ”ç©¶ä¸­ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œä¸¦æ¡ç”¨é«”å¤–æ¶ˆåŒ–æ¨¡å‹ä¾†æ¨¡æ“¬èƒƒè…¸é“çš„æ¶ˆåŒ–éç¨‹ã€‚ç ”ç©¶è€…é‹ç”¨äº†å¤šç¨®æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰ï¼Œä¸¦ä½¿ç”¨Folin-Ciocalteuæ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„é€²è¡Œäº†å¾®ç”Ÿç‰©ç‰¹å¾µåˆ†æå’ŒåŒ–å­¸æˆåˆ†åˆ†æï¼Œä»¥ç¢ºä¿é’èŠ±æ¤°èœèŠ½çš„å®‰å…¨æ€§å’Œç‡Ÿé¤Šåƒ¹å€¼ã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œç¶“éæ¶ˆåŒ–å¾Œï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸å‰‡ç‚º27.8 mg/gï¼Œå…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gï¼Œé¡¯ç¤ºæ¶ˆåŒ–éç¨‹å°é€™äº›åŒ–åˆç‰©çš„å½±éŸ¿æ˜¯é¡¯è‘—çš„ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶æä¾›äº†ä¸€äº›é—œæ–¼å¦‚ä½•é€éé£²é£Ÿä¾†ä¿ƒé€²å¥åº·æˆ–é é˜²ç–¾ç—…çš„å•Ÿç¤ºã€‚é’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–é…šé¡åŒ–åˆç‰©è¢«èªç‚ºå…·æœ‰æŠ—æ°§åŒ–ç‰¹æ€§ï¼Œé€™äº›ç‰¹æ€§å¯èƒ½æœ‰åŠ©æ–¼å°æŠ—è‡ªç”±åŸºï¼Œæ¸›å°‘ç´°èƒæå‚·ï¼Œé€²è€Œé™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚äº†è§£é€™äº›åŒ–åˆç‰©åœ¨æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ï¼Œå°æ–¼æˆ‘å€‘å¦‚ä½•æœ‰æ•ˆåœ°åˆ©ç”¨é€™äº›å¥åº·æˆåˆ†è‡³é—œé‡è¦ï¼Œé€™å¯èƒ½æœƒå½±éŸ¿æˆ‘å€‘çš„é£²é£Ÿé¸æ“‡å’Œå¥åº·ç®¡ç†ç­–ç•¥ã€‚\n\næœ¬ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„æŠ—æ°§åŒ–èƒ½åŠ›ä»¥åŠå…¶ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ï¼Œç‰¹åˆ¥æ˜¯åœ¨æ¨¡æ“¬èƒƒè…¸é“æ¶ˆåŒ–éç¨‹ä¸­çš„è®ŠåŒ–ã€‚ç ”ç©¶è€…å¸Œæœ›äº†è§£é€™äº›é‡è¦æˆåˆ†åœ¨æ¶ˆåŒ–éç¨‹ä¸­æ˜¯å¦æœƒå—åˆ°å½±éŸ¿ï¼Œä¸¦é€²ä¸€æ­¥è©•ä¼°å…¶ç”Ÿç‰©å¯åˆ©ç”¨æ€§ï¼Œé€™å°æ–¼ç‡Ÿé¤Šå­¸å’Œé£Ÿå“ç§‘å­¸é ˜åŸŸéƒ½å…·æœ‰é‡è¦æ„ç¾©ã€‚\n\nç ”ç©¶ä¸­ä½¿ç”¨äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œä¸¦æ¡ç”¨é«”å¤–æ¶ˆåŒ–æ¨¡å‹ä¾†æ¨¡æ“¬èƒƒè…¸é“çš„æ¶ˆåŒ–éç¨‹ã€‚ç ”ç©¶è€…é‹ç”¨äº†å¤šç¨®æ¸¬è©¦æ–¹æ³•ä¾†è©•ä¼°æŠ—æ°§åŒ–èƒ½åŠ›ï¼ŒåŒ…æ‹¬FRAPã€ABTSå’ŒDPPHç­‰ï¼Œä¸¦ä½¿ç”¨Folin-Ciocalteuæ³•å’Œé«˜æ•ˆæ¶²ç›¸è‰²è­œï¼ˆHPLCï¼‰ä¾†æ¸¬é‡ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚æ­¤å¤–ï¼Œç ”ç©¶é‚„é€²è¡Œäº†å¾®ç”Ÿç‰©ç‰¹å¾µåˆ†æå’ŒåŒ–å­¸æˆåˆ†åˆ†æï¼Œä»¥ç¢ºä¿é’èŠ±æ¤°èœèŠ½çš„å®‰å…¨æ€§å’Œç‡Ÿé¤Šåƒ¹å€¼ã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ¨¡æ“¬æ¶ˆåŒ–éç¨‹é¡¯è‘—é™ä½äº†é’èŠ±æ¤°èœèŠ½æå–ç‰©ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡ã€‚ç ”ç©¶çµæœæŒ‡å‡ºï¼Œç¶“éæ¶ˆåŒ–å¾Œï¼Œç¸½é…šé¡åŒ–åˆç‰©çš„å«é‡å¾æ¶ˆåŒ–å‰çš„1740.0 Î¼g eq. GAE/gé™è‡³èƒƒç›¸çš„536.5 Î¼g eq. GAE/gå’Œè…¸ç›¸çš„211.0 Î¼g eq. GAE/gï¼ŒæŠ—æ°§åŒ–èƒ½åŠ›ä¹Ÿé¡¯è‘—ä¸‹é™ã€‚æ­¤å¤–ï¼Œèƒƒç›¸ä¸­çš„è˜¿è””ç¡«ç´ å«é‡ç‚º18.6 mg/gï¼Œè€Œè…¸ç›¸å‰‡ç‚º27.8 mg/gï¼Œå…©è€…å‡ä½æ–¼æœªæ¶ˆåŒ–æ¨£æœ¬çš„72.2 mg/gï¼Œé¡¯ç¤ºæ¶ˆåŒ–éç¨‹å°é€™äº›åŒ–åˆç‰©çš„å½±éŸ¿æ˜¯é¡¯è‘—çš„ã€‚",
    "fb_post": "ğŸ½ï¸ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœä¸åªæ˜¯å¥½åƒï¼Œé‚„æœ‰å¾ˆå¤šå¥åº·çš„ç§˜å¯†ï¼é€™ç¯‡ç ”ç©¶å‘Šè¨´æˆ‘å€‘ï¼Œé’èŠ±æ¤°èœä¸­çš„è˜¿è””ç¡«ç´ å’Œå…¶ä»–ç‡Ÿé¤Šæˆåˆ†å°æˆ‘å€‘çš„å¥åº·æœ‰å¤šé‡è¦ã€‚ç ”ç©¶è€…å€‘æƒ³çŸ¥é“ï¼Œé€™äº›æˆåˆ†åœ¨æˆ‘å€‘æ¶ˆåŒ–éç¨‹ä¸­æœƒç™¼ç”Ÿä»€éº¼è®ŠåŒ–ï¼Œæ–¼æ˜¯ä»–å€‘é€²è¡Œäº†ä¸€ç³»åˆ—çš„å¯¦é©—ã€‚  \n  \nä»–å€‘ç”¨é’èŠ±æ¤°èœèŠ½æå–ç‰©ï¼Œæ¨¡æ“¬äº†æˆ‘å€‘çš„èƒƒè…¸é“æ¶ˆåŒ–éç¨‹ï¼Œä¸¦æ¸¬è©¦äº†é€™äº›æˆåˆ†çš„æŠ—æ°§åŒ–èƒ½åŠ›ã€‚çµæœç™¼ç¾ï¼Œç¶“éæ¶ˆåŒ–å¾Œï¼Œé’èŠ±æ¤°èœèŠ½ä¸­çš„ç¸½é…šé¡åŒ–åˆç‰©å’Œè˜¿è””ç¡«ç´ çš„å«é‡é¡¯è‘—ä¸‹é™ï¼Œé€™æ„å‘³è‘—æˆ‘å€‘åœ¨åƒé’èŠ±æ¤°èœå¾Œï¼Œä¸¦ä¸æ˜¯æ‰€æœ‰çš„ç‡Ÿé¤Šæˆåˆ†éƒ½èƒ½å®Œå…¨è¢«å¸æ”¶ã€‚  \n  \næ‰€ä»¥ï¼Œé€™ç¯‡ç ”ç©¶æé†’æˆ‘å€‘ï¼š  \n1ï¸âƒ£ é’èŠ±æ¤°èœèŠ½ä¸­çš„ç‡Ÿé¤Šæˆåˆ†å°å¥åº·æœ‰ç›Šï¼Œä½†æ¶ˆåŒ–éç¨‹æœƒå½±éŸ¿å®ƒå€‘çš„å«é‡ã€‚  \n2ï¸âƒ£ æˆ‘å€‘çš„é£²é£Ÿé¸æ“‡è¦è€ƒæ…®åˆ°é€™äº›ç‡Ÿé¤Šæˆåˆ†çš„ç”Ÿç‰©å¯åˆ©ç”¨æ€§ã€‚  \n3ï¸âƒ£ ç¹¼çºŒæ¢ç´¢å¦‚ä½•æ›´å¥½åœ°åˆ©ç”¨é€™äº›å¥åº·é£Ÿæï¼Œè®“æˆ‘å€‘çš„é£²é£Ÿæ›´æœ‰ç›Šï¼",
    "image_prompt": "Create a flat design infographic illustrating the experiment and main results of a study on broccoli sprouts. Include symbols for broccoli and sulforaphane, simplified representations of experimental subjects like humans or cells, arrows or flow lines showing the steps of the experiment, and a section labeled 'Main Results' highlighting key findings such as the decrease in antioxidant compounds after digestion.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": false,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/40597512/"
  },
  {
    "id": "41026407",
    "title_en": "The Adaptive Laboratory Evolution Technology Enhances Sulforaphane Production of Lactobacillus plantarum CR12.",
    "pub_date": "2025 Sep",
    "abstract_en": "T he sulforaphane production of wild-type Lactobacillus plantarum CR12 (L. plantarum CR12) is limited. Researchers found that adaptive laboratory evolution (ALE) technology can enhance the production of microorganism by altering the growth environment of microorganisms. However, the effectiveness of enhancing the transformation function of L. plantarum CR12 and the safety of the adaptive strain are unknown. To clarify the above problem, ALE technology was used to enhance the sulforaphane conversion rate of L. plantarum CR12. The results showed that the glucoraphanin conversion rate, sulforaphane production rate, and sulforaphane conversion efficiency of adaptive strain were significantly higher than those of the wild-type strain. The adaptive strain could produce sulforaphane in vivo and regulate the gut microbiota structure. The genomes showed that the adaptive strain consists of a 4,165,885Â bp chromosome with a GC content of 36.8%, encoding 4172 protein-coding genes. Compared with the wild-type strain, the adaptive strain expresses more glycoside hydrolases and glycosyl transferases, indicating that the adaptive strain possesses higher carbohydrate metabolic capability. Genes related to glucoraphanin metabolism (cliT, bglF, and bglA) were detected in both the genomes of the wild-type strain and adaptive strain, indicating that both the wild-type strain and adaptive strain possess sulforaphane production capabilities. Therefore, the adaptive strain can be safely used to increase the in vivo production of sulforaphane, ultimately improving human health. This research is aimed at providing genetic evidence for further formulating rational genetic engineering strategies to transform the wild-type strain into an overproducer.",
    "para1": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·å’Œå¢å¼·å…ç–«ç³»çµ±æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå·²çŸ¥å°äººé«”æœ‰ç›Šï¼Œèƒ½å¤ å¹«åŠ©é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éæå‡å¾®ç”Ÿç‰©çš„è˜¿è””ç¡«ç´ ç”¢é‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿ƒé€²äººé«”çš„å¥åº·ï¼Œé€²è€Œæ”¹å–„ç”Ÿæ´»å“è³ªã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£å¾®ç”Ÿç‰©å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„ç‡Ÿé¤Šè£œå……å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ã€‚",
    "para2": "é€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒï¼ˆLactobacillus plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æ”¹å–„é€™ç¨®å¾®ç”Ÿç‰©åœ¨ç‰¹å®šç’°å¢ƒä¸‹çš„ç”Ÿé•·ï¼Œä¸¦æå‡å…¶ç”¢ç”Ÿè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚åŒæ™‚ï¼Œç ”ç©¶ä¹Ÿè‘—é‡æ–¼è©•ä¼°é€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªæ˜¯å¦å®‰å…¨ï¼Œä¸¦èƒ½å¦åœ¨é«”å…§æœ‰æ•ˆç”¢ç”Ÿè˜¿è””ç¡«ç´ ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·æ‡‰ç”¨è‡³é—œé‡è¦ã€‚",
    "para3": "åœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€ ä¹³é…¸èŒCR12ï¼Œç›®çš„æ˜¯æé«˜å…¶è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†æ”¹é€ å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªåœ¨ç”Ÿé•·ç’°å¢ƒä¸­çš„è¡¨ç¾ï¼Œä¸¦åˆ†æäº†å®ƒå€‘çš„åŸºå› çµ„ã€‚é€™äº›å¯¦é©—ä¸åƒ…è©•ä¼°äº†èŒæ ªçš„ç”Ÿé•·é€Ÿåº¦ï¼Œé‚„æª¢æ¸¬äº†å…¶ç”¢ç”Ÿè˜¿è””ç¡«ç´ çš„èƒ½åŠ›ï¼Œä¸¦æ¯”è¼ƒäº†å…©è€…åœ¨åŸºå› è¡¨é”ä¸Šçš„å·®ç•°ï¼Œä»¥äº†è§£æ”¹é€ çš„æ•ˆæœã€‚",
    "para4": "ä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ”¹é€ å¾Œçš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡å’Œç”¢é‡ä¸Šå‡é¡¯è‘—é«˜æ–¼é‡ç”Ÿå‹èŒæ ªã€‚æ­¤å¤–ï¼Œæ”¹é€ èŒæ ªèƒ½å¤ åœ¨é«”å…§ç”¢ç”Ÿè˜¿è””ç¡«ç´ ï¼Œä¸¦èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çš„çµæ§‹ã€‚åŸºå› çµ„åˆ†æé¡¯ç¤ºï¼Œæ”¹é€ èŒæ ªæ“æœ‰æ›´é«˜çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ï¼Œä¸¦è¡¨é”äº†æ›´å¤šèˆ‡è˜¿è””ç¡«ç´ ä»£è¬ç›¸é—œçš„åŸºå› ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ”¹é€ èŒæ ªåœ¨å®‰å…¨æ€§ä¸Šæ˜¯å¯è¡Œçš„ï¼Œæœªä¾†æœ‰æ½›åŠ›ç”¨æ–¼æå‡é«”å…§è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œé€²è€Œä¿ƒé€²äººé¡å¥åº·ã€‚",
    "explanation_zh": "é€™é …ç ”ç©¶å¯èƒ½å°å¥åº·å’Œç–¾ç—…é é˜²æœ‰é‡è¦çš„å•Ÿç¤ºï¼Œç‰¹åˆ¥æ˜¯åœ¨æ”¹å–„è…¸é“å¥åº·å’Œå¢å¼·å…ç–«ç³»çµ±æ–¹é¢ã€‚è˜¿è””ç¡«ç´ æ˜¯ä¸€ç¨®å­˜åœ¨æ–¼é’èŠ±æ¤°èœä¸­çš„å¤©ç„¶åŒ–åˆç‰©ï¼Œå·²çŸ¥å°äººé«”æœ‰ç›Šï¼Œèƒ½å¤ å¹«åŠ©é™ä½æŸäº›ç–¾ç—…çš„é¢¨éšªã€‚é€éæå‡å¾®ç”Ÿç‰©çš„è˜¿è””ç¡«ç´ ç”¢é‡ï¼Œå¯èƒ½æœ‰åŠ©æ–¼ä¿ƒé€²äººé«”çš„å¥åº·ï¼Œé€²è€Œæ”¹å–„ç”Ÿæ´»å“è³ªã€‚é€™æ¨£çš„ç ”ç©¶ä¸åƒ…æœ‰åŠ©æ–¼äº†è§£å¾®ç”Ÿç‰©å¦‚ä½•å½±éŸ¿æˆ‘å€‘çš„å¥åº·ï¼Œé‚„å¯èƒ½ç‚ºæœªä¾†çš„ç‡Ÿé¤Šè£œå……å“é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ã€‚\n\né€™é …ç ”ç©¶çš„ä¸»é¡Œæ˜¯æ¢è¨å¦‚ä½•åˆ©ç”¨é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†å¢å¼·ä¹³é…¸èŒï¼ˆLactobacillus plantarum CR12ï¼‰å°è˜¿è””ç¡«ç´ çš„è½‰åŒ–èƒ½åŠ›ã€‚ç ”ç©¶è€…é—œå¿ƒçš„å•é¡Œæ˜¯ï¼Œå¦‚ä½•æ”¹å–„é€™ç¨®å¾®ç”Ÿç‰©åœ¨ç‰¹å®šç’°å¢ƒä¸‹çš„ç”Ÿé•·ï¼Œä¸¦æå‡å…¶ç”¢ç”Ÿè˜¿è””ç¡«ç´ çš„æ•ˆç‡ã€‚åŒæ™‚ï¼Œç ”ç©¶ä¹Ÿè‘—é‡æ–¼è©•ä¼°é€™ç¨®æ”¹é€ å¾Œçš„èŒæ ªæ˜¯å¦å®‰å…¨ï¼Œä¸¦èƒ½å¦åœ¨é«”å…§æœ‰æ•ˆç”¢ç”Ÿè˜¿è””ç¡«ç´ ï¼Œé€™å°æ–¼æœªä¾†çš„å¥åº·æ‡‰ç”¨è‡³é—œé‡è¦ã€‚\n\nåœ¨å¯¦é©—ä¸­ï¼Œç ”ç©¶è€…ä½¿ç”¨äº†é©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–æŠ€è¡“ä¾†æ”¹é€ ä¹³é…¸èŒCR12ï¼Œç›®çš„æ˜¯æé«˜å…¶è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡ã€‚ç ”ç©¶åœ˜éšŠè§€å¯Ÿäº†æ”¹é€ å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªåœ¨ç”Ÿé•·ç’°å¢ƒä¸­çš„è¡¨ç¾ï¼Œä¸¦åˆ†æäº†å®ƒå€‘çš„åŸºå› çµ„ã€‚é€™äº›å¯¦é©—ä¸åƒ…è©•ä¼°äº†èŒæ ªçš„ç”Ÿé•·é€Ÿåº¦ï¼Œé‚„æª¢æ¸¬äº†å…¶ç”¢ç”Ÿè˜¿è””ç¡«ç´ çš„èƒ½åŠ›ï¼Œä¸¦æ¯”è¼ƒäº†å…©è€…åœ¨åŸºå› è¡¨é”ä¸Šçš„å·®ç•°ï¼Œä»¥äº†è§£æ”¹é€ çš„æ•ˆæœã€‚\n\nä¸»è¦ç™¼ç¾é¡¯ç¤ºï¼Œæ”¹é€ å¾Œçš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡å’Œç”¢é‡ä¸Šå‡é¡¯è‘—é«˜æ–¼é‡ç”Ÿå‹èŒæ ªã€‚æ­¤å¤–ï¼Œæ”¹é€ èŒæ ªèƒ½å¤ åœ¨é«”å…§ç”¢ç”Ÿè˜¿è””ç¡«ç´ ï¼Œä¸¦èª¿ç¯€è…¸é“å¾®ç”Ÿç‰©çš„çµæ§‹ã€‚åŸºå› çµ„åˆ†æé¡¯ç¤ºï¼Œæ”¹é€ èŒæ ªæ“æœ‰æ›´é«˜çš„ç¢³æ°´åŒ–åˆç‰©ä»£è¬èƒ½åŠ›ï¼Œä¸¦è¡¨é”äº†æ›´å¤šèˆ‡è˜¿è””ç¡«ç´ ä»£è¬ç›¸é—œçš„åŸºå› ã€‚é€™äº›çµæœè¡¨æ˜ï¼Œæ”¹é€ èŒæ ªåœ¨å®‰å…¨æ€§ä¸Šæ˜¯å¯è¡Œçš„ï¼Œæœªä¾†æœ‰æ½›åŠ›ç”¨æ–¼æå‡é«”å…§è˜¿è””ç¡«ç´ çš„ç”¢é‡ï¼Œé€²è€Œä¿ƒé€²äººé¡å¥åº·ã€‚",
    "fb_post": "ä½ çŸ¥é“å—ï¼Ÿé’èŠ±æ¤°èœè£¡æœ‰ä¸€ç¨®å«åšè˜¿è””ç¡«ç´ çš„å¤©ç„¶æˆåˆ†ï¼Œå°æˆ‘å€‘çš„å¥åº·æœ‰å¾ˆå¤§å¹«åŠ©ï¼æœ€è¿‘æœ‰ä¸€é …ç ”ç©¶å°ˆæ³¨æ–¼å¦‚ä½•æé«˜ä¸€ç¨®ä¹³é…¸èŒï¼ˆLactobacillus plantarum CR12ï¼‰è½‰åŒ–è˜¿è””ç¡«ç´ çš„èƒ½åŠ›ï¼Œé€™ä¸åƒ…èƒ½æ”¹å–„è…¸é“å¥åº·ï¼Œé‚„èƒ½å¢å¼·æˆ‘å€‘çš„å…ç–«ç³»çµ±ã€‚  \n  \nç ”ç©¶äººå“¡åˆ©ç”¨ä¸€ç¨®å«åšé©æ‡‰æ€§å¯¦é©—å®¤é€²åŒ–çš„æŠ€è¡“ï¼Œæ”¹é€ äº†é€™ç¨®ä¹³é…¸èŒï¼Œè®“å®ƒåœ¨ç‰¹å®šç’°å¢ƒä¸‹æ›´æœ‰æ•ˆåœ°ç”Ÿé•·ä¸¦ç”¢ç”Ÿè˜¿è””ç¡«ç´ ã€‚åœ¨å¯¦é©—ä¸­ï¼Œä»–å€‘è§€å¯Ÿäº†æ”¹é€ å¾Œçš„èŒæ ªèˆ‡é‡ç”Ÿå‹èŒæ ªçš„è¡¨ç¾ï¼Œä¸¦æª¢æ¸¬äº†å®ƒå€‘çš„åŸºå› çµ„ã€‚çµæœç™¼ç¾ï¼Œæ”¹é€ å¾Œçš„èŒæ ªåœ¨è˜¿è””ç¡«ç´ çš„è½‰åŒ–ç‡å’Œç”¢é‡ä¸Šéƒ½é¡¯è‘—æé«˜ï¼Œä¸¦ä¸”èƒ½å¤ åœ¨é«”å…§ç”¢ç”Ÿé€™ç¨®æœ‰ç›Šçš„æˆåˆ†ï¼  \n  \né€™äº›ç™¼ç¾è®“æˆ‘å€‘çœ‹åˆ°æœªä¾†çš„å¸Œæœ›ï¼Œæˆ–è¨±èƒ½ç‚ºå¥åº·è£œå……å“çš„é–‹ç™¼æä¾›æ–°çš„æ–¹å‘ã€‚  \n  \nğŸ” ä¸»è¦é‡é»ï¼š  \n1. æ”¹é€ çš„ä¹³é…¸èŒèƒ½æ›´æœ‰æ•ˆåœ°ç”¢ç”Ÿè˜¿è””ç¡«ç´   \n2. é€™æœ‰åŠ©æ–¼æ”¹å–„è…¸é“å¥åº·å’Œå¢å¼·å…ç–«åŠ›  \n3. ç ”ç©¶ç‚ºæœªä¾†çš„å¥åº·æ‡‰ç”¨æä¾›äº†æ–°æ€è·¯",
    "image_prompt": "Create an infographic that explains the experimental process and main findings of a study on enhancing the conversion of sulforaphane in a specific lactic acid bacteria strain (Lactobacillus plantarum CR12). Include simple illustrations of broccoli or sulforaphane, simplified representations of experimental subjects like humans or cells, arrows or flow lines to indicate the experimental steps, and a section highlighting the main results, such as increased conversion rates and potential health benefits.",
    "is_human_study": false,
    "is_animal_study": false,
    "is_disease_related": true,
    "disease_name": "",
    "is_clinical_trial": false,
    "pubmed_url": "https://pubmed.ncbi.nlm.nih.gov/41026407/"
  }
]